Press Releases

Webcast ImageWebcast
Q2 2014 OraSure Technologies, Inc. Earnings Conference Call (Live)
08/06/14 at 5:00 p.m. ET
Keyword Search
 
This portion of our Web site contains archival information. Archived information contained or referenced herein should not be considered current and may no longer be accurate.
Current | Archive | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008
DateTitle 
05/07/14OraSure Announces 2014 First Quarter Financial Results
BETHLEHEM, Pa., May 7, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the first quarter of 2014. Financial Highlights Consolidated net revenues for the first quarter of 2014 were $23.5 million, an 11% increase from the comparable quarter of 2013. Net product revenues increased 12% primarily due to higher revenues from the Company's molecular collection systems subsidi... 
Printer Friendly Version
04/22/14OraSure Technologies Earnings Conference Call Invitation
2014 First Quarter Earnings Conference Call Wednesday, May 7, 2014, 5:00 p.m. ET BETHLEHEM, Pa., April 22, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2014 first quarter results and certain 2014 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, May 7, 2014. An update on certain business developments will also be provided. May 7, 2014 Schedule     ... 
Printer Friendly Version
04/04/14OraSure Technologies' Debra Fraser-Howze Receives 2014 "Top Blacks in Healthcare" Award
OraSure Executive Recognized by Johns Hopkins Center for Health Disparities Solutions and BlackDoctor.org BETHLEHEM, Pa., April 4, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) is proud to announce that Debra Fraser-Howze, the Company's Senior Vice President of Government and External Affairs, received a 2014 "Top Blacks in Healthcare" Award from BlackDoctor.org in partnership with Johns Hopkins Center for Health Disparities Solutions. The award honors those who have out... 
Printer Friendly Version
02/26/14OraSure Technologies to Present at the Cowen & Company 34th Annual Health Care Conference
BETHLEHEM, Pa., Feb. 26, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Co. 34th Annual Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak March 5, 2014, at approximately 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). Interested investors can access the live w... 
Printer Friendly Version
02/24/14OraSure Technologies to Present at the Raymond James 35th Annual Institutional Investors Conference
BETHLEHEM, Pa., Feb. 24, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Raymond James 35th Annual Institutional Investors Conference in Orlando, Florida. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak March 3, 2014, at approximately 8:40 am Eastern Time (5:40 am Pacific Time). Interested investors can access the live ... 
Printer Friendly Version
02/20/14OraSure Technologies to Present at the 2014 Citi Global Healthcare Conference
BETHLEHEM, Pa., Feb. 20, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2014 Citi Global Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak February 25, 2014, at approximately 1:50pm Eastern Time (10:50am Pacific Time). Interested investors can access the live webcast of the present... 
Printer Friendly Version
02/06/14OraSure Technologies to Present at the Leerink Swan Global Healthcare Conference
BETHLEHEM, Pa., Feb. 6, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Ronald Spair, Chief Operating Officer & Chief Financial Officer, will speak to the investment community at the Leerink Swan Global Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Spair is scheduled to speak February 13, 2014, at approximately 1:25 pm Eastern Time (10:25 am Pacific Time). Interested investors can access... 
Printer Friendly Version
02/05/14OraSure Announces Record Full-Year and Quarterly Revenues
BETHLEHEM, Pa., Feb. 5, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the full-year and fourth quarter of 2013. Financial Highlights The Company reported record revenues for both the fourth quarter and full-year 2013. Consolidated net revenues for the fourth quarter were $28.8 million, a 30% increase from the comparable quarter of 2012. Consolidated net revenues for ... 
Printer Friendly Version
01/28/14OraSure Technologies Announces 2014 Annual Meeting Date
BETHLEHEM, Pa., Jan. 28, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2014 Annual Meeting of Stockholders is scheduled to be held on Thursday, May 22, 2014. Further details regarding the meeting will be provided at a later date. About OraSure Technologies OraSure Technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critic... 
Printer Friendly Version
01/20/14OraSure Technologies Earnings Conference Call Invitation
2013 Fourth Quarter Earnings Conference Call Wednesday, February 5, 2014, 5:00 p.m. ET BETHLEHEM, Pa., Jan. 20, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2013 fourth quarter and full year financial results and certain 2014 financial guidance for 5:00 pm ET (2:00 pm PT) Wednesday, February 5, 2014. An update on certain business developments will also be provided. February 5, 2014 Schedule ... 
Printer Friendly Version
01/07/14OraSure Technologies Addresses FDA Warning Letter Received by Its Subsidiary DNA Genotek
BETHLEHEM, Pa., Jan. 7, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced that its molecular collection systems subsidiary, DNA Genotek, received a warning letter from the U.S. Food and Drug Administration (FDA) which the FDA posted today on its website. The warning letter primarily focuses on DNA Genotek's response to two observations issued by the FDA on Form 483 as a result of a routine inspection of DNA Genotek's Ottawa, Canada facilities in September 2013. DNA ... 
Printer Friendly Version
11/25/13OraSure Technologies Reaffirms 4th Quarter 2013 Financial Guidance
BETHLEHEM, Pa., Nov. 25, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that it is reaffirming its fourth quarter 2013 financial guidance, which the Company last updated in a press release it issued on November 21, 2013. This reaffirmation is being made after the Company learned today that a customer of its molecular collection systems subsidiary, DNA Genotek, received a warning letter from the U.S. Food and Drug Administration (FDA) requesting that this cu... 
Printer Friendly Version
11/21/13OraSure Technologies Announces New Agreement with Thermo Fisher Scientific for Development and Distribution of Fully Automated Oral Fluid Drugs of Abuse Assays
OraSure Transitions From Prior Oral Fluid Assay Collaboration BETHLEHEM, Pa. – November 21, 2013 – OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that it has reached an agreement with Thermo Fisher Scientific (Thermo Fisher), to develop and supply up to 12 homogenous fully automated oral fluid drugs of abuse assays to be used with a new Intercept® oral fluid specimen collection device. OraSure will have the right to purchase and resell the assays in the U.S. and in certain foreign cou... 
Printer Friendly Version
11/21/13OraSure Technologies Terminates Oral Fluid Drugs of Abuse Assay Collaboration with Roche Diagnostics
Updated Financial Guidance Announced for Fourth Quarter BETHLEHEM, Pa. – November 21, 2013 – OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that its assay collaboration agreement with Roche Diagnostics has been terminated. As part of the termination, Roche will continue to supply certain of the assays developed under that collaboration on a transitional basis for use with OraSure’s existing Intercept® collection device. Under the termination agreement, Roche will make an initial pay... 
Printer Friendly Version
11/07/13OraSure Technologies to Present at Canaccord|Genuity's Medical Technology & Diagnostics Forum
BETHLEHEM, Pa., Nov. 7, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Ronald H. Spair, COO & CFO, will speak to the investment community at Canaccord|Genuity's Medical Technology & Diagnostics Forum in New York City. The conference will be simultaneously webcast over the Internet. Mr. Spair is scheduled to speak November 14, at approximately 11:00 am Eastern Time (8:00 am Pacific Time). Interested investors can access the live webcast of the p... 
Printer Friendly Version
11/06/13OraSure Announces 2013 Third Quarter Financial Results
Quarterly Revenues Reach Record High BETHLEHEM, Pa., Nov. 6, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the third quarter and nine months ended September 30, 2013. Financial Highlights Consolidated net revenues for the third quarter of 2013 were $24.7 million, a 12% increase from the comparable quarter of 2012. Consolidated net revenues for the nine months ended ... 
Printer Friendly Version
10/23/13OraSure Technologies Commends New York State Hepatitis C Testing Law
New Law Requires Health Service Providers to Offer a One-Time Hepatitis C Test to Individuals Born Between 1945 and 1965 BETHLEHEM, Pa., Oct. 23, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) applauds New York State's new hepatitis C (HCV) testing law, which requires providers in all clinical settings in the state of New York (except emergency rooms) to offer a one-time HCV test to individuals born between 1945 and 1965. Governor Andrew Cuomo signed the bill into law today a... 
Printer Friendly Version
10/16/13OraSure Technologies Earnings Conference Call Invitation
2013 Third Quarter Earnings Conference Call Wednesday, November 6, 2013, 5:00 p.m. ET BETHLEHEM, Pa., Oct. 16, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2013 third quarter results and certain 2013 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, November 6, 2013. An update on certain business developments will also be provided.    November 6, 2013 Schedule ... 
Printer Friendly Version
09/30/13OraQuick(R) In-Home HIV Test Launches New Targeted Campaign Strategy -- "Life. As we know it.(TM)" Encourages HIV Testing Among High Risk Groups
Ross Mathews, Dr. Rachael Ross and Other Leading Community Voices Join OraSure to Promote Sexual Health and HIV Testing BETHLEHEM, Pa., Sept. 30, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), makers of the OraQuick® In-Home HIV Test, announced today the launch of its newly revamped targeted nationwide awareness campaign to encourage open and honest dialogue about sexual health and the importance of learning your HIV status. The "Life. As we know it." campaign takes a bo... 
Printer Friendly Version
08/07/13OraSure Announces 2013 Second Quarter Financial Results
BETHLEHEM, Pa., Aug. 7, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the second quarter and six months ended June 30, 2013. Financial Highlights Consolidated net revenues for the second quarter of 2013 were $24.3 million, an 8% increase from the comparable quarter of 2012. Consolidated net revenues for the six months ended June 30, 2013 were $45.5 million, a 4% incr... 
Printer Friendly Version
08/06/13OraSure Technologies to Present at Canaccord|Genuity's 33rd Annual Growth Conference
BETHLEHEM, Pa., Aug. 6, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Canaccord|Genuity's 33rd Annual Growth Conference in Boston, MA. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak August 14, 2013, at approximately 10:30 am Eastern Time (7:30 am Pacific Time). Interested investors can access the live webcast of the pres... 
Printer Friendly Version
07/18/13OraSure Technologies Earnings Conference Call Invitation
2013 Second Quarter Earnings Conference Call Wednesday, August 7, 2013, 5:00 p.m. ET BETHLEHEM, Pa., July 18, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2013 second quarter results and certain 2013 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, August 7, 2013. An update on certain business developments will also be provided.   August 7, 2013 Schedule ... 
Printer Friendly Version
07/08/13OraSure Technologies to Present at the Eighth Annual JMP Securities Healthcare Conference
BETHLEHEM, Pa., July 8, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Eighth Annual JMP Securities Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak July 10, 2013, at approximately 1:00 pm Eastern Time (10:00 am Pacific Time). Interested investors can access the live webcast of th... 
Printer Friendly Version
06/26/13OraSure Technologies Teams with The Reed For Hope Foundation, Singer/Songwriter/Actress Keri Hilson and Dr. Rachael Ross to Encourage America to Get Tested for HIV
BETHLEHEM, Pa. – June 26, 2013 – OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that it has teamed up with The Reed For Hope Foundation and their new ambassador, award-winning singer/songwriter/actress Keri Hilson, and medical doctor and sexologist Dr. Rachael Ross, to encourage individuals to get tested for HIV on National HIV Testing Day on June 27th using the new OraQuick® In-Home HIV Test. National HIV Testing Day is an annual observance created to encourage Americans to get tes... 
Printer Friendly Version
06/25/13OraSure Technologies Praises New Hepatitis C Testing Recommendations by U.S. Preventive Services Task Force
New Recommendations Now Advocate One-Time Testing for All Individuals Born Between 1945 and 1965 BETHLEHEM, Pa. – June 25, 2013 – OraSure Technologies, Inc. (NASDAQ:OSUR) announced today its support for the new recommendations issued today by the U.S. Preventive Services Task Force (USPSTF), giving both hepatitis C (HCV) screening for at-risk individuals and age-cohort screening a ‘B’ grade. Under the Affordable Care Act, preventive services that have received an ‘A’ or ‘B’ grade from the USP... 
Printer Friendly Version
05/28/13OraSure Technologies to Present at Jefferies 2013 Global Healthcare Conference
BETHLEHEM, Pa., May 28, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Jefferies 2013 Global Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak June 3, 2013, at approximately 4:00 pm Eastern Time (1:00 pm Pacific Time). Interested investors can access the live webcast of the presentatio... 
Printer Friendly Version
05/16/13DNA Genotek Inc. Announces Spit for Africa Program
... 
Printer Friendly Version
05/13/13OraSure Technologies, Walgreens and Chronic Liver Disease Foundation to Launch Rapid Hepatitis C Testing Initiative in Support of National Hepatitis Testing Day
Select Walgreens Locations to Offer Rapid HCV Testing With OraQuick(R) HCV Rapid Test BETHLEHEM, Pa., May 13, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), Walgreens (NYSE:WAG), and the Chronic Liver Disease Foundation announced today that they have joined with local health organizations to offer hepatitis C (HCV) testing with the OraQuick® HCV Rapid Test to individuals who may be at risk for HCV infection. The testing will be available in select Walgreens locations across ... 
Printer Friendly Version
05/10/13OraSure Technologies to Webcast Annual Meeting of Stockholders
BETHLEHEM, Pa., May 10, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced that it will webcast its 2013 Annual Meeting of Stockholders beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) on Tuesday, May 14, 2013. In order to access the webcast, interested parties should go to OraSure Technologies' web site, www.orasure.com, and click on the Investor Info link at least ten minutes prior to the start of the webca... 
Printer Friendly Version
05/08/13OraSure Announces 2013 First Quarter Financial Results
BETHLEHEM, Pa., May 8, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the first quarter of 2013. Quarterly Highlights Consolidated net revenues were $21.2 million for the first quarter of 2013, a 1% increase from the comparable quarter of 2012. Net product revenues increased 6% primarily due to sales of the Company's OraQuick® In-Home HIV test and higher sales from th... 
Printer Friendly Version
04/29/13OraSure Technologies to Participate at Needham's Twelfth Annual Healthcare Conference
BETHLEHEM, Pa., April 29, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at Needham's Twelfth Annual Healthcare Conference in New York City at approximately 3:40 pm Eastern Time (12:40 pm Pacific Time) on Wednesday, May 1, 2013. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audio webcast of the di... 
Printer Friendly Version
04/18/13OraSure Technologies Earnings Conference Call Invitation
2013 First Quarter Earnings Conference Call Wednesday, May 8, 2013, 5:00 p.m. ET BETHLEHEM, Pa., April 18, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2013 first quarter results and certain 2013 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, May 8, 2013. An update on certain business developments will also be provided. May 8, 2013 Schedule 4:00 p.m. ET 2013 first quart... 
Printer Friendly Version
03/25/13OraQuick(R) Launches "Make Knowing Your Thing Today" Campaign to Promote the Importance of Knowing Your HIV Status
Earvin "Magic" Johnson Helps Kick Off Awareness Campaign, Encouraging and Inspiring Others to Share their Story About their Decision to Test for HIV LOS ANGELES, March 25, 2013 /PRNewswire/ -- OraSure Technologies, Inc. (NASDAQ:OSUR), maker of the OraQuick® In-Home HIV Test, announced today the launch of a nationwide awareness campaign to encourage everyone to learn their HIV status. The campaign, "Make Knowing Your Thing Today" asks people across the country to share their st... 
Printer Friendly Version
02/26/13OraSure Technologies to Present at the Cowen & Company 33rd Annual Health Care Conference
BETHLEHEM, Pa., Feb. 26, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Co. 33rd Annual Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak March 6, 2013, at approximately 8:00 am Eastern Time (5:00 am Pacific Time). Interested investors can access the live webca... 
Printer Friendly Version
02/22/13OraSure Technologies to Present at the Raymond James 34th Annual Institutional Investors Conference
BETHLEHEM, Pa., Feb. 22, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Raymond James 34th Annual Institutional Investors Conference in Orlando, Florida. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak March 4, 2013, at approximately 10:25 am Eastern Time (7:25 am Pacific Time). Interested investors can access the live... 
Printer Friendly Version
02/19/13OraSure Technologies to Present at the 2013 Citi Global Healthcare Conference
BETHLEHEM, Pa., Feb. 19, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2013 Citi Global Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak February 26, 2013, at approximately 9:35am Eastern Time (6:35am Pacific Time). Interested investors can access the live webcast of the presenta... 
Printer Friendly Version
02/14/13OraQuick(R) In-Home HIV Test Named a "Top Health Breakthrough of 2012" by Men's Health Magazine
BETHLEHEM, Pa., Feb. 14, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that the Company's OraQuick® In-Home HIV Test, the first ever in-home rapid infectious disease test made available directly to consumers, has been named a "Top Health Breakthrough of 2012" by Men's Health magazine. The OraQuick® In-Home HIV Test was listed as the #1 breakthrough on this list for 2012. The OraQuick® In-Home HIV Test, approved... 
Printer Friendly Version
02/06/13OraSure Announces Full-Year and Fourth Quarter 2012 Financial Results
BETHLEHEM, Pa., Feb. 6, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the full-year and fourth quarter of 2012. Quarterly Highlights Consolidated net revenues were $87.8 million for the full-year 2012, a 7% increase from the comparable period of 2011. Net revenues for the current period included $14.3 million from the Company's molecular collection systems subsidiary... 
Printer Friendly Version
02/06/13Photo Release -- OraSure Joins Interactive One's HelloBeautiful.com to Promote HIV Testing at a Private Concert and Conversation With Alicia Keys Beginning on February 7th
OraQuick(R) In-Home HIV Test is Exclusive Sponsor of Hello Beautiful Interludes: A Concert and Conversation With Alicia Keys to Air During February in Recognition of National Black HIV/AIDS Awareness Day BETHLEHEM, Pa., Feb. 6, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that in support of National Black HIV/AIDS Awareness Day (NBHAAD) on February 7th, the Company has joined together with Interactive One and Rad... 
Printer Friendly Version
02/06/13DNA Genotek Inc. Announces $10,000 GenoFIND™ Genomic Services Award
... 
Printer Friendly Version
01/16/13OraSure Technologies Earnings Conference Call Invitation
2012 Fourth Quarter Earnings Conference Call Wednesday, February 6, 2013, 5:00 p.m. ET BETHLEHEM, Pa., Jan. 16, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2012 fourth quarter and full year financial results and certain 2013 financial guidance for 5:00 pm ET (2:00 pm PT) Wednesday, February 6, 2013. An update on certain business developments will also be provided. February 6, 2013 Schedule ... 
Printer Friendly Version
11/28/12OraSure Technologies Appoints Senior Vice President and General Manager of Consumer Products Business
Company to Launch National Television Advertising Campaign for OraQuick(R) In-Home HIV Test on World AIDS Day, December 1st BETHLEHEM, Pa., Nov. 28, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it has appointed Kathleen G. Weber as the Company's Senior Vice President and General Manager, Consumer Products. Her appointment is the culmination of an extensive national search which began this past July following... 
Printer Friendly Version
11/21/12OraSure Technologies Praises New Routine HIV Screening Recommendations by U.S. Preventive Services Task Force
New Recommendations Advocate HIV Screening as Part of Routine Medical Care for All People Ages 15 to 65 BETHLEHEM, Pa., Nov. 21, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today its support for the draft recommendations issued yesterday by the U.S. Preventive Services Task Force (USPSTF), calling for routine HIV testing for all people ages 15 to 65. The new recommendations, entitled Screening for HIV: , are a significant expansion of the USPSTF's previous recom... 
Printer Friendly Version
11/07/12OraSure Announces 2012 Third Quarter Financial Results
BETHLEHEM, Pa., Nov. 7, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the third quarter and nine months ended September 30, 2012. Quarterly Highlights Consolidated revenues were $22.1 million for the third quarter of 2012, a 2% increase from the comparable quarter of 2011. Revenues for the current quarter included $3.3 million from the Company's molecular collection ... 
Printer Friendly Version
11/07/12DNA Genotek Inc. Launches GenoFIND(TM) Genomic Services
... 
Printer Friendly Version
11/07/12OraSure Technologies to Present at the Stephens, Inc. Fall Investment Conference
BETHLEHEM, Pa., Nov. 7, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Stephens Fall Investment Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak November 14, 2012, at approximately 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time). Interested investors can access the audio webcast of the pres... 
Printer Friendly Version
11/05/12OraQuick(R) In-Home HIV Test Named a "Best Invention of 2012" by TIME Magazine
First and Only In-Home Rapid Oral HIV Test Recognized as a Top Innovation of the Year BETHLEHEM, Pa., Nov. 5, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the company's OraQuick, the first ever in-home rapid infectious disease test made available directly to consumers, has been named one of the "Best Inventions of 2012" by TIME. The OraQuick® In-Home HIV Test is the only health innovation included on this prestigious list for 2012. "With just a swab of sali... 
Printer Friendly Version
10/25/12OraSure Technologies Earnings Conference Call Invitation
2012 Third Quarter Earnings Conference Call Wednesday, November 7, 2012, 5:00 p.m. ET BETHLEHEM, Pa., Oct. 25, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2012 third quarter financial results and certain 2012 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, November 7, 2012. An update on certain business developments will also be provided. November 7, 2012 Schedule     4:00 p.... 
Printer Friendly Version
10/15/12OraSure Technologies Joins With Actress/Model Dayana Mendoza and the Latino Commission on AIDS to Promote the OraQuick(R) In-Home HIV Test for National Latino AIDS Awareness Day
OraQuick® In-Home HIV Test Now Available in Retail Stores Nationwide Press Conference at New York City Hall Monday, October 15 @ 10:00 AM BETHLEHEM, Pa., Oct. 15, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that it will join with actress/model and former Miss Universe Dayana Mendoza and the Latino Commission on AIDS to promote the OraQuick® In-Home HIV test and the importance of knowing your HIV status for National Latino AIDS Awareness Day, taking place ... 
Printer Friendly Version
10/09/12First and Only In-Home Rapid Oral HIV Test Now Available to Consumers Across the U.S.
A Major Breakthrough in the Fight Against HIV – the OraQuick® In-Home HIV Test Now Can Be Purchased at Retailers Nationwide and Online BETHLEHEM, Pa., Oct. 9, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the availability of the OraQuick® In-Home HIV Test at retailers nationwide and online, making it the first rapid infectious disease test ever to be made available directly to consumers for in-home use. To mark the launch, the Company is collaborating w... 
Printer Friendly Version
09/11/12OraSure Technologies to Participate at the UBS Global Life Sciences Conference
BETHLEHEM, Pa., Sept. 11, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the UBS Global Life Sciences Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak September 19, 2012, at approximately 9:30 am Eastern Time (6:30 am Pacific Time). Interested investors can access the live webca... 
Printer Friendly Version
09/05/12OraSure Technologies to Present at ThinkEquity's Ninth Annual Growth Conference
BETHLEHEM, Pa., Sept. 5, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at ThinkEquity's Ninth Annual Growth Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak September 12, 2012, at approximately 2:00 pm Eastern Time (11:00 am Pacific Time). Interested investors can access the live webcast of the pr... 
Printer Friendly Version
08/22/12OraSure Technologies Announces 2013 Annual Meeting Date
BETHLEHEM, Pa., Aug. 22, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2013 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 14, 2013. Further details regarding the meeting will be provided at a later date. About OraSure Technologies OraSure Technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critica... 
Printer Friendly Version
08/16/12OraSure Technologies Applauds New CDC Recommendations That All Baby Boomers be Tested for Hepatitis C
Rapid HCV Testing Expected to Play Critical Role in Implementation of Recommendations BETHLEHEM, Pa., Aug. 16, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its enthusiastic support for the expanded hepatitis C testing recommendations issued by the Centers for Disease Control and Prevention (CDC), urging that all U.S. baby boomers get a one-time test for the hepatitis C virus (HCV). Recommendations for the Identi... 
Printer Friendly Version
08/08/12OraSure Technologies to Present at Canaccord|Genuity's 32nd Annual Growth Conference
BETHLEHEM, Pa., Aug. 8, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Canaccord|Genuity's 32nd Annual Growth Conference in Boston, MA. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak August 15, 2012, at approximately 11:30 am Eastern Time (8:30 am Pacific Time). Interested investors can access the live webcast of the pres... 
Printer Friendly Version
08/07/12OraSure Announces 2012 Second Quarter Financial Results
BETHLEHEM, Pa., Aug. 7, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the second quarter and six months ended June 30, 2012. Financial Highlights Consolidated revenues were $22.6 million for the second quarter of 2012, a 19% increase from the comparable quarter of 2011. Revenues for the current quarter included $3.3 million in revenues from the Company's molecular di... 
Printer Friendly Version
08/02/12DNA Genotek Inc. and BioServe Biotechnologies, Ltd. to Support Genetic Study of Craniofacial Anomalies in Ethiopia
OTTAWA, ON, August 2, 2012. DNA Genotek, a subsidiary of OraSure Technologies Inc. and a leading provider of products for biological sample collection, and BioServe Biotechnologies, Ltd today announced that they are jointly providing support for a new genomic study into craniofacial anomalies (cleft lip and palate) in Ethiopia. The project, titled "Collaborative study on gene- environment interaction in craniofacial anomalies", will investigate the genetic and environmental causes of craniofacia... 
Printer Friendly Version
07/26/12OraSure Technologies Supports Rapid HCV Testing Initiatives for World Hepatitis Day
BETHLEHEM, Pa., July 26, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its support of numerous rapid hepatitis C (HCV) testing initiatives for World Hepatitis Day, taking place on July 28, 2012. These testing initiatives will occur in various cities in the U.S., including Chicago, New York, and Washington, D.C., and in several foreign countries, to help encourage thousands of people to get tested for hepatitis C. O... 
Printer Friendly Version
07/25/12OraSure Technologies Earnings Conference Call Invitation
2012 Second Quarter Earnings Conference Call Tuesday, August 7, 2012, 5:00 p.m. ET BETHLEHEM, Pa., July 25, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2012 second quarter financial results and certain 2012 financial guidance for 5:00 pm ET (2:00 pm PT) on Tuesday, August 7, 2012. An update on certain business developments will also be provided. August 7, 2012 Schedule     4:00 p.m. ET 2... 
Printer Friendly Version
07/16/12OraSure Technologies, Inc. Announces Closing of Underwritten Offering of Common Stock
BETHLEHEM, Pa., July 16, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the closing of its previously announced public offering of common stock. As a result, the Company issued a total of 6,100,000 shares in the offering at a price of $12.30 per share. After the underwriting discounts and estimated offering expenses, OraSure received net proceeds of approximately $70.2 million. Citigroup and Jefferies served as joint book-running managers and Canaccord Genuity... 
Printer Friendly Version
07/10/12OraSure Technologies, Inc. Prices Underwritten Offering of Common Stock
BETHLEHEM, Pa., July 10, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the pricing of an underwritten offering of 6,100,000 shares of its common stock at a price of $12.30 per share. After the underwriting discount and estimated offering expenses, OraSure expects to receive net proceeds of approximately $70.2 million. In addition, OraSure has granted the underwriters a 30-day option to purchase up to an additional 915,000 shares of its common stock. The offeri... 
Printer Friendly Version
07/09/12OraSure Technologies, Inc. Announces Proposed Public Offering of Common Stock
BETHLEHEM, Pa., July 9, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced it has commenced an underwritten public offering of its common stock in an amount of up to $75.0 million. Citigroup and Jefferies are acting as joint book-running managers. Canaccord Genuity, Stephens Inc., ThinkEquity LLC and JMP Securities are acting as co-managers. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common sto... 
Printer Friendly Version
07/09/12OraSure Technologies to Present at the Seventh Annual JMP Securities Healthcare Conference
BETHLEHEM, Pa., July 9, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Seventh Annual JMP Securities Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak July 13, 2012, at approximately 9:00 am Eastern Time (6:00 am Pacific Time). Interested investors can access the live webcast of the p... 
Printer Friendly Version
07/03/12OraSure Technologies Conference Call Invitation
BETHLEHEM, Pa., July 3, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that it will hold a conference call covering the recent U.S. Food and Drug Administration approval of the OraQuick® In-Home HIV Test and the Company's plans to commercialize this product, at 8:00 am ET (5:00 am PT) on Thursday, July 5, 2012. To participate in the conference call, dial 877-348-9357 (Domestic) or 970-315-0488 (International) and reference Conference ID #98134091. The confe... 
Printer Friendly Version
07/03/12OraSure Receives FDA Approval of OraQuick(R) In-Home HIV Test
First and Only Rapid HIV Test for Over the Counter Use --- To be Available in October for Purchase Online and at Retail Stores Nationwide BETHLEHEM, Pa., July 3, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's OraQuick® In-Home HIV Test for sale directly to consumers in the over-the-counter (OTC) market – making it the first and only rapid OTC HIV test approved in the U.S. The OraQuick®... 
Printer Friendly Version
06/27/12OraSure Supports Rapid HIV Testing Initiatives in Recognition of 18th Annual National HIV Testing Day
Company Joins Public Health Departments, Community-Based Organizations and Hospitals to Encourage People to Get Tested for HIV BETHLEHEM, Pa., June 27, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its support of various rapid HIV testing initiatives in recognition of National HIV Testing Day, held each year on June 27th. National HIV Testing Day was founded by the National Association of People with AIDS (NAPWA) ... 
Printer Friendly Version
06/01/12DNA Genotek’s Oragene®DNA kit chosen by ScotlandsDNA for ancestry testing
... 
Printer Friendly Version
05/29/12OraSure Technologies to Present at Jefferies 2012 Global Healthcare Conference
BETHLEHEM, Pa., May 29, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Jefferies 2012 Global Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak June 4, 2012, at approximately 8:00 am Eastern Time (5:00 am Pacific Time). Interested investors can access the live webcast of the presentatio... 
Printer Friendly Version
05/18/12OraSure Technologies Applauds CDC Proposed Draft Guidelines for Testing of Baby Boomers for Hepatitis C
Draft Recommendations Call for HCV Testing of All Persons Born Between 1945 and 1965 BETHLEHEM, Pa., May 18, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today issued a statement in strong support of the Center for Disease Control and Prevention (CDC) draft guidelines proposing that all U.S. baby boomers get a one-time test for the hepatitis C virus (HCV). The CDC issued a press release (http://www.cdc.gov/nchhstp/newsroom/HepTestingRecsPressRelease2012.html) earlier today ... 
Printer Friendly Version
05/18/12OraSure Technologies Announces Rapid HCV Testing Initiatives for First National Hepatitis Testing Day
OraQuick(R) HCV Tests to be Deployed in New York City Department of Health "Check Hep C NYC" Campaign BETHLEHEM, Pa., May 18, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced its support of numerous rapid hepatitis C (HCV) testing initiatives for the first National Hepatitis Testing Day, taking place on May 19, 2012. These testing initiatives, happening in more than 20 cities across the country, will help encourage thousands of people across the U.S. to get test... 
Printer Friendly Version
05/15/12OraQuick(R) In-Home HIV Test Receives Unanimous Positive Recommendation From FDA Advisory Committee
BETHLEHEM, Pa., May 15, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that the U.S. Food and Drug Administration (FDA) Blood Products Advisory Committee (BPAC) provided a unanimous positive recommendation for the Company's OraQuick® In-Home HIV Test. The BPAC provides advice to the FDA on issues related to the safety and effectiveness of biological products and medical devices seeking FDA approval. The BPAC voted on two questions posed by FDA: Do the proje... 
Printer Friendly Version
05/08/12OraSure Technologies to Webcast Annual Meeting of Stockholders
BETHLEHEM, Pa., May 8, 2012 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced that it will webcast its 2012 Annual Meeting of Stockholders beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) on Tuesday, May 15, 2012. In order to access the webcast, interested parties should go to OraSure Technologies' web site, www.orasure.com, and click on the Investor Info link at least ten minutes prior to the start of the... 
Printer Friendly Version
05/03/12DNA Genotek Inc. Announces Recipients of the DNA Genotek Grant Program
... 
Printer Friendly Version
05/02/12OraSure Announces 2012 First Quarter Financial Results
BETHLEHEM, Pa., May 2, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the first quarter of 2012. Financial Highlights Consolidated revenues were $20.9 million for the first quarter of 2012, a 20% increase from the comparable quarter of 2011. Revenues for the current quarter included $3.3 million in revenues from the Company's molecular diagnostic collection subsidiary, DNA Geno... 
Printer Friendly Version
04/30/12OraSure Technologies to Present at Deutsche Bank's 37th Annual Health Care Conference
BETHLEHEM, Pa., April 30, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Deutsche Bank's 37th Annual Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak May 7, 2012, at approximately 8:40am Eastern Time (5:40 am Pacific Time). Interested investors can access the live webcast of the... 
Printer Friendly Version
04/18/12OraSure Technologies Earnings Conference Call Invitation
2012 First Quarter Earnings Conference Call Wednesday, May 2, 2012, 5:00 p.m. ET BETHLEHEM, Pa., Apr 18, 2012 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2012 first quarter financial results and certain 2012 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, May 2, 2012. An update on certain business developments will also be provided. May 2, 2012 Schedule ... 
Printer Friendly Version
04/04/12FDA Sets Date for Advisory Committee Review of OraSure Over-the-Counter Rapid HIV Test
Final Phase of Clinical Testing to be Among Agenda Topics for Blood Products Advisory Committee Meeting on May 15th BETHLEHEM, Pa., April 4, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that the U.S. Food and Drug Administration (FDA) Blood Products Advisory Committee (BPAC) will consider the Company's application for the approval of its OraQuick® Rapid HIV-1/2 test for sale in the U.S. consumer or over-the-counter (OTC) market at a meeting scheduled for May... 
Printer Friendly Version
03/28/12OraSure Technologies to Present at the 11th Annual Needham Healthcare Conference
BETHLEHEM, Pa., March 28, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President & CEO, will speak to the investment community at the 11th Annual Needham Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak April 4, 2012, at approximately 10:40 am Eastern Time (7:40 am Pacific Time). Interested investors can access the live webcast of the pre... 
Printer Friendly Version
02/27/12OraSure Technologies to Present at the Cowen & Co. 32nd Annual Health Care Conference
BETHLEHEM, Pa., Feb. 27, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Co. 32nd Annual Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak March 5, 2012, at approximately 1:30 pm Eastern Time (10:30 am Pacific Time). Interested investors can access the live webc... 
Printer Friendly Version
02/22/12OraSure Technologies to Present at the 2012 RBC Capital Markets' Healthcare Conference
BETHLEHEM, Pa., Feb. 22, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Ronald H. Spair, COO & CFO, will speak to the investment community at the 2012 RBC Capital Markets Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Spair is scheduled to speak February 29, 2012, at approximately 3:30pm Eastern Time (12:30 pm Pacific Time). Interested investors can access the live webcast of the present... 
Printer Friendly Version
02/21/12OraSure Technologies to Present at the 2012 Citi Global Healthcare Conference
BETHLEHEM, Pa., Feb. 21, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2012 Citi Global Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak February 28, 2012, at approximately 10:00 am Eastern Time (7:00 am Pacific Time). Interested investors can access the live webcast of the prese... 
Printer Friendly Version
02/08/12OraSure Announces Fourth Quarter and Full-Year 2011 Financial Results
Company Reports Record Quarterly Revenues BETHLEHEM, Pa., Feb. 8, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the fourth quarter and full year of 2011. Financial Highlights Consolidated revenues were $23.7 million for the fourth quarter of 2011, a 26% increase from the comparable quarter of 2010. Revenues for the current quarter included $19.5 million from OraSure operati... 
Printer Friendly Version
01/26/12OraSure Technologies Earnings Conference Call Invitation
2011 Fourth Quarter Earnings Conference Call Wednesday, February 8, 2012, 5:00 p.m. ET BETHLEHEM, Pa., Jan. 26, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2011 fourth quarter financial results and certain 2012 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, February 8, 2012. An update on certain business developments will also be provided.February 8, 2012 Schedule   ... 
Printer Friendly Version
01/06/12OraSure Technologies to Participate at the Fourteenth Annual Needham Growth Conference
BETHLEHEM, Pa., Jan. 6, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Fourteenth Annual Needham Growth Conference in New York at approximately 8:00 am Eastern Time (5:00 am Pacific Time) on Wednesday, January 11, 2012. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audio webcast of the discuss... 
Printer Friendly Version
01/03/12OraSure Makes Final FDA Submission for Approval of Over-the-Counter Rapid HIV Test
BETHLEHEM, Pa., Jan 3, 2012 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in rapid point-of-care infectious disease diagnostics and biological sample collection, stabilization and preparation products, announced today that it has submitted the final of three modules in its application to the U. S. Food and Drug Administration (FDA) for the approval of the Company's OraQuick(R) Rapid HIV-1/2 test for sale in the U.S. consumer or over-the-counter (OTC) mark... 
Printer Friendly Version
12/08/11Photo Release -- OraSure Technologies Subsidiary, DNA Genotek Receives FDA 510(k) Clearance for Oragene(R) Dx Collection Device
First Saliva DNA Collection and Stabilization Device to Receive 510(k) Clearance OTTAWA, Dec. 8, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies', Inc. (Nasdaq:OSUR) subsidiary, DNA Genotek, a leading provider of products for biological sample collection, stabilization and preparation, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for DNA Genotek's Oragene•Dx collection device. Oragene•Dx is the first and only saliva DNA collection and stabilization... 
Printer Friendly Version
11/29/11OraSure Technologies Receives CLIA Waiver for OraQuick(R) HCV Rapid Test
BETHLEHEM, Pa., Nov. 29, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that the U.S. Food and Drug Administration ("FDA") has granted a waiver under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") for its OraQuick® HCV Rapid Antibody Test for use with fingerstick whole blood and venous whole blood specimens. The OraQuick® HCV Rapid Antibody Test is the first and only FDA-approved rapid test for the detection of antibodies to the hepatitis C... 
Printer Friendly Version
11/10/11OraSure Technologies Appoints Veteran Consumer Products Executive to Its Board of Directors
BETHLEHEM, Pa., Nov 10, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the appointment of Gerald M. Ostrov as a member of the Company's Board of Directors. Mr. Ostrov will serve as a Class I Director with an initial term expiring in 2013. "We are very pleased to welcome Gerald Ostrov, a highly successful and seasoned healthcare executive, to our Board of Directors," said Douglas G. Watson, Chairman of the Board of OraSure Technologies. "Jerry has... 
Printer Friendly Version
11/09/11OraSure Technologies to Present at the Stephens, Inc. Fall Investment Conference
BETHLEHEM, Pa, Nov 9, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Stephens Fall Investment Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak November 16, 2011, at approximately 10:00am Eastern Time (7:00am Pacific Time). Interested investors can access the live webcast of the pr... 
Printer Friendly Version
11/02/11OraSure Announces 2011 Third Quarter Consolidated Financial Results
BETHLEHEM, Pa., Nov 2, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the third quarter of 2011. Quarterly Highlights -- The Company completed the acquisition of DNA Genotek Inc. ("DNAG") on August 17, 2011. -- Consolidated revenues totaled $21.7 million for the quarter, a 14% increase from the comparable period of 2010. Revenues included $19.7... 
Printer Friendly Version
11/01/11OraSure Applauds American Academy of Pediatrics Updated Recommendations for Routine HIV Screening for Adolescents
BETHLEHEM, Pa., Nov 1, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today issued a statement in support of updated recommendations issued by the American Academy of Pediatrics ("AAP") on HIV screening for adolescents. These recommendations, which advocate regular, routine HIV screening for all adolescents 16 to 18 years of age in healthcare settings when the prevalence of HIV in the patient population is more than 0.1%, were included in a policy statement entitled... 
Printer Friendly Version
10/19/11OraSure Technologies Earnings Conference Call Invitation
2011 Third Quarter Earnings Conference Call Wednesday, November 2, 2011, 5:00 p.m. ET BETHLEHEM, Pa., Oct 19, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2011 third quarter financial results and certain 2011 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, November 2, 2011. An update on certain business developments will also be provided. Nove... 
Printer Friendly Version
10/11/11DNA Genotek Launches Grant Program Aimed at Cancer, Personalized Medicine and Infectious Disease Research
FOR IMMEDIATE RELEASE OTTAWA, ON, October 11, 2011. DNA Genotek, a leading provider of products for biological sample collection, stabilization and preparation, today launched a grant program that encompasses three primary areas of focus – cancer, personalized medicine and infectious disease. The DNA Genotek Grant Program invites research proposals that showcase innovative and novel use of the company's saliva-based collection and... 
Printer Friendly Version
09/21/11OraSure Technologies to Participate at the Sixth Annual JMP Securities Healthcare Conference
BETHLEHEM, Pa., Sep 21, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Sixth Annual JMP Securities Healthcare Conference in New York City at approximately 10:00am Eastern Time (7:00am Pacific Time) on Tuesday, September 27, 2011. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audi... 
Printer Friendly Version
09/13/11OraSure Technologies to Participate at the UBS Global Life Sciences Conference
BETHLEHEM, Penn., Sep 13, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the UBS Global Life Sciences Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak September 19, 2011, at approximately 8:00 am Eastern Time (5:00 am Pacific Time). Interested investors can access ... 
Printer Friendly Version
09/06/11OraSure Technologies Announces 2012 Annual Meeting Date
BETHLEHEM, Pa., Sep 6, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2012 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 15, 2012. Further details regarding the meeting will be provided at a later date. About OraSure Technologies OraSure Technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose ... 
Printer Friendly Version
09/01/11OraSure Technologies to Participate at the William Blair 2011 Life Sciences Conference
BETHLEHEM, Pa., Sep 1, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Dr. Stephen R. Lee, Chief Science Officer & EVP R&D, will participate on a panel at the William Blair 2011 Life Sciences Conference in New York City. The panel discussion will be simultaneously webcast over the Internet. Dr. Lee is scheduled to participate on the Hepatitis C Value Chain panel September 7, 2011, at approximately 3:20 pm Eastern Time (12:20 pm Pacifi... 
Printer Friendly Version
08/18/11OraSure Technologies Announces Closing of DNA Genotek Acquisition
BETHLEHEM, Pa., Aug 18, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that it has completed its previously-announced acquisition of DNA Genotek Inc., a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, for 50 million Canadian dollars in cash (approximately US $50.7 million at current exchange rates). The acquisition was funded by OraSure with cash on hand. The acquisiti... 
Printer Friendly Version
08/09/11OraSure Closes Enrollment in Final Clinical Study for Rapid HIV Over-the-Counter Test
BETHLEHEM, Pa., Aug 9, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it has closed enrollment for its multi-site clinical study of the Company's OraQuick(R) Rapid HIV-1/2 test for sale in the U.S. consumer or over-the-counter (OTC) market. As previously announced, OraSure initiated the final phase of clinical testing for an in-home HIV self-test kit in December 2010. This phase consists of a mul... 
Printer Friendly Version
08/03/11OraSure Announces 2011 Second Quarter Financial Results
BETHLEHEM, Pa., Aug 3, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced total revenues of $19.1 million for the three months ended June 30, 2011, compared to $19.2 million recorded for the three months ended June 30, 2010. Product revenues for the current quarter increased 6% as higher sales of the Company's infectious disease and substance abuse testing products were partially offset by lower sales of it... 
Printer Friendly Version
08/03/11OraSure Technologies to Present at Canaccord Genuity's 31st Annual Growth Conference
BETHLEHEM, Pa., Aug 3, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Canaccord|Genuity's 31st Annual Growth Conference in Boston, MA. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak August 9, 2011, at approximately 1:00 pm Eastern Time (10:00 am Pacific Time). Interested investors can access the live webcast of ... 
Printer Friendly Version
07/25/11OraSure Technologies to Acquire DNA Genotek Inc.; Acquisition Provides Entry Into Rapidly Growing Molecular Diagnostics Market and Strengthens Company's Leadership in Oral Fluid Diagnostics
BETHLEHEM, Pa., Jul 25, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that it will acquire privately-held DNA Genotek Inc., a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, for approximately US $53 million in cash, subject to certain adjustments. The transaction is anticipated to close in the third quarter of this year. DNA Genotek generated approximately US $14.0 milli... 
Printer Friendly Version
07/20/11OraSure Technologies Earnings Conference Call Invitation
2011 Second Quarter Earnings Conference Call Wednesday, August 3, 2011, 5:00 p.m. ET BETHLEHEM, Pa., Jul 20, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2011 second quarter financial results and certain 2011 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, August 3, 2011. An update on certain business developments will also be provided. August 3, 2... 
Printer Friendly Version
06/27/11OraSure Technologies Supports 17th Annual National HIV Testing Day
Thousands of People to be Tested With OraQuick ADVANCE(R) Rapid HIV Test BETHLEHEM, Pa., Jun 27, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its support of numerous rapid HIV testing initiatives in recognition of National HIV Testing Day, held annually on June 27th. Now in its 17th year, National HIV Testing Day is an annual event led by the National Association of People with AIDS (NAPWA) to encoura... 
Printer Friendly Version
06/02/11OraSure Technologies to Present at Jefferies 2011 Global Healthcare Conference
BETHLEHEM, Pa., Jun 2, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Jefferies 2011 Global Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak June 6, 2011, at approximately 11:30 am Eastern Time (8:30 am Pacific Time). Interested investors can access the live webcast of the p... 
Printer Friendly Version
05/19/11OraSure Technologies to Present At ThinkEquity's 2nd Annual Healthcare Conference
BETHLEHEM, Pa., May 19, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at ThinkEquity's 2nd Annual Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak May 25, 2011, at approximately 12:00 pm Eastern Time (9:00 am Pacific Time). Interested investors can access the live webcast of t... 
Printer Friendly Version
05/10/11OraSure Technologies to Webcast Annual Meeting of Stockholders
BETHLEHEM, Pa., May 10, 2011 (GlobeNewswire via COMTEX) -- The webcast will include the formal portion of the meeting and a presentation by the Company's President and CEO, Douglas A. Michels. In order to access the webcast, interested parties should go to OraSure Technologies' web site, www.orasure.com, and click on the Investor Info link at least ten minutes prior to the start of the webcast to register, download and install any necessary software. A replay of the webcast will be archiv... 
Printer Friendly Version
05/04/11OraSure Announces 2011 First Quarter Financial Results
BETHLEHEM, Pa., May 4, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR), a market leader in oral fluid diagnostics, today announced total revenues of $17.4 million for the three months ended March 31, 2011, compared to $17.9 million recorded for the three months ended March 31, 2010. Product revenues for the quarter increased 3% as higher sales of the Company's infectious disease and substance abuse testing products were partially offset by lower sales of its cryosurgical sys... 
Printer Friendly Version
04/25/11OraSure Technologies to Present at Deutsche Bank's 36th Annual Health Care Conference
BETHLEHEM, Pa., Apr 25, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Deutsche Bank's 36th Annual Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak May 2, 2011, at approximately 11:20 am Eastern Time (8:20 am Pacific Time). Interested investors can access the l... 
Printer Friendly Version
04/20/11OraSure Technologies Earnings Conference Call Invitation
2011 First Quarter Earnings Conference Call Wednesday, May 4, 2011, 5:00 p.m. ET BETHLEHEM, Pa., Apr 20, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2011 first quarter financial results and certain 2011 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, May 4, 2011. An update on certain business developments will also be provided. May 4, 2011 Schedule... 
Printer Friendly Version
04/07/11OraSure Technologies Appoints Stephen S. Tang, Ph.D. to Its Board of Directors
BETHLEHEM, Pa., Apr 7, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), today announced the appointment of Stephen S. Tang, Ph.D. as a member of the Company's Board of Directors. Dr. Tang will serve as a Class I Director with an initial term expiring at the Company's 2013 Annual Meeting of Stockholders. "I am very pleased to welcome Stephen Tang, a seasoned healthcare executive, to our Board of Directors," said Douglas G. Watson, Chairman of the Board of OraSure T... 
Printer Friendly Version
03/28/11OraSure Technologies to Present at the 10th Annual Needham Healthcare Conference
BETHLEHEM, Pa., Mar 28, 2011 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President & CEO, will speak to the investment community at the 10th Annual Needham Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak April 5, 2011, at approximately 9:20 am Eastern Time (6:20 am Pacific Time). Interested investors can access the live webcast of ... 
Printer Friendly Version
03/23/11OraSure Technologies Submits CLIA Waiver Application for OraQuick(R) HCV Rapid Test
BETHLEHEM, Pa., Mar 23, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that it has submitted to the U.S. Food and Drug Administration ("FDA") an application for a waiver under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") for its OraQuick(R) HCV Rapid Antibody Test for use with venous whole blood and fingerstick whole blood specimens. The OraQuick(R) HCV Rapid Antibody Test is the first and only FDA-approved rapid test for the d... 
Printer Friendly Version
03/04/11OraSure Technologies to Present at the Roth 23rd Annual OC Growth Stock Conference
BETHLEHEM, Pa., Mar 4, 2011 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Ronald H. Spair, COO & CFO, will speak to the investment community at the Roth 23rd Annual OC Growth Stock Conference in Dana Point, California. The conference will be simultaneously webcast over the Internet. Mr. Spair is scheduled to speak March 14, 2011, at approximately 6:30 pm Eastern Time (3:30 pm Pacific Time). Interested investors can access the live webcast of ... 
Printer Friendly Version
03/03/11OraSure Technologies and Roche Announce FDA 510(k) Clearance for Four Fully Automated Oral Fluid Drugs of Abuse Assays
PCP, Cocaine, Opiates and Methamphetamine Assays to be Used Exclusively as Part of OraSure's Intercept(R) Oral Fluid Drug Testing System BETHLEHEM, Pa., Mar 3, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) and Roche announced today that the U.S. Food and Drug Administration ("FDA") has granted the Companies 510(k) clearance on four homogeneous fully automated oral fluid drugs of abuse assays developed to be used exclusively as part of OraSure's Intercept(R) Oral F... 
Printer Friendly Version
03/01/11OraSure Technologies to Present at the Cowen & Co. Health Care Conference
BETHLEHEM, Pa., Mar 1, 2011 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Co. Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak March 7, 2011, at approximately 4:00 pm Eastern Time (1:00 pm Pacific Time). Interested investors can access the live webcast o... 
Printer Friendly Version
02/28/11OraSure Technologies to Present at the 2011 RBC Capital Markets Healthcare Conference
BETHLEHEM, Pa., Feb 28, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2011 RBC Capital Markets Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak March 3, 2011, at approximately 10:30am Eastern Time (7:30 am Pacific Time). Interested investors can access the live webcast... 
Printer Friendly Version
02/24/11OraSure Technologies to Present at the 2011 Citi Global Healthcare Conference
BETHLEHEM, Pa., Feb 24, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2011 Citi Global Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak March 1, 2011, at approximately 10:00 am Eastern Time (7:00 am Pacific Time). Interested investors can access the live webcast of the... 
Printer Friendly Version
02/22/11OraSure Technologies Receives FDA Approval for Its OraQuick(R) HCV Rapid Test Using Fingerstick Whole Blood
BETHLEHEM, Pa., Feb 22, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that its OraQuick(R) HCV Rapid Antibody Test has now been approved by the U.S. Food and Drug Administration ("FDA") for use in detecting HCV antibodies with a fingerstick whole blood sample. The fingerstick whole blood claim is the second application to be approved by the FDA for the OraQuick(R) HCV test. The product received an initial approval for use in persons at risk for HCV ... 
Printer Friendly Version
02/09/11OraSure Announces Fourth Quarter and Full Year 2010 Financial Results
BETHLEHEM, Pa., Feb 9, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $75.0 million and $18.8 million for the year and quarter ended December 31, 2010, respectively. This compares to revenues of $77.0 million and $20.9 million for the year and quarter ended December 31, 2009. The Company recorded a net loss of $3.5 million, or $0.08 per share, and $1.0 million, or $0.02 per share, for the ye... 
Printer Friendly Version
01/31/11OraSure Technologies Earnings Conference Call Invitation
2010 Fourth Quarter and Full Year Earnings Conference Call Wednesday, February 9, 2011, 5:00 p.m. ET BETHLEHEM, Pa., Jan 31, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2010 fourth quarter and full-year financial results and certain 2011 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, February 9, 2011. An update on certain business developments will also be provided. ... 
Printer Friendly Version
01/26/11Oral Fluid Drug Testing Reveals More Heroin Use
BETHLEHEM, Pa., Jan 26, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that Quest Diagnostics Incorporated (NYSE:DGX) released new data indicating that oral fluid revealed approximately five times more heroin use in the general U.S. workforce than previously believed. In the Quest Diagnostics Drug Testing Index special report, with more than 320,000 oral-fluid samples analyzed from the general U.S. wor... 
Printer Friendly Version
01/11/11OraSure Technologies to Launch OraSure QuickFlu(TM) Rapid Flu A+B Test
Test Provides Accurate Rapid Differential Diagnosis for Influenza Virus Type A and Type B BETHLEHEM, Pa., Jan 11, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today the impending launch of the OraSure QuickFlu(TM) Rapid Flu A+B Test, a U.S. Food and Drug and Administration ("FDA") approved in vitro rapid qualitative test for the detection of influenza (flu) type A and type B, including H1N1 viral infections. The test specimen is collected with a nasal ... 
Printer Friendly Version
01/07/11OraSure Technologies to Participate at the Thirteenth Annual Needham Growth Conference
BETHLEHEM, Pa., Jan 7, 2011 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Thirteenth Annual Needham Growth Conference in New York at approximately 10:40 am Eastern Time (7:40 am Pacific Time) on Tuesday, January 11, 2011. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audio webcast of t... 
Printer Friendly Version
01/04/11Accomplished Sales and Marketing Executive Joins OraSure Technologies Management Team
BETHLEHEM, Pa., Jan 4, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that Tony Zezzo has joined the Company as its new Executive Vice President, Marketing and Sales, effective January 3, 2011. In this position, Zezzo will have overall responsibility for the Company's global marketing and sales operations, which includes the domestic and international sales teams for our infectious disease and substance abuse businesses, marketing, and client ser... 
Printer Friendly Version
12/13/10OraSure Initiates Enrollment in Final Clinical Study for OraQuick(R) Rapid HIV Over-the-Counter Test
FDA Approves 24-Month Shelf Life for OraQuick ADVANCE(R) Rapid HIV-1/2 Test BETHLEHEM, Pa., Dec 13, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it has enrolled the first subject in its final phase of clinical studies for United States Food and Drug Administration ("FDA") approval of the Company's OraQuick(R) Rapid HIV-1/2 test for sale in the U.S. consumer or over-the-counter ("OTC") market. ... 
Printer Friendly Version
12/02/10OraSure Technologies Announces 2011 Annual Meeting Date
BETHLEHEM, Pa., Dec 2, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2011 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 17, 2011. A location for the meeting will be announced at a later date. About OraSure Technologies OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in ... 
Printer Friendly Version
12/01/10OraSure Technologies Supports Rapid HIV Testing Initiatives for World AIDS Day
OraSure to Preside Over NASDAQ Market Open on December 1 BETHLEHEM, Pa., Dec 1, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its support of more than 150 rapid HIV testing initiatives taking place in more than 25 states in the U.S. and numerous countries globally, in recognition of World AIDS Day, commemorated annually on December 1st. OraSure's support of these initiatives, taking place in Africa, Asi... 
Printer Friendly Version
11/22/10OraSure Technologies Receives FDA Approval to Conduct Final Phase of Clinical Studies for OraQuick(R) Over-the-Counter HIV Test
BETHLEHEM, Pa., Nov 22, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that the U.S. Food and Drug Administration ("FDA") has granted an investigational device exemption (IDE) for the Company to conduct the final phase of clinical testing for FDA approval of its OraQuick(R) Rapid HIV-1/2 Antibody Test for sale in the consumer or over-the-counter ("OTC") market. Receipt of the IDE allows the Company to... 
Printer Friendly Version
11/17/10Photo Release -- OraSure Technologies Receives Popular Science "Best of What's New" Award for OraQuick(R) HCV Rapid Antibody Test
OraQuick(R) HCV Rapid Antibody Test Named One of the Top 100 Technical Innovations of the Year BETHLEHEM, Pa., Nov 17, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that the editors of Popular Science have named the OraQuick(R) HCV Rapid Antibody Test one of the top technology innovations of 2010. As a winner of a "Best of What's New" Award, the OraQuick HCV Rapid Antibody Test was recognized for its t... 
Printer Friendly Version
11/10/10OraSure Technologies to Participate at the Stephens Fall Investment Conference
BETHLEHEM, Pa., Nov 10, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Stephens Fall Investment Conference in New York City at approximately 10:30am Eastern Time, (7:30am Pacific Time) on Wednesday, November 17, 2010. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audio webcast of... 
Printer Friendly Version
11/09/10OraSure Announces 2010 Third Quarter Financial Results
BETHLEHEM, Pa., Nov 9, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $19.0 million for the three months ended September 30, 2010, compared to $21.6 million recorded for the three months ended September 30, 2009. Revenues in the third quarter of 2009 were higher primarily because they included the elimination of a $2.2 million backlog for OraQuick(R) HIV orders which existed at June 30, 2009. R... 
Printer Friendly Version
10/27/10OraSure Technologies Earnings Conference Call Invitation
2010 Third Quarter Earnings Conference Call Tuesday, November 9, 2010, 5:00 p.m. ET BETHLEHEM, Pa., Oct 27, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2010 third quarter financial results and certain 2010 financial guidance for 5:00 pm ET (2:00 pm PT) on Tuesday, November 9, 2010. An update on certain business developments will also be provided. November 9, 2010 Schedule ... 
Printer Friendly Version
09/22/10OraSure Technologies to Participate at the Fifth Annual JMP Securities Healthcare Conference
BETHLEHEM, Pa., Sep 22, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Fifth Annual JMP Securities Healthcare Conference in New York City at approximately 3:30pm Eastern Time, (12:30pm Pacific Time) on Tuesday, September 28, 2010. The conference will be simultaneously webcast over the Internet. Interested investors can access the live aud... 
Printer Friendly Version
09/14/10OraSure Technologies to Participate at the UBS Global Life Sciences Conference
BETHLEHEM, Pa., Sep 14, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the UBS Global Life Sciences Conference in New York City at approximately 4:00pm Eastern Time, (1:00pm Pacific Time) on Monday, September 20, 2010. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audio webcast of th... 
Printer Friendly Version
08/05/10OraSure Technologies to Participate at the Canaccord Adams 30th Annual Global Growth Conference
BETHLEHEM, Pa., Aug 5, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Canaccord Adams 30th Annual Global Growth Conference in Boston at approximately 4:30 pm Eastern Time (1:30 pm Pacific Time) on Wednesday, August 11, 2010. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audio web... 
Printer Friendly Version
08/04/10OraSure Announces 2010 Second Quarter Financial Results
OraSure Also Provides Update on OraQuick(R) HIV Shelf Life Extension and OraQuick(R) HCV Clinical Program BETHLEHEM, Pa., Aug 4, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $19.2 million for the three months ended June 30, 2010, compared to $17.3 million recorded for the three months ended June 30, 2009. Revenues in the current quarter reflect increases for each of the Company's product... 
Printer Friendly Version
08/03/10OraSure Technologies to Participate at the BMO Capital Markets 10th Annual Focus on Healthcare Conference
BETHLEHEM, Pa., Aug 3, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the BMO Capital Markets 10th Annual Focus on Healthcare Conference in New York at approximately 4:00 pm Eastern Time (1:00 pm Pacific Time) on Thursday, August 5, 2010. The conference will be simultaneously webcast over the Internet. Interested investors can access the live... 
Printer Friendly Version
07/21/10OraSure Technologies Earnings Conference Call Invitation
2010 Second Quarter Earnings Conference Call Wednesday, August 4, 2010, 5:00 p.m. ET BETHLEHEM, Pa., Jul 21, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2010 second quarter financial results and certain 2010 financial guidance for 5:00 pm ET (2:00 p.m. PT) on Wednesday, August 4, 2010. An update on certain business developments will also be provided. August 4, 2010 Schedule ... 
Printer Friendly Version
06/25/10OraSure Technologies Receives FDA Approval for OraQuick(R) HCV Rapid Test, the First Rapid HCV Test Approved for Sale in the U.S.
BETHLEHEM, Pa., Jun 25, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that its OraQuick(R) Hepatitis C ("HCV") Rapid Antibody Test has been approved by the U.S. Food and Drug Administration ("FDA") for use in detecting HCV antibodies in venous whole blood specimens, making it the first rapid HCV test approved by the FDA for use in the United States. "The OraQuick HCV test efficiently identifies previously undiagnosed HCV infected individuals who are... 
Printer Friendly Version
06/25/10OraSure Technologies and the National Association of People With AIDS Launch Sixth Annual "Mayors Campaign Against HIV(TM)" for National HIV Testing Day
More Than 100 U.S. Mayors Unite to Promote HIV Screening BETHLEHEM, Pa., Jun 25, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) and the National Association of People with AIDS (NAPWA) announced today the launch of the sixth annual Mayors Campaign Against HIV(TM), a national campaign to encourage testing for HIV and promote the benefits of knowing one's HIV status. The Campaign is part of the annual observance of National HIV Testing Day (NHTD) on Sunday, June 27, 2... 
Printer Friendly Version
06/07/10OraSure Technologies to Participate at ThinkEquity's Mid Year Check-Up on Healthcare
BETHLEHEM, Pa., Jun 10, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at ThinkEquity's Mid-Year Check-Up on Healthcare Conference in New York City at approximately 9:30 am Eastern Time (6:30 am Pacific Time) on Wednesday, June 16, 2010. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audio w... 
Printer Friendly Version
06/04/10OraSure Technologies to Participate at Jefferies 2010 Global Life Sciences Conference
BETHLEHEM, Pa., Jun 4, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Jefferies 2010 Global Life Sciences Conference in New York City at approximately 12:15 pm Eastern Time (9:15 am Pacific Time) on Friday, June 11, 2010. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audio webcast of... 
Printer Friendly Version
06/02/10OraSure Technologies to Participate at the Ninth Annual Needham Healthcare Conference
BETHLEHEM, Pa., Jun 2, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Ninth Annual Needham Healthcare Conference in New York at approximately 2:40 pm Eastern Time (11:40 am Pacific Time) on Wednesday, June 9, 2010. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audio webcast of the di... 
Printer Friendly Version
05/05/10OraSure Announces 2010 First Quarter Financial Results
BETHLEHEM, Pa., May 5, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $17.9 million for the three months ended March 31, 2010, compared to $17.3 million recorded for the three months ended March 31, 2009. Increased sales of cryosurgical systems products and higher licensing and product development revenues were partially offset by lower revenues from the Company's infectious disease testing and in... 
Printer Friendly Version
04/21/10OraSure Technologies Earnings Conference Call Invitation
2010 First Quarter Earnings Conference Call Wednesday, May 5, 2010, 5:00 p.m. ET BETHLEHEM, Pa., Apr 21, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2010 first quarter financial results and certain 2010 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, May 5, 2010. An update on certain business developments will also be provided. May 5, 2010 Schedule 4:00 p.m. ... 
Printer Friendly Version
03/03/10OraSure Technologies to Present at the Cowen & Co. Health Care Conference
BETHLEHEM, Pa., Mar 3, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Co. Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak March 9, 2010, at approximately 2:15 pm Eastern Time (11:15 am Pacific Time). Interested investors can access the live webcast of... 
Printer Friendly Version
02/10/10OraSure Announces Fourth Quarter and Full Year 2009 Financial Results
BETHLEHEM, Pa., Feb 10, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $77.0 million and $20.9 million for the year and quarter ended December 31, 2009, respectively. This compares to revenues of $71.1 million and $17.2 million for the year and quarter ended December 31, 2008. The Company recorded a net loss of $7.8 million or $0.17 per share, and $2.8 million or $0.06 per share, on a GAAP1 bas... 
Printer Friendly Version
02/03/10OraSure CEO Appointed to Presidential Advisory Council on HIV/AIDS
BETHLEHEM, Pa., Feb 3, 2010 (GlobeNewswire via COMTEX) -- Douglas A. Michels, President and Chief Executive Officer of OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, was sworn in yesterday by U.S. Health and Human Services Secretary Kathleen Sebelius, as a new member of the Presidential Advisory Council on HIV/AIDS (PACHA). PACHA provides advice, information, and recommendations to the President of the United States through the Secretary of Health and Huma... 
Printer Friendly Version
01/28/10OraSure Technologies Earnings Conference Call Invitation
2009 Fourth Quarter and Full Year Earnings Conference Call Wednesday, February 10, 2010, 5:00 p.m. ETBETHLEHEM, Pa., Jan 28, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2009 fourth quarter and full‑year financial results and certain 2010 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, February 10, 2010. An update on certain business developments will also be provided. ... 
Printer Friendly Version
01/19/10OraSure Technologies and Roche Diagnostics Sign Worldwide Commercialization Agreement for Fully Automated Oral Fluid Drugs of Abuse Assays
BETHLEHEM, Pa., Jan 19, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) and Roche Diagnostics today announced that the companies have signed an agreement for the worldwide commercialization of homogeneous fully automated oral fluid drugs of abuse assays with OraSure's Intercept(R) oral specimen collection device. The oral fluid assays use Roche's KIMS (kinetic interaction of micro-particles in solution) technology and are being jointly developed under an agreement pre... 
Printer Friendly Version
01/07/10OraSure Technologies Files Additional Data With FDA in Support of PMA Application for OraQuick Rapid HCV Test
BETHLEHEM, Pa., Jan 7, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today the recent filing of a pre-market approval ("PMA") amendment with the U.S. Food and Drug Administration ("FDA") for the Company's OraQuick(R) Rapid HCV Antibody Test. The amendment contains additional clinical data requested by the FDA for use of the test in detecting antibodies to the Hepatitis C Virus ("HCV") in venous whole blood samples. When approved for use with venous whole... 
Printer Friendly Version
01/05/10OraSure Technologies to Participate at the Twelfth Annual Needham Growth Conference
BETHLEHEM, Pa., Jan 5, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Twelfth Annual Needham Growth Conference in New York at approximately 10:00 am Eastern Time (7:00 am Pacific Time) on Tuesday, January 12, 2010. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audio webcast of the d... 
Printer Friendly Version
12/15/09OraSure Technologies Receives CE Mark for OraQuick(R) Rapid HCV Antibody Test
First and Only Oral Fluid Rapid HCV Test Bearing a CE Mark BETHLEHEM, Pa., Dec. 15, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that it has received approval to affix the CE mark to its OraQuick(R) Rapid HCV Antibody Test. A CE mark is required to sell this test in the 27 countries that currently make up the European Union. The OraQuick(R) Rapid HCV Antibody Test is the first and only rapid Hepatitis C test bearing a CE mark that can be used with oral fluid... 
Printer Friendly Version
11/19/09OraSure Technologies Announces Settlement of Patent Infringement Lawsuit With Inverness and Church & Dwight
BETHLEHEM, Pa., Nov. 19, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the settlement of the patent infringement lawsuit filed against OraSure by Inverness Medical Innovations, Inc. (NYSE:IMA), Inverness Medical Switzerland GmbH and Church & Dwight, Co., Inc. (NYSE:CHD). Under the settlement, OraSure has agreed to pay Inverness a sum of $3,000,000 in cash and Inverness has agreed to grant OraSure certain licenses to its lateral flow patents. In addition, ... 
Printer Friendly Version
11/18/09OraSure Technologies Participates in BPAC Meeting on HIV Over-the-Counter Test
BETHLEHEM, Pa., Nov. 18, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that it participated in a Blood Products Advisory Committee ("BPAC") meeting held November 17, 2009 in which the BPAC considered, among other topics, the public need and performance characteristics for over-the-counter ("OTC") home use HIV test kits. The BPAC provides advice to the U.S. Food and Drug Administration ("FDA") on issues related to the safety and effectiveness of biological prod... 
Printer Friendly Version
11/04/09OraSure Announces 2009 Third Quarter Financial Results
BETHLEHEM, Pa., Nov. 4, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $21.6 million for the three months ended September 30, 2009, compared to $16.9 million recorded for the three months ended September 30, 2008. The revenue increase for the third quarter reflects double digit growth in sales of the Company's infectious disease testing, cryosurgical systems and insurance risk assessment testing produ... 
Printer Friendly Version
10/22/09OraSure Technologies Earnings Conference Call Invitation
2009 Third Quarter Earnings Conference Call Wednesday, November 4, 2009, 5:00 p.m. ET BETHLEHEM, Pa., Oct. 22, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2009 third quarter financial results and certain 2009 financial guidance for 5:00 p.m. ET (2:00 p.m. PT) on Wednesday, November 4, 2009. An update on certain business developments will also be provided. November 4, 2009 Schedule ... 
Printer Friendly Version
09/24/09OraSure Technologies Awarded Premier Contract for Its OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test
OraQuick ADVANCE(R) Will Also be Offered Through Premier's ASCEND Program BETHLEHEM, Pa., Sep 24, 2009 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that it has been awarded a 36-month contract for its OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test with Premier Purchasing Partners, L.P., the group purchasing unit of Premier, Inc. The new agreement, effective November 1, 2009, provides Premier's more than... 
Printer Friendly Version
09/17/09OraSure Technologies to Participate At the UBS Global Life Sciences Conference
BETHLEHEM, Pa., Sept. 17, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the UBS Global Life Sciences Conference in New York City at approximately 8:30am Eastern Time (5:30am Pacific Time), on Tuesday, September 22, 2009. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audio webcast of the discu... 
Printer Friendly Version
09/10/09OraSure Technologies Appoints Robert A. Gregg, Ph.D. as Vice President, Regulatory Affairs and Quality Assurance
BETHLEHEM, Pa., Sept. 10, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that Robert A. Gregg, Ph.D., has been appointed as the Company's Vice President, Regulatory Affairs and Quality Assurance, effective September 14, 2009. In this capacity, Dr. Gregg will have responsibility for the Company's regulatory, quality assurance and clinical affairs functions. Dr. Gregg will report to Douglas A. Michels, OraSure's ... 
Printer Friendly Version
08/27/09OraSure Technologies Announces 2010 Annual Meeting Date
BETHLEHEM, Pa., Aug. 27, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2010 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 11, 2010. Stockholder proposals must be received no later than December 2, 2009, in order to be considered for inclusion in the Company's Proxy Statement under relevant Securities and Exchange Commission rules and no later than February 11, 2010, in order to be considered at the Annual Meeting or to nominat... 
Printer Friendly Version
08/05/09OraSure Announces 2009 Second Quarter Financial Results and Resumption of Full-Scale OraQuick(r) Production
BETHLEHEM, Pa., Aug. 5, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $17.3 million for the three months ended June 30, 2009, compared to $18.9 million recorded for the three months ended June 30, 2008. The Company also announced the resolution of the previously disclosed manufacturing issue related to its OraQuick(r) rapid HIV-1/2 antibody test and the resumption of full-scale production of that product.... 
Printer Friendly Version
07/27/09OraSure Technologies Earnings Conference Call Invitation
2009 Second Quarter Earnings Conference Call Wednesday, August 5, 2009, 5:00 p.m. ET BETHLEHEM, Pa., July 27, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2009 second quarter financial results and certain 2009 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, August 5, 2009. An update on certain business developments will also be provided. August 5, 2009 Schedule ... 
Printer Friendly Version
06/25/09OraSure Technologies Provides Update on Clinical Development Programs and OraQuick Manufacturing
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jun. 25, 2009-- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced an update regarding the status of its application for U.S. Food and Drug Administration (“FDA”) approval of an OraQuick® Hepatitis C (“HCV”) test for professional use and its clinical program for an OraQuick® HIV-1/2 test for sale in the consumer or over-the-counter (“OTC”) market. In addition, the Company announced its efforts to address ... 
Printer Friendly Version
05/06/09OraSure Announces 2009 First Quarter Financial Results
BETHLEHEM, Pa.--(BUSINESS WIRE)--May. 6, 2009-- OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $17.3 million for the three months ended March 31, 2009, compared to $18.1 million recorded for the three months ended March 31, 2008. Increased sales of the Company’s OraQuick ADVANCE® rapid HIV-1/2 antibody test and insurance risk assessment products during the first quarter 2009 were ... 
Printer Friendly Version
05/04/09OraSure Technologies to Webcast Annual Meeting of Stockholders
BETHLEHEM, Pa.--(BUSINESS WIRE)--May. 4, 2009-- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, announced that it will webcast its 2009 Annual Meeting of Stockholders beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) on Tuesday, May 12, 2009. The webcast will include the formal portion of the meeting and a presentation by the Company’s President and CEO, Douglas A. Michels. In ... 
Printer Friendly Version
04/22/09OraSure Technologies Earnings Conference Call Invitation
2009 First Quarter Earnings Conference Call Wednesday, May 6, 2009, 5:00 p.m. ET BETHLEHEM, Pa.--(BUSINESS WIRE)--Apr. 22, 2009-- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering 2009 first quarter financial results and certain 2009 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, May 6, 2009. An update on certain business developments will also be provided. ... 
Printer Friendly Version
02/11/09OraSure Announces Fourth Quarter and Full Year 2008 Financial Results
BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 11, 2009-- OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $71.1 million and $17.2 million for the year and quarter ended December 31, 2008, respectively. This compares to revenues of $82.7 million and $19.8 million for the year and quarter ended December 31, 2007, respectively. The Company recorded a net loss of $31.3 million or $0.67 per s... 
Printer Friendly Version
02/04/09OraSure Technologies Earnings Conference Call Invitation
2008 Fourth Quarter and Full Year Earnings Conference Call Wednesday, February 11, 2009, 5:00 p.m. ET BETHLEHEM, Pa.--(BUSINESS WIRE)-- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering 2008 fourth quarter and full-year financial results and certain 2009 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, February 11, 2009. An update on certain business developments will also be provided. ... 
Printer Friendly Version
01/28/09U.S. FDA Approves OraQuick ADVANCE(R) 12-Month Shelf Life Dating
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 28, 2009--OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that the United States Food and Drug Administration (FDA) has approved its request for 12-month shelf life from the date of manufacture for its OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test. The FDA approval is based on enhancements made by OraSure to the manufacturing process and product packaging of its OraQuick ADVANCE(R) test, and re... 
Printer Friendly Version
01/05/09OraSure Technologies to Participate at the Eleventh Annual Needham Growth Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 5, 2009--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Eleventh Annual Needham Growth Conference in New York at approximately 10:30 am Eastern Time (7:30 am Pacific Time) on Wednesday, January 7, 2009. The conference will be simultaneously webcast over the Internet. Interested investors... 
Printer Friendly Version
12/01/08OraSure Technologies Supports Global and Domestic Rapid HIV Testing Initiatives for World AIDS Day
BETHLEHEM, Pa., Dec 01, 2008 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced its support of rapid HIV testing initiatives taking place in more than 20 states in the U.S. and several countries globally, in recognition of World AIDS Day, commemorated annually on December 1st. OraSure's support of these initiatives includes the production of HIV testing promotional materials, co... 
Printer Friendly Version
11/17/08OraSure Technologies to Participate at the Lazard Capital Markets 5th Annual Healthcare Conference
BETHLEHEM, Pa., Nov 17, 2008 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Lazard Capital Markets Fifth Annual Healthcare Conference in New York City at approximately 9:30 am Eastern Time, (6:30 am Pacific Time) on Wednesday, November 19, 2008. The conference will be simultaneously webcast over the Internet. Intereste... 
Printer Friendly Version
11/05/08OraSure Technologies Announces 2008 Third Quarter Results
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 5, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced quarterly revenues of $16.9 million for the three months ended September 30, 2008, compared to $21.4 million in revenues for the three months ended September 30, 2007. Sales of the Company's OraQuick ADVANCE(R) rapid HIV-1/2 antibody test increased 18% for the third quarter 2008. This increase was offset primarily by an expected decrease i... 
Printer Friendly Version
11/05/08OraSure Technologies to Sell OraQuick ADVANCE Rapid HIV-1/2 Antibody Test Directly to U.S. Hospitals
OraSure Sales Force Expansion will Support Hospital Customers BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 5, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced that it will begin to sell its OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test directly into the U.S. hospital market beginning in 2009. In recent years, the U.S. hospital market has received this product through an exclusive distribution arrangement with Abbott. In early... 
Printer Friendly Version
11/04/08OraSure's Intercept Oral Fluid Drug Test Results Comparable to Urine Drug Screening According to Landmark Five-Year Analysis
SAMHSA Sponsored Study of 650,000 Oral Fluid Specimen Drug Test Results Presented at the Annual Meeting of the Society of Forensic Toxicologists BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 4, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that findings from a recent large-scale study of laboratory-based oral fluid drug testing results are comparable to urine drug testing positive rates for the same classes of drugs. The 650,000 oral flu... 
Printer Friendly Version
10/28/08OraSure Technologies Files For FDA Approval of OraQuick Rapid Hepatitis C Test
When Approved, OraQuick(R) HCV is Expected to be the First Rapid HCV Test in U.S. BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 28, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that it has submitted a pre-market approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for a rapid test for antibodies to the Hepatitis C virus ("HCV") utilizing OraSure Technologies' OraQuick(R) technology platform. When approved, the OraQuick(R) HCV test is expected to be ... 
Printer Friendly Version
10/20/08OraSure Technologies Earnings Conference Call Invitation
2008 Third Quarter Earnings Conference Call Wednesday, November 5, 2008, 5:00 p.m. ET BETHLEHEM, Pa.--(BUSINESS WIRE)--OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular quarterly earnings conference call covering 2008 third quarter financial results for 5:00 p.m. ET (2:00 p.m. PT) on Wednesday, November 5, 2008. An update on certain business developments will also be provided. November 5, 2008 Schedule ---------------------------------------... 
Printer Friendly Version
10/13/08OraSure Technologies Helps Expand Access to Rapid HIV Testing in Recognition of National Latino AIDS Awareness Day, October 15, 2008
Company Joins the Latino Commission on AIDS in Urging All Latinos to Get Tested and Learn Their HIV Status BETHLEHEM, Pa.--(BUSINESS WIRE)--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, announced today its support to expand access to rapid HIV testing in recognition of National Latino AIDS Awareness Day (NLAAD) taking place on October 15, 2008. The effort to help increase opportunities for Latinos to learn their HIV status is being executed in p... 
Printer Friendly Version
09/29/08OraSure Applauds Congress for Passing Legislation to Enable Routine HIV Testing Throughout the U.S. Veterans Health Care System
BETHLEHEM, Pa.--(BUSINESS WIRE)--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today issued a statement applauding the U.S. Congress for passage of The Veterans Mental Health and Other Care Improvements Act of 2008 (S. 2162). The bill includes a provision that repeals the 1988 Veterans Benefits and Services law which has limited the implementation of the Centers for Disease Control and Prevention (CDC) guidelines for routine HIV testing, counsel... 
Printer Friendly Version
09/18/08OraSure Technologies to Participate at the 2008 UBS Global Life Sciences Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 18, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the 2008 UBS Global Life Sciences Conference in New York City at approximately 2:30pm Eastern Time, (11:30am Pacific Time) on Tuesday, September 23, 2008. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audio webcas... 
Printer Friendly Version
09/10/08Brian W. Reid to Join OraSure Technologies as Vice President, International Sales
BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 10, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, is pleased to announce that Brian W. Reid will join the Company as Vice President, International Sales, effective September 22, 2008. Reid will be responsible for leading OraSure's international sales efforts for the Company's diagnostic businesses. Reid will report to Douglas A. Michels, OraSure's President and CEO. "We are delighted that Br... 
Printer Friendly Version
09/02/08Walter Reed Evaluation Concludes OraQuick(R) HCV Test is Preferred Over Other Rapid Tests
OraQuick(R) HCV Test Found to Have Higher Sensitivity and Specificity Than Other Rapid HCV Tests BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 2, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced that an evaluation by the Walter Reed Army Institute of Research of the OraQuick(R) HCV Test, currently in clinical development by OraSure Technologies, was recently released at the Advanced Technology Applications for Combat Casualty Care me... 
Printer Friendly Version
08/26/08OraSure Technologies Announces 2009 Annual Meeting Date
BETHLEHEM, Pa., Aug 26, 2008 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that its 2009 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 12, 2009, at the Historic Hotel Bethlehem, Bethlehem, Pennsylvania. Stockholder proposals must be received no later than December 9, 2008, in order to be considered for inclusion in the Company's Proxy Statement under relevant Securities and Exchange Commission rules ... 
Printer Friendly Version
08/05/08OraSure Technologies Announces 2008 Second Quarter Results
Significant Milestones Achieved in Clinical Development Programs BETHLEHEM, Pa.--(BUSINESS WIRE)--Aug. 5, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced quarterly revenues of $18.9 million for the three months ended June 30, 2008, compared to $21.4 million in revenues for the three months ended June 30, 2007. Increased sales of the Company's OraQuick ADVANCE(R) rapid HIV-1/2 antibody test and insurance risk assessment pro... 
Printer Friendly Version
08/05/08OraSure Technologies Announces $25 Million Share Repurchase Program
BETHLEHEM, Pa.--(BUSINESS WIRE)--Aug. 5, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced that its Board of Directors has approved a share repurchase program to acquire up to $25 million of its outstanding common shares. Purchases under the program will be made at the Company's discretion, subject to market conditions, in the open market, in privately-negotiated transactions or otherwise, including pursuant to a 10b5-1 pla... 
Printer Friendly Version
07/18/08OraSure Technologies Earnings Conference Call Invitation
2008 Second Quarter Earnings Conference Call Tuesday, August 5, 2008, 5:00 p.m. ET BETHLEHEM, Pa.--(BUSINESS WIRE)--July 18, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly earnings conference call covering 2008 second quarter financial results for 5:00 pm ET (2:00 pm PT) on Tuesday, August 5, 2008. An update on certain business developments will also be provided. August 5, 2008 Schedule ... 
Printer Friendly Version
06/26/08OraSure Technologies and the National Association of People with AIDS Will Open the NASDAQ Stock Market on June 27 in Observance of National HIV Testing Day
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 26, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR) and the National Association of People with AIDS (NAPWA) announced today that OraSure officials will be joined by Frank Oldham, Jr., President and CEO of NAPWA, and the Honorable Johnny Ford, Mayor of Tuskegee, Alabama and Director General of the World Conference of Mayors to preside over the NASDAQ Stock Market opening on June 27, 2008 in observance of National HIV Testing Day. This event will sp... 
Printer Friendly Version
06/23/0865 U.S. Mayors to Join OraSure Technologies and the National Association of People with AIDS in Fourth Annual 'Mayors Campaign against HIV(TM)' for National HIV Testing Day
Record Number of U.S. Mayors Unite to Promote HIV Screening on June 27thBETHLEHEM, Pa., Jun 23, 2008 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) and the National Association of People with AIDS (NAPWA) announced today that more than 65 mayors and/or Department of Health offices in major metropolitan cities nationwide have committed their participation and support for the fourth annual Mayors Campaign Against HIV(TM), a national campaign to encourage testing for HIV and prom... 
Printer Friendly Version
06/16/08Nationwide Data Indicate a Very High Degree of Accuracy for OraQuick ADVANCE Rapid HIV-1/2 Antibody Test with Oral Fluid
Nationwide Accuracy for 2007 Through May 2008 of 99.8% Reported From Over 400 Testing Sites and More Than 250,000 Tests BETHLEHEM, Pa.--(BUSINESS WIRE)--June 16, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that aggregate nationwide performance data for 2007 and the first five months of 2008 indicate that its widely used rapid HIV-1/2 antibody screening test, OraQuick ADVANCE(R), has a very high degree of accuracy with oral fluid - at rates that are within the U.S. ... 
Printer Friendly Version
06/05/08OraSure Technologies to Present at the Seventh Annual Needham & Company, LLC Biotechnology & Medical Technology Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 5, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Seventh Annual Needham & Company, LLC Biotechnology & Medical Technology Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on June 11, 2008, at approximately 11:00 am Eastern Time (8:00 am Pacific Time). Intereste... 
Printer Friendly Version
05/06/08OraSure Technologies Announces 2008 First Quarter Results
BETHLEHEM, Pa., May 06, 2008 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced quarterly revenues of $18.1 million for the three months ended March 31, 2008, compared to $20.1 million in revenues recorded for the three months ended March 31, 2007. Increased sales of the Company's OraQuick ADVANCE(R) rapid HIV-1/2 antibody test, professional cryosurgical products and insurance risk assessment products during the first qua... 
Printer Friendly Version
05/01/08OraSure Technologies to Webcast Annual Meeting of Stockholders
BETHLEHEM, Pa.--(BUSINESS WIRE)--May 1, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, announced that it will webcast its 2008 Annual Meeting of Stockholders beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) on Tuesday, May 13, 2008. The formal portion of the meeting will be immediately followed by a management presentation and a question and answer session. Persons accessing the webcast who desire to ask questions will be ... 
Printer Friendly Version
04/23/08OraSure Technologies Earnings Conference Call Invitation
2008 First Quarter Earnings Conference Call Tuesday, May 6, 2008, 5:00 p.m. ET BETHLEHEM, Pa.--(BUSINESS WIRE)--April 23, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly earnings conference call covering 2008 first quarter financial results for 5:00 pm ET (2:00 pm PT) on Tuesday, May 6, 2008. An update on certain business developments will also be provided. May 6, 2008 Schedule -----------------... 
Printer Friendly Version
04/17/08OraSure Technologies to Defend Patent Infringement Lawsuit
BETHLEHEM, Pa.--(BUSINESS WIRE)--April 17, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR) announced that it has received a complaint from Inverness Medical Innovations, Inc. (AMEX:IMA), Inverness Medical Switzerland GmbH and Church & Dwight, Co., Inc. (NYSE:CHD), filed in the United States District Court for the District of New Jersey, alleging that the manufacture and sale of the Company's OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test infringes U.S. Patent No. 6,485,982. OraSure Te... 
Printer Friendly Version
03/17/08OraSure Technologies to Present at the Cowen & Co. Health Care Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--March 17, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Ronald H. Spair, Chief Operating Officer and Chief Financial Officer, will speak to the investment community at the Cowen & Co. Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet. Mr. Spair is scheduled to speak on March 20, 2008, at approximately 10:15 am Eastern Time (7:15 am Pacific Time). Interested invest... 
Printer Friendly Version
03/04/08OraSure Technologies Expands Distribution of Over-the-Counter Cryosurgical Wart Removal Product in Latin America
Genomma Lab to Distribute Product under the POINTTS TradenameBETHLEHEM, Pa., Mar 04, 2008 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) announced today the execution of new agreements to expand distribution of OraSure's cryosurgical wart removal product by Genomma Lab in the over-the-counter ("OTC") or consumer retail market in Central and South America. In addition, the parties renewed and extended their prior distribution arrangement for Mexico and signed a new agreement to... 
Printer Friendly Version
02/27/08OraSure Technologies to Participate at the Susquehanna Financial Group's Second Annual SIGnificant Options in Healthcare Conference
BETHLEHEM, Pa., Feb 27, 2008 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Susquehanna Financial Group's Second Annual SIGnificant Options in Healthcare Conference in New York City at approximately 9:30 a.m. Eastern Time, (6:30 a.m. Pacific Time) on Wednesday, March 5, 2008. The conference will be simultaneously webcast over the Internet. Interested ... 
Printer Friendly Version
02/12/08OraSure Announces Fourth Quarter and Full Year 2007 Financial Results
Annual Revenues Reach Record Level with 21% Growth Over 2006 BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 12, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $82.7 million and $19.8 million for the year and quarter ended December 31, 2007, respectively. This compares to revenues of $68.2 million and $17.7 million for the year and quarter ended December 31, 2006, respectively. The Company reported net income of $2.5... 
Printer Friendly Version
02/11/08Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
New Agreement Provides for Development and Promotion of OraQuick(R) HCV Test Outside the United States KENILWORTH, N.J. & BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 11, 2008--Schering-Plough Corporation (NYSE:SGP) and OraSure Technologies, Inc. (NASDAQ:OSUR) today announced an agreement to collaborate on the development and promotion of a rapid oral hepatitis C virus (HCV) test utilizing OraSure Technologies' OraQuick(R) technology platform on a worldwide basis outside the United States. ... 
Printer Friendly Version
02/07/08OraSure Technologies Pledges Support for National Black HIV/AIDS Awareness Day
Joins Nationwide Call to Action to Encourage the African American Community to Learn Their HIV Status BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 7, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced its support of National Black HIV/AIDS Awareness Day (NBHAAD), through the distribution of complimentary OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test kits and educational materials to more than 25 HIV testing sites ... 
Printer Friendly Version
01/31/08OraSure Technologies Earnings Conference Call Invitation
2007 Fourth-Quarter and Full-Year Earnings Conference Call Tuesday, February 12, 2008, 5:00 p.m. ET BETHLEHEM, Pa., Jan 31, 2008 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), has scheduled its regular quarterly earnings conference call covering 2007 fourth-quarter and full-year financial results and 2008 financial guidance for 5:00 p.m. ET (2:00 p.m. PT) on Tuesday, February 12, 2008. An update on certain business developments will also be provided. ... 
Printer Friendly Version
01/04/08OraSure Technologies to Participate at the Tenth Annual Needham Growth Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 4, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Tenth Annual Needham Growth Conference in New York at approximately 8:30 am Eastern Time, (5:30 am Pacific Time) on January 9, 2008. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audio webcast of the discussion... 
Printer Friendly Version
01/02/08Debra Fraser-Howze to Join OraSure Technologies as Vice President, Government and External Affairs
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 2, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, is pleased to announce that Debra Fraser-Howze, current President/CEO of the National Black Leadership Commission on AIDS (NBLCA), will join the Company as Vice President, Government and External Affairs on January 7, 2008. Fraser-Howze will represent OraSure with government officials regarding the issues, policies, and laws impacting the Company's ... 
Printer Friendly Version
11/29/07OraSure Technologies Supports Global and Domestic Rapid HIV Testing Initiatives for World AIDS Day
OraSure to Participate in NASDAQ Market Open and HIV/AIDS Industry Panel Discussion on November 30, 2007 BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 29, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced its support of more than 150 global and domestic rapid HIV testing initiatives in recognition of World AIDS Day, commemorated annually on December 1st. OraSure's support of these initiatives, taking place in Afri... 
Printer Friendly Version
11/20/07OraSure Technologies to Host Analyst Day
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 20, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced that it will host an Analyst Day meeting on Wednesday, November 28, 2007 in New York City, New York, at the NASDAQ MarketSite at Times Square. Presentations by OraSure's senior executive team are scheduled to begin at 11:30 a.m. (Eastern Time) and conclude by 3:00 p.m. (Eastern Time) and will cover product development, including clinical ... 
Printer Friendly Version
11/19/07OraSure Technologies to Participate at the Lazard Capital Markets 4th Annual Healthcare Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 19, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Lazard Capital Markets Fourth Annual Healthcare Conference in New York City at approximately 10:30 am Eastern Time, (7:30 am Pacific Time) on Tuesday, November 27, 2007. The conference will be simultaneously webcast over the Internet. Interested investors can access the... 
Printer Friendly Version
11/14/07OraSure Technologies and Schering-Plough to Settle Patent Infringement Litigation
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 14, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that an agreement has been reached on the principal terms to settle its pending patent infringement litigation against Schering-Plough Healthcare Products, Inc. (NYSE:SGP). The settlement is subject to completion and execution of a final settlement agreement. Under the terms of the settlement, Schering-Plough will receive a license to OraSure's patents in the U.S. OTC market an... 
Printer Friendly Version
10/30/07OraSure Technologies Announces Third Quarter Financial Results
Quarterly Revenues Increase 21% Over 2006 BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 30, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced quarterly revenues of $21.4 million for the three months ended September 30, 2007, a 21% increase over the $17.6 million in revenues recorded for the three months ended September 30, 2006. Increased sales of the Company's OraQuick ADVANCE(R) rapid HIV-1/2 antibody test and over-the-counter ("O... 
Printer Friendly Version
10/23/07OraSure Technologies Announces Results of Arbitration With Prestige Brands
Prestige Brands Found To Have Breached Non-Compete Provision BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 23, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced the results of its arbitration with Prestige Brands Holdings, Inc (NYSE:PBH). Since April 2003, Prestige has exclusively distributed OraSure's cryosurgical wart removal product in the United States over-the-counter or retail ("OTC") market under the Compound W Freeze Off(R) tradename. The arbitration arose after Presti... 
Printer Friendly Version
10/19/07OraSure Technologies Quarterly Conference Call Invitation
2007 Third Quarter Conference Call Tuesday, October 30, 2007, 5:00 p.m. ET BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 19, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly earnings conference call covering 2007 third quarter financial results and 2007 financial guidance for 5:00 pm ET (2:00 pm PT) on Tuesday, October 30, 2007. October 30, 2007 Schedule ------------------------------------------------------... 
Printer Friendly Version
10/10/07OraSure Technologies and the Latino Commission on AIDS Launch HIV Testing Initiative in Recognition of National Latino AIDS Awareness Day, October 15, 2007
Congressional Hispanic Caucus Joins Effort to Help Latinos Learn Their HIV Status BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 10, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced the launch of a Rapid HIV Testing Initiative in connection with National Latino Awareness Day 2007. This Initiative is being conducted in partnership with the Latino Commission on AIDS with support from the Congressional Hispanic Caucus. As part of ... 
Printer Friendly Version
09/20/07OraSure Technologies to Participate at the 2007 UBS Global Life Sciences Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 20, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the 2007 UBS Global Life Sciences Conference in New York City at approximately 8:00 am Eastern Time, (5:00 am Pacific Time) on Wednesday, September 26, 2007. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audio web... 
Printer Friendly Version
07/31/07OraSure Technologies Announces Record 2007 Second Quarter Results
Increases 2007 Full Year Revenue GuidanceBETHLEHEM, Pa., Jul 31, 2007 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced record quarterly revenues of $21.4 million for the three months ended June 30, 2007, a 22% increase over the $17.6 million in revenues recorded for the three months ended June 30, 2006. Increased sales of the Company's OraQuick ADVANCE(R) rapid HIV-1/2 antibody test, substance abuse testing products and ... 
Printer Friendly Version
07/26/07OraSure Technologies Signs Agreement with the Supply Chain Management System for Supply of OraQuick(R) HIV Test to PEPFAR Countries
BETHLEHEM, Pa.--(BUSINESS WIRE)--July 26, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced the execution of an agreement for the supply of its OraQuick(R) Rapid HIV-1/2 Antibody Test to the Supply Chain Management System ("SCMS"). Created with funds from the President's Emergency Plan for AIDS Relief, or PEPFAR, SCMS procures essential medicines, diagnostic tests and other supplies for the prevention and treatment of HIV for ... 
Printer Friendly Version
07/19/07OraSure Technologies Announces Pre-Clinical Study Results for Prototype Rapid HCV Antibody Test at AACC Annual Meeting
Prototype Test Performance Equivalent to Lab-Based Testing in Pre-clinical Trials of Human SubjectsBETHLEHEM, Pa., Jul 19, 2007 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced pre-clinical study results for a prototype rapid Hepatitis C ("HCV") antibody test on the Company's OraQuick(R) test platform, using oral fluid, finger-stick whole blood, venous whole blood, serum and plasma samples. These results were reported... 
Printer Friendly Version
07/18/07OraSure Technologies Appoints Vice President, Consumer Marketing
BETHLEHEM, Pa., Jul 18, 2007 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced that Kenneth A. Adach will be appointed as the Company's Vice President, Consumer Marketing. Mr. Adach joins OraSure with extensive experience in consumer sales and marketing, including over twenty-five years of relevant over-the-counter ("OTC") marketing experience. Since 2005, Mr. Adach has served as Director of Marketing for Bausch & Lomb... 
Printer Friendly Version
07/17/07OraSure Technologies Quarterly Conference Call Invitation
2007 Second Quarter Conference Call Tuesday, July 31, 2007, 5:00 p.m. ET BETHLEHEM, Pa.--(BUSINESS WIRE)--July 17, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly earnings conference call covering 2007 second quarter financial results and 2007 financial guidance for 5:00 pm ET (2:00 pm PT) on Tuesday, July 31, 2007. July 31, 2007 Schedule ----------------------------------------------------------... 
Printer Friendly Version
06/26/07OraSure and the National Association of People with AIDS Launch Third Annual ''Mayors Campaign against HIV(TM)'' for National HIV Testing Day
33 U.S. Mayors Unite to Promote HIV Screening on June 27th, National HIV Testing Day OraSure, NAPWA, City, State and Local Agencies to Open NASDAQ Stock Market BETHLEHEM, Pa.--(BUSINESS WIRE)--June 26, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR) and the National Association of People with AIDS (NAPWA) announced today the launch of the third annual Mayors Campaign Against HIV(TM), a national campaign to encourage te... 
Printer Friendly Version
06/22/07OraSure Technologies Sets 2008 Annual Meeting Date
BETHLEHEM, Pa., Jun 22, 2007 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that its 2008 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 13, 2008, at the Historic Hotel Bethlehem, Bethlehem, Pennsylvania. Stockholder proposals must be received no later than December 10, 2007, in order to be considered for inclusion in the Company's Proxy Statement under relevant Securities and Exchange Commission rules and no later than February 13, 2008... 
Printer Friendly Version
06/11/07OraSure Technologies Receives CE Mark for OraQuick ADVANCE(R) Rapid HIV Test
Approval Required for Sales in European Union BETHLEHEM, Pa.--(BUSINESS WIRE)--June 11, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that it has received approval to affix the CE mark to its OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test, which is required to sell this product in the 27 countries that currently make up the European Union. The OraQuick ADVANCE(R) HIV test is the first and only rapid HIV test bearing a CE mark that can be used with oral fluid, in add... 
Printer Friendly Version
06/08/07OraSure Technologies to Present at the Sixth Annual Needham & Company, LLC Biotechnology & Medical Technology Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 8, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Ronald H. Spair, Chief Operating Officer and Chief Financial Officer, will speak to the investment community at the Sixth Annual Needham & Company, LLC Biotechnology & Medical Technology Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Spair is scheduled to speak on June 13, 2007, at approximately 11:30 am Eastern Time (8:30 ... 
Printer Friendly Version
06/04/07OraSure Applauds $35 Million in CDC Funding to Support Increased HIV Testing and Prevention
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 4, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics and the manufacturer of the OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test, today issued a statement in support of the recent program announcement by the Centers for Disease Control and Prevention ("CDC") that it has identified $35 million in additional funding to expand HIV testing and prevention programs. These funds are expected to be allocated to sp... 
Printer Friendly Version
05/29/07OraSure Technologies to Present at the Bank of America 2007 Health Care Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--May 29, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Bank of America 2007 Health Care Conference, Four Seasons Hotel in Las Vegas, NV. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on May 31, 2007, at approximately 3:40pm EDT (12:40pm PDT). Interested investors can acce... 
Printer Friendly Version
05/10/07OraSure Technologies to Webcast Annual Meeting of Stockholders
BETHLEHEM, Pa., May 10, 2007 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, announced that it will webcast its 2007 Annual Meeting of Stockholders beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) on Tuesday, May 15, 2007. The formal portion of the meeting will be immediately followed by a management presentation and a question and answer session. Persons accessing the webcast who desire to ask questions will be permitt... 
Printer Friendly Version
05/08/07OraSure Technologies Announces 2007 First Quarter Results
Record Quarterly Revenues Led by OraQuick ADVANCE(R) SalesBETHLEHEM, Pa., May 08, 2007 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics, today announced record quarterly revenues of $20.1 million for the three months ended March 31, 2007, compared to $15.2 million in revenues recorded for the three months ended March 31, 2006. Increased sales of the Company's OraQuick ADVANCE(R) rapid HIV-1/2 antibody test, substance abuse testing produ... 
Printer Friendly Version
04/30/07OraQuick(R) Rapid HIV Test Chosen for Madagascar National AIDS Control Program
Use of Oral Fluid Key to Selection - Madagascar Estimates Approximately 400,000 Individuals Will Be Tested in 2007 BETHLEHEM, Pa.--(BUSINESS WIRE)--April 30, 2007--OraSure Technologies, Inc. (NASDAQ: OSUR), the market leader in oral fluid diagnostics, announced today that it has been selected by the Malagasy government and its National AIDS Control Program to be the exclusive first-line provider of rapid HIV screening tests for the country's outreach program over the next five years.... 
Printer Friendly Version
04/25/07OraSure Technologies Quarterly Conference Call Invitation
First Quarter Earnings Conference Call Tuesday, May 08, 2007, 5:00 p.m. ET BETHLEHEM, Pa.--(BUSINESS WIRE)--April 25, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly earnings conference call for 5:00 pm ET (2:00 pm PT) on Tuesday, May 8, 2007, covering 2007 first quarter financial results, business developments and the Company's 2007 outlook. May 8, 2007 Schedule -------------------- 4:00 p.m. E... 
Printer Friendly Version
04/02/07OraSure Technologies Signs Agreement for Development of Counseling and Referral System for Home Use Rapid HIV Test Kit
BETHLEHEM, Pa.--(BUSINESS WIRE)--April 2, 2007--OraSure Technologies, Inc. (NASDAQ: OSUR), the market leader in oral fluid diagnostics and the manufacturer of the OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test, announced today that it has signed an agreement with Constella Group LLC, to design and develop a telephonic and Internet accessible consumer counseling and referral system for use with the Company's OraQuick ADVANCE(R) test in the consumer or over-the-counter (OTC) market. Co... 
Printer Friendly Version
03/09/07OraSure Technologies to Present at the Cowen & Co. Health Care Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--March 9, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Cowen & Co. Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on March 13, 2007, at approximately 3:15 pm Eastern Time (12:15 pm Pacific Time). Interested investors can ac... 
Printer Friendly Version
02/28/07OraSure Technologies to Launch First Over-the-Counter Cryosurgical Wart Removal Product in Mexico
Genomma Lab to Distribute Product under the POINTTS Tradename BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 28, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR) announced today the commercial launch of the first cryosurgical wart removal product in the over-the-counter ("OTC") or consumer retail market in Mexico. The product will be manufactured by OraSure for its Mexican distributor, Producciones Infovision, S.A. de C.V. The product will be sold under the POINTTS tradename by Producciones ... 
Printer Friendly Version
02/13/07OraSure Announces 2006 Financial Results
BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 13, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $68.2 million and $17.7 million for the year and quarter ended December 31, 2006, respectively. This compares to revenues of $69.4 million and $18.0 million for the year and quarter ended December 31, 2005, respectively. The Company reported net income of $5.3 million, or $0.11 per share on a fully-diluted basis, for the ... 
Printer Friendly Version
02/06/07OraSure Technologies Quarterly Conference Call Invitation
2006 Fourth Quarter and Year End Earnings Conference Call Tuesday, February 13, 2007, 5:00 p.m. ET BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 6, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly earnings conference call covering 2006 fourth quarter and full-year financial results and 2007 financial guidance for 5:00 pm ET (2:00 pm PT) on Tuesday, February 13, 2007. February 13, 2007 Schedule -----------------... 
Printer Friendly Version
02/06/07OraSure Technologies Donates OraQuick ADVANCE(R) Rapid HIV-1/2 Tests in Honor of National Black HIV/AIDS Awareness Day
BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 6, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced that, in an effort to encourage rapid HIV testing for National Black HIV/AIDS Awareness Day (NBHAAD), it has donated OraQuick ADVANCE(R) Rapid HIV-1/2 Tests to more than 20 community-based organizations and testing sites across the country. The tests will be utilized by these locations to conduct free HIV testing in observance of NBHAAD ... 
Printer Friendly Version
01/05/07OraSure Technologies to Participate at the Ninth Annual Needham Growth Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 5, 2007--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Ninth Annual Needham Growth Conference in New York at approximately 1:30 pm Eastern Time, (10:30 am Pacific Time) on January 11, 2007. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audio webcast of the discussi... 
Printer Friendly Version
01/04/07Schering-Plough and OraSure Technologies Sign Agreement for Development and Promotion of Rapid Point-of-Care Oral Hepatitis C Test
Test Will Utilize OraSure's OraQuick(R) Technology Platform KENILWORTH, N.J. and BETHLEHEM, Pa., Jan. 4 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) and OraSure Technologies, Inc. (Nasdaq: OSUR) today announced an agreement to collaborate on the development and promotion of a rapid oral test for the detection of antibodies to the hepatitis C virus (HCV) utilizing OraSure Technologies' OraQuick(R) technology platform. The agreement brings together OraSure - th... 
Printer Friendly Version
12/07/06OraQuick ADVANCE(R) to Be Centerpiece of Expanded HIV Testing in Philadelphia
Initial $1.5 Million Funding Increase Approved for the City's HIV/AIDS Programs BETHLEHEM, Pa.--(BUSINESS WIRE)--Dec. 7, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR), the leader in oral fluid diagnostics, announced that its OraQuick ADVANCE(R) Rapid HIV 1/2 Antibody Test will be the centerpiece of a planned initiative in the City of Philadelphia to provide oral fluid rapid HIV 1/2 testing to populations that are traditionally underserved and in many inst... 
Printer Friendly Version
12/07/06OraSure Technologies to Participate At RBC Capital Markets Healthcare Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--Dec. 7, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will participate in a panel discussion related to the development of Point-of-Care Diagnostics on December 14, 2006, at 2:00 pm EST as part of the 2006 RBC Capital Markets Healthcare Conference being held at the Westin New York at Times Square Hotel in New York City. Interested investors can access the live audio we... 
Printer Friendly Version
11/30/06OraSure Technologies to Participate in NASDAQ Industry Panel Discussion and Market Close in Observance of World AIDS Day on December 1, 2006
Company Will Also Support Local and Global Campaigns to Encourage Individuals to Learn Their HIV Status BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 30, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced it will participate in the NASDAQ's Stock Market Closing Bell Ceremony and a special industry panel discussion in observance of World AIDS Day on December 1, 2006. In addition, as part of this commemorative day, OraSure will actively ... 
Printer Friendly Version
11/01/06OraSure Announces Third Quarter Financial Results
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 1, 2006--OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics, today announced revenues of $17.6 million for the quarter ended September 30, 2006, compared to $18.1 million in revenues recorded for the comparable period in 2005. The Company's net income was $2.1 million, or $0.05 per share on a basic and fully-diluted basis, for the third quarter of 2006, which includes charges for stock option expense and a pro... 
Printer Friendly Version
10/27/06OraSure Technologies Sets 2007 Annual Meeting Date
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 27, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that its 2007 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 15, 2007, at the Historic Hotel Bethlehem, Bethlehem, Pennsylvania. Stockholder proposals must be received no later than December 9, 2006, in order to be considered for inclusion in the Company's Proxy Statement under relevant Securities and Exchange Commission rules and no later than February 14, ... 
Printer Friendly Version
10/23/06OraSure Technologies Quarterly Conference Call Invitation
Third Quarter Earnings Conference Call Wednesday, November 1, 2006, 5:00 p.m. ETBETHLEHEM, Pa., Oct 23, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly earnings conference call covering its 2006 third quarter financial results and an update of business developments and financial guidance, for 5:00 pm ET (2:00 pm PT) on Wednesday, November 1, 2006. November 1, 2006 Schedule 4:00 p.m. ET 2006 third quarter finan... 
Printer Friendly Version
10/12/06OraSure Technologies Donates OraQuick ADVANCE(R) Tests in Recognition of National Latino AIDS Awareness Day
4th Annual Awareness Day to Be Held on Oct. 15th Interview Footage and B-Roll Available via Satellite Uplink, Friday, October 13 at 2:00 PM EDTBETHLEHEM, Pa., Oct 12, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, in conjunction with the Latino Commission on AIDS and the Congressional Hispanic Caucus, announced today the donation of OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Tests in recognition of the 4th Annual National Latino... 
Printer Friendly Version
10/05/06OraSure Technologies Announces Director Appointments and Organizational Changes
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 5, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced the appointment of two new members of the Company's Board of Directors, the promotions of two executive officers and the addition of a new member to its management team. Michael Celano has been appointed as a member of the Board of Directors to serve as a Class III Director with an initial term expiring at the Company's 2009 Annual M... 
Printer Friendly Version
10/04/06Roche Diagnostics and OraSure Technologies Sign Letter of Intent to Develop Fully Automated Oral Fluid Drugs of Abuse Assays
This partnership will enable laboratories to increase efficiencies while offering an improved level of service by providing quicker turnaround times INDIANAPOLIS, Oct. 4 /PRNewswire/ -- Roche Diagnostics today signed a letter of intent to negotiate an agreement for the joint development and commercialization of homogeneous fully-automated oral fluid drugs of abuse assays that can run on random access chemistry analyzers with OraSure Technologies, Inc. (Nasdaq: OSUR - News). The oral fluid as... 
Printer Friendly Version
09/27/06OraSure Technologies Commences Initial Studies for FDA Approval of Home Use Rapid HIV Test Kit
BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 27, 2006--OraSure Technologies, Inc. (NASDAQ: OSUR), the market leader in oral fluid diagnostics and the manufacturer of the OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test, announced today that it has commenced several laboratory-based operational studies as the initial stage of the process to obtain U.S. Food and Drug Administration ("FDA") approval of the OraQuick ADVANCE(R) test for use in the consumer or over-the-counter ("OTC") market in th... 
Printer Friendly Version
09/25/06OraSure Technologies Responds to Acquisition of Wartner Cryosurgical Product Line by Prestige Brands
BETHLEHEM, Pa.--(BUSINESS WIRE)--OraSure Technologies, Inc. (NASDAQ: OSUR) today issued a statement in response to the announcement by Prestige Brands, Inc. that it has acquired the Wartner cryosurgical wart removal product line, which is sold in the retail or over the counter ("OTC") market in the United States. The Wartner product competes directly in the OTC market against OraSure's cryosurgical wart removal product, which is distributed by Prestige on an exclusive basis under its Compo... 
Printer Friendly Version
09/21/06OraSure Technologies Applauds CDC's Call for Routine HIV Testing; Revised HIV Testing Recommendations Advocate HIV Screening as Routine Part of Medical Care
BETHLEHEM, Pa., Sep 21, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics and the manufacturer of the OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test, today issued a statement in support of "The Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health Care Settings," issued today by the Centers for Disease Control and Prevention ("CDC"). These recommendations, which advocate routine HIV screenin... 
Printer Friendly Version
09/19/06OraSure Technologies to Present at UBS Global Life Sciences Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 19, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the UBS Global Life Sciences Conference 2006 in New York, at approximately 1:00 pm Eastern Time (10:00 am Pacific Time) on September 27, 2006. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audio webcast of the di... 
Printer Friendly Version
08/28/06OraSure Technologies to Present at Thomas Weisel Partners' Healthcare Conference 2006
BETHLEHEM, Pa.--(BUSINESS WIRE)--Aug. 28, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Thomas Weisel Partners' Healthcare Conference 2006 in Boston, Massachusetts, at approximately 8:00 am Eastern Time (5:00 am Pacific Time) on September 7, 2006. The conference will be simultaneously webcast over the Internet. Interested investors can access the live audi... 
Printer Friendly Version
08/08/06OraSure Announces Second Quarter Financial Results
BETHLEHEM, Pa., Aug 08, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $17.6 million for the quarter ended June 30, 2006, representing a slight increase over the $17.4 million in revenues recorded for the comparable period in 2005. The Company's net income was $1.2 million, or $0.03 per share on a basic and fully-diluted basis, for the second quarter of 2006, which includes $953,000 of stock option... 
Printer Friendly Version
07/31/06OraSure Technologies Appoints Senior Vice President, Business Development
BETHLEHEM, Pa.--(BUSINESS WIRE)--July 31, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced that Mark Kirtland has been appointed as the Company's Senior Vice President, Business Development. Mr. Kirtland has over fourteen years of experience in healthcare and medical diagnostics, with a particular focus on the assessment and commercialization of new technologies. He brings to OraSure Technologies extensive transactional e... 
Printer Friendly Version
07/25/06OraSure Technologies Quarterly Conference Call Invitation; Second Quarter Earnings Conference Call Tuesday, August 08, 2006, 5:00 p.m. ET
BETHLEHEM, Pa.--(BUSINESS WIRE)--July 25, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly earnings conference call covering its 2006 second quarter financial results and an update of business developments and financial guidance, for 5:00 pm ET (2:00 pm PT) on Tuesday, August 8, 2006. August 8, 2006 Schedule 4:00 p.m. ET 2006 second quarter financial results will be distributed by Business Wire ... 
Printer Friendly Version
06/27/06OraSure Technologies Signs Purchase Contract with New York City Department of Mental Health and Hygiene for OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Tests
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 27, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced that it has entered into an approximate $6 million, multi-year purchase contract with the New York City Department of Mental Health and Hygiene to expand the use of OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Tests in the City. The contract will commence on July 1, 2006, and will extend New York City's aggressive program of HIV p... 
Printer Friendly Version
06/26/06Washington, DC Launches City-Wide HIV Testing and Prevention Campaign with OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test
BETHLEHEM, Pa., Jun 26, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that the City of Washington, DC has agreed to purchase OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Tests for use in a city-wide HIV testing campaign being launched this week on June 27th, National HIV Testing Day. The campaign, led by Dr. Marsha Martin, Senior Deputy Director for HIV Policy and Programs and DC Mayor Anthony Williams will offer increased HIV testing services with OraQ... 
Printer Friendly Version
06/25/06OraQuick(R) Advance(TM) to Be Featured as Part of D.C Health Department's City-Wide HIV Testing Campaign Launch on June 27, 2006
--(BUSINESS WIRE)--OraSure Technologies, Inc. (NASDAQ: OSUR): WHAT: OraSure Technologies, Inc. (NASDAQ: OSUR) will take part in the official launch of the D.C. Health Department's city-wide HIV testing campaign on June 27, National HIV Testing Day (NHTD). The citywide campaign will encourage all District residents to learn their HIV status. The D.C. Health Department plans on distributing tests through a variety of settings includi... 
Printer Friendly Version
06/22/06OraSure Technologies, the National Association of People with AIDS and POZ Magazine to Open the NASDAQ Stock Market in Recognition of National HIV Testing Day
BETHLEHEM, Pa., Jun 22, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced it will participate in The NASDAQ Stock Market Opening Bell Ceremony on June 27th in recognition of National HIV Testing Day 2006, a national effort that is commemorated annually. Joining OraSure President and Chief Executive Officer, Douglas A. Michels, at the NASDAQ Market Open will be Frank J. Oldham Jr., Executive Director of the Nationa... 
Printer Friendly Version
06/20/06OraSure Technologies and the National Association of People with AIDS Launch Second Annual ''Mayors Campaign Against HIV'' for National HIV Testing Day 2006; Mayors Across the U.S. Promote HIV Testing and Prevention
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 20, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR) and the National Association of People with AIDS (NAPWA) announced today the launch of the second annual Mayors Campaign Against HIV, a national campaign to encourage testing for HIV and promote the benefits of individuals knowing their HIV status. The Campaign is being sponsored by OraSure Technologies, the manufacturer of the OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test, in observance of ... 
Printer Friendly Version
06/08/06OraSure Technologies to Present at Needham Biotechnology and Medical Technology Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 8, 2006--OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Needham & Company, LLC Biotechnology and Medical Technology Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on June 15, 2006, at approximately 2:30 pm Eastern Time (11:30 am Pacific Time). ... 
Printer Friendly Version
06/06/06OraSure Technologies to Present at Pacific Growth Equities Life Sciences Growth Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 6, 2006--OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Pacific Growth Equities Life Sciences Growth Conference in San Francisco, California. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on June 13, 2006, at approximately 12:30 pm Pacific Time (3:30 pm Eastern Time). Int... 
Printer Friendly Version
05/22/06OraSure Technologies Appoints New Director
BETHLEHEM, Pa., May 22, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced the appointment of Jack Goldstein, Ph.D. as a member of the Company's Board of Directors. Dr. Goldstein will serve as a Class I Director with an initial term expiring at the Company's 2007 Annual Meeting of Stockholders. Dr. Goldstein has enjoyed a distinguished career in the medical diagnostic and pharmaceutical industries. Since 2002, Dr... 
Printer Friendly Version
05/18/06CDC Commits to Bulk Purchase of OraQuick(R) Advance(TM) Tests to Support Continuing HIV Prevention Programs; OraSure Increases 2006 Full Year Guidance
BETHLEHEM, Pa.--(BUSINESS WIRE)--May 18, 2006--OraSure Technologies, Inc. (NASDAQ: OSUR), the market leader in oral fluid diagnostics, announced today that The Centers for Disease Control and Prevention ("CDC") has provided the Company with a purchase order for the immediate bulk procurement of its OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test. The CDC placed the order to further support its prevention initiatives. This order is the fourth bulk purchase of OraQuick(R) devices ma... 
Printer Friendly Version
05/10/06OraSure Technologies to Webcast Annual Meeting of Stockholders
BETHLEHEM, Pa., May 10, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, announced that it will webcast its 2006 Annual Meeting of Stockholders beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) on Tuesday, May 16, 2006. The formal portion of the meeting will be immediately followed by a management presentation and a question and answer session. Persons accessing the webcast who desire to ask questions will be permi... 
Printer Friendly Version
05/08/06OraSure Applauds CDC's Expected Call for Routine HIV Testing Nationwide; CDC to Issue Revised HIV Testing Guidelines Recommending Routine HIV Testing
BETHLEHEM, Pa.--(BUSINESS WIRE)--May 8, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics and the manufacturer of the OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test, today issued a statement in support of the U.S. Centers for Disease Control and Prevention's (CDC) plans to issue revised HIV testing guidelines that call for voluntary HIV testing as part of routine medical care, for all Americans ages 13 to 64 - regardless of their perceive... 
Printer Friendly Version
05/02/06OraSure Technologies Announces 2006 First Quarter Results
BETHLEHEM, Pa., May 02, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $15.2 million for the quarter ended March 31, 2006, compared to $15.8 million in revenues recorded for the quarter ended March 31, 2005. Increased sales of both the Company's OraQuick(R) ADVANCE(TM) rapid HIV-1/2 antibody test and substance abuse testing products during the first quarter of 2006, were offset by decreased sales of t... 
Printer Friendly Version
04/21/06OraSure Technologies Quarterly Conference Call Invitation; First Quarter Earnings Conference Call Tuesday, May 2, 2006, 5:00 p.m. ET
BETHLEHEM, Pa.--(BUSINESS WIRE)--April 21, 2006--OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular quarterly earnings conference call covering 2006 first quarter financial results for 5:00 p.m. ET (2:00 p.m. PT) on Tuesday, May 2, 2006. May 2, 2006 Schedule 4:00 p.m. ET 2006 first quarter financial results will be distributed by Business Wire 4:50 p.m. ET To participate in the conference call, dial 888... 
Printer Friendly Version
04/19/06Novation Signs Single Source Agreement for OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test
BETHLEHEM, Pa.--(BUSINESS WIRE)--April 19, 2006--OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that Novation, the health care contracting services company of VHA, Inc., a health care provider alliance of more than 2,400 not-for-profit health care organizations, and the University HealthSystem Consortium (UHC), has signed an agreement with Abbott Laboratories to make the OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test available throughout Novation's network of healthcar... 
Printer Friendly Version
03/13/06OraSure Technologies Issues Statement Regarding Proceedings of the Blood Products Advisory Committee Meeting of the FDA; Company Applauds FDA's Recommendations for Proposed Studies To Support Approval of Home-Use HIV Test Kits
BETHLEHEM, Pa.--(BUSINESS WIRE)--March 13, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics and the manufacturer of the OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test, today issued a statement following a meeting of the Blood Products Advisory Committee ("BPAC") of the Food and Drug Administration ("FDA"), held Friday, March 10, 2006, in Gaithersburg, MD. The BPAC meeting included a discussion of proposed studies to support the appr... 
Printer Friendly Version
03/09/06ADVISORY/OraSure Technologies to Host Media Briefing Following Blood Products Advisory Committee Meeting of the FDA; March 10th Committee Meeting to Address Proposed Studies to Support Approval of Over-the-Counter HIV Test Kits
--(BUSINESS WIRE)--OraSure Technologies, Inc. (NASDAQ:OSUR): WHAT: OraSure Technologies, Inc. (NASDAQ:OSUR) CEO and President Douglas Michels will host an on-site media briefing following the Blood Products Advisory Committee (BPAC) meeting on March 10, 2006, to address the outcomes and next steps resulting from the BPAC discussion, as well as the potential for an OTC rapid HIV test from OraSure. The Com... 
Printer Friendly Version
02/22/06OraSure Technologies to Present at the Cowen & Co. Health Care Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 22, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Cowen & Co. Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on March 7, 2006, at approximately 9:40 am Eastern Time (6:40 am Pacific Time). Interested investors can acce... 
Printer Friendly Version
02/09/06OraSure Announces Record Full Year Financial Results; 2005 Results Include $18.2 Million Tax Benefit
BETHLEHEM, Pa., Feb 09, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $69.4 million and $18.0 million for the year and quarter ended December 31, 2005, respectively. Full year 2005 revenues represent record revenues for the Company and a 28% increase over the $54.0 million in revenues recorded in 2004. Revenues for the quarter ended December 31, 2005 were 27% higher than those for the same period in ... 
Printer Friendly Version
02/02/06OraSure Applauds President's Initiative to Prevent, Treat and Defeat HIV/AIDS; President Bush calls for Nation-Wide Deployment of Rapid HIV Tests
BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 2, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics and the manufacturer of the OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test, today issued a statement in support of the Administration's recently-announced initiative to increase efforts to prevent, treat and ultimately defeat HIV/AIDS. The initiative includes a proposal to distribute rapid HIV test kits in areas of the country with the highest rates... 
Printer Friendly Version
01/25/06OraSure Technologies Quarterly Conference Call Invitation; 2005 Fourth Quarter and Year End Earnings Conference Call Thursday February 09, 2006, 5:00 p.m. ET
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 25, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly earnings conference call covering 2005 fourth quarter and full-year financial results for 5:00 pm ET (2:00 pm PT) on Thursday, February 9, 2006. February 9, 2006 Schedule ------------------------- 4:00 p.m. ET 2005 fourth quarter and full-year financial results will be distributed by... 
Printer Friendly Version
01/24/06Johns Hopkins Hospital Successfully Implements Routine Oral Fluid HIV Screening Program with OraQuick(R) ADVANCE(TM); OraQuick(R) ADVANCE(TM) Is Most Used Rapid HIV Test in Hospitals
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 24, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that The Johns Hopkins Hospital Department of Emergency Medicine has implemented an oral fluid HIV screening program in the emergency department of The Johns Hopkins Hospital using the OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody test. The program, which was initiated in September 2005, recently completed its start-up phase and is becoming fully operational. The Johns Hopkins pro... 
Printer Friendly Version
01/09/06OraSure Technologies Appoints New Director
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 9, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced the appointment of Charles W. Patrick as a member of the Company's Board of Directors. Mr. Patrick has been appointed to fill a vacancy on the Company's Board and will serve as a Class III Director with an initial term expiring at the Company's 2006 Annual Meeting of Stockholders. Mr. Patrick has had extensive experience managing hig... 
Printer Friendly Version
01/04/06OraSure Technologies to Present at Needham & Company, LLC Growth Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 4, 2006--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Needham & Company, LLC Growth Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on January 10, 2006, at approximately 11:30 am Eastern Time (8:30 am Pacific Time). Interested investors can acc... 
Printer Friendly Version
12/20/05OraSure Technologies Provides Update Regarding OraQuick(R) ADVANCE(TM)
BETHLEHEM, Pa.--(BUSINESS WIRE)--Dec. 20, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that it has taken several actions in response to recent reports that specific clinical sites in San Francisco and New York City and the L.A. Gay and Lesbian Center have recently experienced an increased level of false positive results using the Company's OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test with oral fluid. The purpose of these actions has been to ensure that custome... 
Printer Friendly Version
12/01/05OraSure Technologies Opens NASDAQ and Donates OraQuick(R) ADVANCE(TM) Tests in Recognition of World AIDS Day; OraSure Also Receives Red Ribbon Leadership Award
BETHLEHEM, Pa.--(BUSINESS WIRE)--Dec. 1, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced it will participate in opening the NASDAQ Stock Market and donate up to 100,000 OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test kits to several African countries and to India in recognition of World AIDS Day, a global effort that is commemorated annually on December 1st. OraSure President and CEO, Douglas A. Michels will announce thi... 
Printer Friendly Version
11/30/05OraSure Launches OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test in Mexico; Event to Be Held at CENSIDA'S Ninth HIV/AIDS Conference on November 30th at 7:00 PM CST
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 30, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, announced today the launch of its OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody test in Mexico. OraQuick(R) ADVANCE(TM) is the only FDA approved and CLIA waived oral fluid rapid HIV-1/2 test currently available in the United States, and will be the only oral fluid rapid HIV test available in Mexico. The OraQuick(R) ADVANCE(TM) test will be sold by... 
Printer Friendly Version
11/09/05OraSure Announces Record Third Quarter Financial Results; Increases Full-Year Earnings Guidance
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 9, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced record revenues of $18.1 million for the quarter ended September 30, 2005, representing a 28% increase over the $14.2 million in revenues recorded for the comparable period in 2004. The Company's net income was $3.8 million, or $0.08 per share on a basic and fully-diluted basis, for the third quarter of 2005. These results compare to a... 
Printer Friendly Version
10/24/05OraSure Technologies Quarterly Conference Call Invitation; 2005 Third Quarter Earnings Conference Call Wednesday November 9, 2005, 5:00 p.m. ET
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 24, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly earnings conference call covering 2005 third quarter financial results for 5:00 pm ET (2:00 pm PT) on Wednesday, November 9, 2005. November 9, 2005 Schedule ------------------------- 4:00 p.m. ET 2005 third quarter financial results will be distributed by Business Wire 4:50 p.m. ET To parti... 
Printer Friendly Version
10/18/05OraSure Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 18, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on October 25, 2005, at approximately 2:20 P.M. Eastern Time (11:20 A.M. Pacific Time). ... 
Printer Friendly Version
10/12/05OraSure Technologies to Present before the FDA Blood Products Advisory Committee on November 3, 2005
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 12, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, announced today that it will present at a meeting of the Blood Products Advisory Committee ("BPAC") of the U.S. Food and Drug Administration ("FDA") in Gaithersburg, Maryland on November 3, 2005. The public meeting will include an OraSure proposal for an Over-the-Counter Home-Use Rapid HIV Test Kit. The full BPAC meeting agenda for the November 3... 
Printer Friendly Version
09/26/05OraSure Technologies Appoints New Chief Science Officer
BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 26, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced that Stephen R. Lee, Ph.D. has been named as the Company's Executive Vice President and Chief Science Officer. Dr. Lee joins OraSure Technologies with twenty years of experience in the immunodiagnostic industry primarily with Ortho Clinical Diagnostics, a Johnson & Johnson company. While at Ortho, Dr. Lee served as Vice President, ... 
Printer Friendly Version
09/12/05OraSure Technologies to Present at UBS Global Life Sciences Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 12, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the UBS Global Life Sciences Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on September 26, 2005, at approximately 3:00 P.M. Eastern Time (12:00 P.M. Pacific Time). Interested investors can ac... 
Printer Friendly Version
08/25/05OraSure Technologies to Present at Thomas Weisel Partners' Healthcare Tailwinds 2005 Conference
BETHLEHEM, Pa., Aug 25, 2005 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, and Ronald H. Spair, Chief Financial Officer, will speak to the investment community at the Thomas Weisel Partners' Healthcare Tailwinds 2005 Conference in Boston, Massachusetts, at approximately 10:55 am Eastern Time (7:55 am Pacific Time) on September 7, 2005. The conference will be simultaneously webcast over the Interne... 
Printer Friendly Version
08/24/05OraSure Technologies Sets 2006 Annual Meeting Date
BETHLEHEM, Pa., Aug 24, 2005 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that its 2006 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 16, 2006, at the Historic Hotel Bethlehem, Bethlehem, Pennsylvania. Stockholder proposals must be received no later than December 9, 2005, in order to be considered for inclusion in the Company's Proxy Statement under relevant Securities and Exchange Commission rules and no later than February 15, 2006,... 
Printer Friendly Version
08/02/05OraSure Receives HCV Patent License from Ortho-Clinical Diagnostics and Chiron Corporation; OraSure to Develop and Commercialize Rapid HCV Test
BETHLEHEM, Pa.--(BUSINESS WIRE)--Aug. 2, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, announced today that it has received a worldwide, non-exclusive license from Ortho-Clinical Diagnostics and Chiron Corporation to patents relating to the hepatitis C ("HCV") virus. Under the terms of the license, OraSure has obtained non-exclusive rights to certain HCV patents from Ortho-Clinical Diagnostics and Chiron Corporation, in exchange for the payme... 
Printer Friendly Version
08/02/05OraSure Announces Record Second Quarter Financial Results; Increases Full-Year Earnings Guidance
BETHLEHEM, Pa.--(BUSINESS WIRE)--Aug. 2, 2005--OraSure Technologies, Inc. (Nasdaq NM:OSUR), a market leader in oral fluid diagnostics, today announced record revenues of $17.4 million for the quarter ended June 30, 2005, representing a 32% increase over the $13.2 million in revenues recorded for the comparable period in 2004. The Company's net income was $1.4 million, or $0.03 per share on a basic and fully-diluted basis, for the second quarter of 2005. These results compare to net ... 
Printer Friendly Version
07/14/05OraSure Technologies Quarterly Conference Call Invitation; 2005 Second Quarter Earnings Conference Call Tuesday August 2, 2005, 5:00 p.m. ET
BETHLEHEM, Pa., Jul 14, 2005 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly earnings conference call covering 2005 second quarter financial results for 5:00 pm ET (2:00 pm PT) on Tuesday, August 2, 2005. August 2, 2005 Schedule ----------------------- 4:00 p.m. ET 2005 second quarter financial results will be distributed by Business Wire 4:50 p.m. ET To participate in the conference cal... 
Printer Friendly Version
06/15/05The National Association of People with AIDS and OraSure Technologies Launch ''Mayors Campaign against HIV'' for National HIV Testing Day 2005; Campaign Urges Mayors across the U.S. to Promote HIV Testing and Prevention
BETHLEHEM, PA.--(BUSINESS WIRE)--June 15, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR) and the National Association of People with AIDS (NAPWA) announced today the launch of the Mayors Campaign Against HIV, a national campaign to encourage testing for HIV and promote the benefits of knowing one's HIV status. The Campaign is being sponsored by OraSure Technologies, the manufacturer of the OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test, in observance of National HIV Testing Day on Ju... 
Printer Friendly Version
06/02/05OraSure and SSL International to Launch Over-the-Counter Cryosurgical Wart Treatment Product in Europe, Australia and New Zealand; OraSure Increases Financial Guidance; SSL International to Distribute Product Under the Scholl Brand
BETHLEHEM, Pa., Jun 02, 2005 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) announced today the execution of an exclusive agreement with SSL International plc (LSE:SSL), under which OraSure will manufacture and supply, and SSL will distribute, the Company's cryosurgical wart removal product in the over-the-counter ("OTC") footcare market in Europe, Australia and New Zealand. The product will be manufactured and sold under SSL International's Scholl and Dr. Scholl trademarks, a... 
Printer Friendly Version
06/01/05OraSure Technologies to Present at Thomas Weisel Partners' Growth Forum 7.0 Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 1, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, and Ronald H. Spair, Executive Vice President and Chief Financial Officer, will speak to the investment community at the Thomas Weisel Partners' Growth Forum 7.0 Conference in San Francisco, California, at approximately 1:55 pm Eastern Time (10:55 am Pacific Time) on June 15, 2005. The conference will be simultaneously webc... 
Printer Friendly Version
05/11/05OraSure Technologies to Webcast Annual Meeting of Stockholders
BETHLEHEM, Pa.--(BUSINESS WIRE)--May 11, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, announced that it will webcast its 2005 Annual Meeting of Stockholders beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) on Tuesday, May 17, 2005. The formal portion of the meeting will be immediately followed by a management presentation and a question and answer session. Persons accessing the webcast who desire to ask questions will be p... 
Printer Friendly Version
05/03/05OraSure Technologies Announces 2005 First Quarter Results; Record Quarterly Revenues of $15.8 Million and Net Income of $1.6 Million; Increases Guidance for 2005 Net Income
BETHLEHEM, Pa.--(BUSINESS WIRE)--May 3, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced record revenues of $15.8 million for the quarter ended March 31, 2005, representing a 28% increase over the $12.4 million in revenues recorded for the comparable period in 2004. Product revenues for the quarter were $15.7 million, also a 28% increase over the first quarter of 2004. The Company's net income was approximately $1.6 million, ... 
Printer Friendly Version
04/15/05OraSure Technologies Quarterly Conference Call Invitation; 2005 First Quarter Earnings Conference Call Tuesday May 3, 2005, 5:00 p.m. ET
BETHLEHEM, Pa., Apr 15, 2005 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly earnings conference call covering 2005 first quarter financial results for 5:00 pm ET (2:00 pm PT) on Tuesday, May 3, 2005. May 3, 2005 Schedule 4:00 p.m. ET 2005 first quarter financial results will be distributed by Business Wire 4:50 p.m. ET To participate in the conference call, dial ... 
Printer Friendly Version
03/30/05OraSure Sponsors ''Road to Hope'' HIV/AIDS Awareness Tour; National Tour of 22 Colleges and Universities Urges HIV Awareness, Testing, Prevention
BETHLEHEM, Pa.--(BUSINESS WIRE)--March 30, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, announced today that it will be the presenting sponsor of the 2005 Road to Hope Tour, a national HIV/AIDS awareness campaign. The tour is being organized by Hope's Voice, a national HIV/AIDS organization committed to promoting the education and prevention of HIV/AIDS to young adults and the Student Global AIDS Campaign (SGAC), a national HIV/AIDS advocacy... 
Printer Friendly Version
03/04/05OraSure Technologies to Present at SG Cowen's Health Care Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--March 4, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the SG Cowen Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on March 15, 2005, at approximately 11:20 am Eastern Time (8:20 am Pacific Time). Interested investors can access ... 
Printer Friendly Version
02/18/05OraSure Technologies to Present at Wells Fargo Securities' Healthcare Fireside Chats
BETHLEHEM, Pa., Feb 18, 2005 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that Douglas A. Michels, President and Chief Executive Officer, and Ronald H. Spair, Executive Vice President and Chief Financial Officer, will speak to the investment community at the Wells Fargo Securities' Health Care Fireside Chats in New York, New York. The conference will be simultaneously webcast over the Internet. Mr. Michels and Mr. Spair are scheduled to speak on March 2,... 
Printer Friendly Version
02/14/05Abbott and OraSure Technologies Enter Agreement for OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Test
Abbott Obtains Exclusive Distribution Rights for Hospitals and Non-Exclusive Rights to Physician Offices in the United States ABBOTT PARK, Ill., and BETHLEHEM, Pa., Feb. 14 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and OraSure Technologies (Nasdaq: OSUR) today announced an agreement for the distribution of OraSure Technologies' OraQuick(R) ADVANCE(TM) rapid antibody test for the detection of antibodies to the Human Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2). Under the... 
Printer Friendly Version
02/10/05OraSure Announces Record Financial Results
BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 10, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced record revenues of $54.0 million and $14.2 million for the year and quarter ended December 31, 2004, respectively. Full year 2004 revenues represent a 34% increase from the $40.5 million in revenues recorded for 2003. Revenues for the quarter ended December 31, 2004 were 20% higher than those for the same period of 2003. The Company ... 
Printer Friendly Version
01/27/05OraSure Technologies Quarterly Conference Call Invitation; 2004 Fourth Quarter and Year End Earnings Conference Call Thursday, February 10, 2005, 5:00 p.m. ET
BETHLEHEM, Pa., Jan 27, 2005 /PRNewswire-FirstCall via COMTEX/ -- OraSure Technologies, Inc. (Nasdaq: OSUR) has scheduled its regular quarterly earnings conference call covering 2004 fourth quarter and full-year financial results for 5:00 pm ET (2:00 pm PT) on Thursday, February 10, 2005. February 10, 2005 Schedule 4:00 p.m. ET 2004 fourth quarter and full-year financial results will be distributed by Business Wire 4:50 p.m. ET To participate in t... 
Printer Friendly Version
12/22/04CDC to Purchase $2.3 Million Worth of OraQuick ADVANCE Rapid HIV-1/2 Antibody Tests; Company Updates Financial Guidance for 2005
BETHLEHEM, Pa.--(BUSINESS WIRE)--Dec. 22, 2004--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, announced today that The Centers for Disease Control and Prevention ("CDC") will purchase approximately $2.3 million of the Company's OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Tests. The CDC purchase is expected to be fulfilled by September 30, 2005. This is the first bulk purchase of the OraQuick(R) ADVANCE(TM) test. Two other bulk purchases of... 
Printer Friendly Version
12/01/04OraSure Technologies Opens NASDAQ Stock Market in Honor of World AIDS Day; Cities Across the U.S. Launch Rapid Oral Fluid HIV Testing with OraQuick ADVANCE
BETHLEHEM, Pa., Dec 1, 2004 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today opened The NASDAQ Stock Market in recognition of World AIDS Day, commemorated annually on December 1. OraSure President and CEO, Douglas A. Michels, presided over The NASDAQ Market Open ceremony this morning in New York City. This year's World AIDS Day is dedicated to women and girls. Nearly half of the estimated 37.2 million adults living with HI... 
Printer Friendly Version
11/10/04OraQuick ADVANCE Rapid HIV-1/2 Antibody Test Receives Popular Science Magazine's '2004 Best of What's New' Award
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 10, 2004--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, announced today that its OraQuick(R) ADVANCE Rapid HIV-1/2 Antibody Test has been awarded a 2004 Best of What's New award by Popular Science magazine in the Personal Health category. The award was announced on November 9, 2004, at the Best of What's New Showcase Event at Vanderbilt Hall in Grand Central Terminal in New York City. The OraQuick(R) ADVA... 
Printer Friendly Version
11/02/04OraSure Announces 2004 Third Quarter Results; Company Reports Record Quarterly Revenues; Increases Full Year Revenue Estimate
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 2, 2004--OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its financial results for the quarter and nine months ended September 30, 2004. Total revenues for the third quarter of 2004 increased 37% to $14.2 million, compared to $10.3 million for the quarter ended September 30, 2003. Product revenues for the third quarter increased 38% to $14.1 million, compared to $10.2 million in 2003. Both amo... 
Printer Friendly Version
10/22/04OraSure Technologies Quarterly Conference Call Invitation; 2004 Third Quarter Earnings Conference Call Tuesday, November 2, 2004, 5:00 p.m. ET
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 22, 2004--OraSure Technologies, Inc. (NASDAQ NM:OSUR) has scheduled its regular quarterly earnings conference call covering third quarter 2004 financial results for 5:00 pm ET (2:00 pm PT) on Tuesday, November 2, 2004. November 2, 2004 Schedule ------------------------- 4:00 p.m. ET Q3 2004 results will be distributed by Business Wire 4:50 p.m. ET To participate in the conference call, ... 
Printer Friendly Version
10/20/04OraSure Announces Launch of OraQuick ADVANCE Rapid HIV-1/2 Antibody Test; Initial Shipments Expected in Early November 2004
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 20, 2004--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, announced today that it is launching its OraQuick(R) ADVANCE Rapid HIV-1/2 Antibody Test, the first and only U.S. Food and Drug Administration ("FDA") approved and CLIA (Clinical Laboratory Improvements Amendments Act of 1988) waived rapid point-of-care test that provides accurate results for both HIV-1 and HIV-2 in 20 minutes, using oral fluid, finger-sti... 
Printer Friendly Version
09/28/04Early Trial Set in OraSure Patent Infringement Lawsuit Against Schering-Plough
BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 28, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR) today announced that an early trial has been set in the Company's patent infringement lawsuit filed against Schering-Plough Healthcare Products, Inc. (NYSE:SGP). As a result, a final trial on the merits in this matter is expected to occur in February 2005. The trial will include an early final determination of the Company's request for permanent injunctive relief, in lieu of its prior reque... 
Printer Friendly Version
09/21/04OraSure Technologies to Present at UBS Global Life Sciences Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 21, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the UBS Global Life Sciences Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on September 28, 2004, at approximately 12:00 P.M. Eastern Time (9:00 am Pacific Time). Interested investors can a... 
Printer Friendly Version
09/01/04OraSure Technologies to Present at Thomas Weisel Partners' Healthcare Tailwinds 2004 Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 1, 2004--OraSure Technologies, Inc. (NASDAQ NM:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, and Ronald H. Spair, Chief Financial Officer, will speak to the investment community at the Thomas Weisel Partners' Healthcare Tailwinds 2004 Conference in Boston, Massachusetts, at approximately 4:25 pm Eastern Time (1:25 pm Pacific Time) on September 8, 2004. The conference will be simultaneously webcast over the Inte... 
Printer Friendly Version
08/11/04OraSure Technologies Sets 2005 Annual Meeting Date
BETHLEHEM, Pa.--(BUSINESS WIRE)--Aug. 11, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR) today announced that its 2005 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 17, 2005, at the Radisson Hotel Bethlehem, Bethlehem, Pennsylvania, 18018. Stockholder proposals must be received no later than December 11, 2004, in order to be considered for inclusion in the Company's Proxy Statement under relevant Securities and Exchange Commission rules and no later than Februa... 
Printer Friendly Version
08/06/04OraSure Receives $4 Million Purchase Order from SAMHSA for OraQuick Rapid HIV Antibody Tests and HIV Confirmatory Test Services
Tests to Be Deployed to over 22,000 Sites Throughout the U.S. BETHLEHEM, Pa.--(BUSINESS WIRE)--Aug. 6, 2004-- OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that the Substance Abuse and Mental Health Services Administration ("SAMHSA") has committed to purchase $4 million of the Company's OraQuick(R) Rapid HIV Antibody Tests and HIV confirmatory test services. The OraQuick(R) tests and related confirmatory service... 
Printer Friendly Version
08/03/04OraSure Announces 2004 Second Quarter Results; Company Reports Net Profit for the Quarter; Increases Full Year Revenue Estimate
BETHLEHEM, Pa.--(BUSINESS WIRE)--Aug. 3, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR), a market leader in oral fluid diagnostics, today announced its financial results for the quarter and six months ended June 30, 2004. Total revenues for the second quarter of 2004 increased 37% to $13.2 million, compared to $9.6 million for the quarter ended June 30, 2003. Product revenues for the second quarter increased 39% to $13.1 million, compared to $9.4 million in 2003. Both amounts rep... 
Printer Friendly Version
07/26/04OraSure Technologies Sues Schering-Plough for Patent Infringement
BETHLEHEM, Pa.--(BUSINESS WIRE)--July 26, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR) today announced that it has filed a lawsuit against Schering-Plough Healthcare Products, Inc. (NYSE:SGP) for infringement of several OraSure patents relating to the technology for the cryosurgical removal (i.e., freezing) of warts and other benign skin lesions. The suit was commenced in the United States District Court for the Eastern District of Pennsylvania, and alleges that Schering-Plough... 
Printer Friendly Version
07/22/04OraSure Technologies Quarterly Conference Call Invitation; 2004 Second Quarter Earnings Conference Call Tuesday, August 3, 2004, 5:00 p.m. ET
BETHLEHEM, Pa.--(BUSINESS WIRE)--July 22, 2004--OraSure Technologies, Inc. (NASDAQ NM:OSUR) has scheduled its regular quarterly earnings conference call covering second quarter 2004 financial results for 5:00 pm ET (2:00 pm PT) on Tuesday, August 3, 2004. August 3, 2004 Schedule ----------------------- 4:00 p.m. ET Q2 2004 results will be distributed by Business Wire 4:50 p.m. ET To participate in the conference call, ... 
Printer Friendly Version
06/25/04OraSure Receives CLIA Waiver for OraQuick Rapid HIV-1/2 Antibody Test
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 25, 2004--OraSure Technologies, Inc. (NASDAQ NM:OSUR), the market leader in oral fluid diagnostics, announced today that the U.S. Food and Drug Administration ("FDA"), through its Center for Devices and Radiological Health, has approved a waiver under the Clinical Laboratory Improvements Amendments of 1988 ("CLIA") for the Company's OraQuick(R) Rapid HIV-1/2 Antibody Test. Specifically, the test has been waived for use in detecting HIV-1 and HI... 
Printer Friendly Version
06/23/04FDA Approves OraQuick HIV-1/2 Test to Detect HIV-2 in Oral Fluid
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 23, 2004--OraSure Technologies, Inc. (NASDAQ NM:OSUR), the market leader in oral fluid diagnostics, announced today that it has received U.S. Food and Drug Administration ("FDA") approval of its OraQuick(R) Rapid HIV-1/2 Antibody Test for use in detecting antibodies to the Human Immunodeficiency Virus Type 2, or HIV-2, in oral fluid samples. With this approval, the OraQuick(R) HIV-1/2 Test is the only rapid, point-of-care test approved by the FDA for ... 
Printer Friendly Version
06/23/04OraSure Technologies Appoints New President and Chief Executive Officer; Conference Call/Webcast Scheduled For 1:00 PM Eastern Time Today
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 23, 2004--OraSure Technologies, Inc. (NASDAQ NM:OSUR), a market leader in oral fluid diagnostics, today announced that Douglas A. Michels has been named President and Chief Executive Officer and appointed to the Company's Board of Directors. Mr. Michels will replace Mike Gausling, who has been OraSure's President and Chief Executive Officer since January 2002 and a member of the Company's Board since September 2000. Mr. Gausling had previously announc... 
Printer Friendly Version
06/22/04OraSure to Open NASDAQ Stock Market in Honor of National HIV Testing Day; Company Will Also Donate OraQuick Rapid HIV-1 Antibody Tests
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 22, 2004--OraSure Technologies, Inc. (NASDAQ NM:OSUR), the market leader in oral fluid diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody Test will be donated to numerous locations across the United States to conduct free HIV testing in observance of National HIV Testing Day on June 27, 2004. Additionally, in further recognition of this annual observance, OraSure Technologies will preside over the opening of The NASDAQ Stock Market... 
Printer Friendly Version
06/21/04OraSure Receives Rapid Test HIV-2 Patent Sublicense From Bio-Rad
Sublicense Enables OraSure To Market OraQuick(R) Rapid HIV-1/2 Antibody Test BETHLEHEM, Pa.--(BUSINESS WIRE)--June 21, 2004-- OraSure Technologies, Inc. (NASDAQ NM:OSUR) announced today that it has received a worldwide, non-exclusive sublicense from Bio-Rad Laboratories (AMEX:BIO and BIOb) under patents relating to the Human Immunodeficiency Virus, Type 2, or HIV-2. Bio-Rad is the exclusive licensee of Institut Pasteur of Paris, France, under the H... 
Printer Friendly Version
06/08/04OraSure Technologies to Present at Thomas Weisel Partners' Growth Forum 6.0 Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 8, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR) today announced that Mike Gausling, President and Chief Executive Officer, and Ron Spair, Executive Vice President and Chief Financial Officer, will speak to the investment community at the Thomas Weisel Partners' Growth Forum 6.0 Conference in Laguna Beach, California, at approximately 6:30 pm Eastern Time (3:30 pm Pacific Time) on June 15, 2004. The conference will be simultaneously webcast over t... 
Printer Friendly Version
05/12/04OraSure Technologies to Webcast Annual Meeting of Stockholders
BETHLEHEM, Pa.--(BUSINESS WIRE)--May 12, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced that it will webcast its 2004 Annual Meeting of Stockholders beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) on Tuesday, May 18, 2004. The formal portion of the meeting will be immediately followed by a management presentation and a question and answer session. Persons accessing the webcast who desire to ask questions will b... 
Printer Friendly Version
05/04/04OraSure Technologies to Present at Rodman & Renshaw Techvest Global Healthcare Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--May 4, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR) today announced that Mike Gausling, President and Chief Executive Officer, and Ronald H. Spair, Executive Vice President and Chief Financial Officer, will speak to the investment community at the Rodman & Renshaw Techvest Global Healthcare Conference in London, England. The conference will be simultaneously webcast over the Internet. Messrs. Gausling and Spair are scheduled to speak on May 13, ... 
Printer Friendly Version
04/27/04OraSure Technologies Announces 2004 First Quarter Results; Revenues Increase 44% to $12.4 Million
BETHLEHEM, Pa.--(BUSINESS WIRE)--April 27, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR), a market leader in oral fluid diagnostics, today announced record revenues of $12.4 million for the quarter ended March 31, 2004, representing a 44% increase over the $8.6 million in revenues recorded for the comparable period in 2003. Product revenues for the quarter were $12.3 million, a 47% increase over the first quarter of 2003. The Company's net loss was approximately $162,000, or $(0... 
Printer Friendly Version
04/20/04OraSure Technologies and Drager Safety Launch UPlink Oral Fluid Rapid Drug Detection System in Europe
BETHLEHEM, Pa.--(BUSINESS WIRE)--April 20, 2004--OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, in conjunction with its development and distribution partner, Drager Safety AG & Co. KGaA, located in Lubeck, Germany, today announced the European launch of the Company's UPlink(R) Oral Fluid Rapid Drug Detection System. The UPlink(R) System is expected to be initially used by law enforcement agencies primarily to test operators and passengers of motor veh... 
Printer Friendly Version
04/14/04OraSure Technologies Invites You to Join Its 2004 First Quarter Financial Results Conference Call
BETHLEHEM, Pa.--(BUSINESS WIRE)--April 14, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR) will host a conference call with analysts and an audio webcast to discuss the Company's first quarter 2004 financial results beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Tuesday, April 27 2004. The call will be preceded by the release of the Company's 2004 first quarter financial results, which will occur immediately after the market closes that day. In order to listen to ... 
Printer Friendly Version
03/26/04OraSure Receives FDA Approval of OraQuick Oral Fluid and Plasma Claims; First and Only Oral Fluid Rapid HIV Test Approved in U.S. by the FDA
Press Conference Footage and B-Roll Available via Satellite Uplink, March 26, at 2 PM EST BETHLEHEM, Pa.--(BUSINESS WIRE)--March 26, 2004--OraSure Technologies, Inc. (NasdaqNM:OSUR), the market leader in oral fluid diagnostics, announced today that it has received U.S. Food and Drug Administration ("FDA") approval of its OraQuick(R) Rapid HIV Antibody Test for use with oral fluid -- making the test the first and only rapid HIV test to be approved in the U.S. by the FDA for use... 
Printer Friendly Version
03/26/04OraSure Required to Submit Additional Data for FDA Clearance of UPlink Oral Fluid Rapid Drug Detection System
BETHLEHEM, Pa.--(BUSINESS WIRE)--March 26, 2004--OraSure Technologies, Inc. (NASDAQNM:OSUR), a market leader in oral fluid diagnostics, today announced that it will need to submit additional performance data to the U.S. Food and Drug Administration ("FDA") in order to obtain 510(k) clearance of its UPlink(R) Oral Fluid Drug Detection System. In September 2003, OraSure submitted an application with the FDA for 510(k) clearance of its UPlink(R) analyzer and oral fluid assays for the ... 
Printer Friendly Version
03/23/04OraSure Receives FDA Approval for Test to Detect HIV-2 Antibodies
BETHLEHEM, Pa.--(BUSINESS WIRE)--March 23, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR) announced today that the U.S. Food and Drug Administration ("FDA") has approved the Company's new OraQuick(R) Rapid HIV-1/2 Antibody Test. This approval will allow the simultaneous detection of antibodies to both the HIV-1 and HIV-2 viruses in finger stick and venipuncture whole blood specimens. "Receiving FDA approval to test for HIV-2 is another significant milestone," said Mike Gausling, ... 
Printer Friendly Version
03/17/04OraSure Technologies to Present at Wells Fargo Securities' Healthcare Fireside Chats
BETHLEHEM, Pa.--(BUSINESS WIRE)--March 17, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR) announced today that Mike Gausling, President and Chief Executive Officer, and Ron Spair, Executive Vice President and Chief Financial Officer, will speak to the investment community at the Wells Fargo Securities' Health Care Fireside Chats in New York, New York. The conference will be simultaneously webcast over the Internet. Mr. Gausling and Mr. Spair are scheduled to speak on March 24, 2... 
Printer Friendly Version
03/10/04OraSure Receives FDA Approval to Transfer Manufacturing
BETHLEHEM, Pa.--(BUSINESS WIRE)--March 10, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced that the U.S. Food and Drug Administration ("FDA") has approved the transfer of manufacturing of its OraSure(R) HIV-1 oral specimen collection device from Oregon to the Company's Bethlehem, Pennsylvania facilities. In late 2003, the Company also received approval to transfer manufacturing of its oral fluid Western blot HIV-1 confirmatory test... 
Printer Friendly Version
03/08/04OraSure CEO To Retire By Year-End
BETHLEHEM, Penn.--(BUSINESS WIRE)--March 8, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR) today announced that Mike Gausling, the Company's President and Chief Executive Officer, will retire from the Company and its Board of Directors by the end of 2004. "After consultation with the Board of Directors, we have decided that 2004 is an opportune time to transition the leadership of the Company," said Mike Gausling. "I have served this Company with my best efforts for 17 years and ... 
Printer Friendly Version
03/04/04CDC Reports That OraQuick Test Produces Fewer False Positive HIV-1 Results Than Other Available Tests
BETHLEHEM, Pa.--(BUSINESS WIRE)--March 4, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody Test was reported to produce substantially fewer false-positive results than traditional lab-based HIV tests or other U.S. Food and Drug Administration ("FDA") approved rapid HIV tests when used in a laboratory setting. This information is based on the results from clinical trials submitted to th... 
Printer Friendly Version
03/03/04OraSure Technologies to Present at SG Cowen's Health Care Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--March 3, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR) today announced that Mike Gausling, President and Chief Executive Officer, will speak to the investment community at the SG Cowen Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet. Mr. Gausling is scheduled to speak on March 10, 2004, at approximately 10:15 am Eastern Time (7:15 am Pacific Time). Interested investors can access t... 
Printer Friendly Version
02/23/04OraSure Announces Resolution of Dispute with Abbott Laboratories
BETHLEHEM, Pa., Feb 23, 2004 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq NM:OSUR) announced the receipt of an arbitrator's decision resolving its dispute with Abbott Laboratories under the parties' distribution agreement for the Company's OraQuick(R) Rapid HIV-1 Antibody Test. The arbitrator ruled that the agreement was not terminated and will remain in effect. In addition, consistent with the arbitrator's rulings OraSure has notified Abbott that the agreement has been converted... 
Printer Friendly Version
02/10/04OraSure Announces Record Financial Results
BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 10, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, today announced record revenues of $40.5 million and $11.9 million for the year and quarter ended December 31, 2003, respectively. Full year 2003 revenues represent a 26% increase from the $32.0 million in revenues recorded for 2002. Revenues for the quarter ended December 31, 2003, were 44% higher than those for the same period of 2002. The Comp... 
Printer Friendly Version
02/06/04OraSure Salutes National Black HIV/AIDS Awareness and Information Day with OraQuick Rapid Testing Initiative on February 7th
OraSure Partners with HIV Testing Sites Across the Country to Encourage Rapid HIV Testing with OraQuick(R) BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 6, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody Test will be utilized by numerous locations across the United States to conduct free HIV testing in observance of National Black HIV/AIDS Awareness and Information Day on February 7, 20... 
Printer Friendly Version
01/30/04OraSure to Receive New Patent Covering Lateral Flow Test for Oral Fluid and Other Specimens
BETHLEHEM, Pa., Jan 30, 2004 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that it has received notice from the United States Patent and Trademark Office that a new patent will be issued with broad claims covering a lateral flow diagnostic test that can be used to test oral fluid or other specimen types for the presence of one or more antibodies or other analytes. The patent's claims will cover the Company's cu... 
Printer Friendly Version
01/29/04OraSure Technologies Appoints New Director of Hospital Sales
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 29, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today the hiring of David G. Stevans as Director, Hospital Sales. Mr. Stevans joins OraSure with extensive sales and hospital management experience in the biopharmaceutical and healthcare industries, with a specialization in HIV/AIDS and infectious diseases. In his role at OraSure, he will be responsible for directing the sales of the Company'... 
Printer Friendly Version
01/28/04OraSure Technologies Invites You To Join Its 2003 Fourth Quarter and Full-Year Financial Results Conference Call
BETHLEHEM, Penn.--(BUSINESS WIRE)--Jan. 28, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR) will host a conference call with analysts and an audio webcast to discuss the Company's 2003 fourth quarter and full-year financial results, and 2004 guidance and major business objectives, beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Tuesday, February 10, 2004. The call will be preceded by the release of the Company's 2003 financial results, which will occur immediately after ... 
Printer Friendly Version
01/26/04OraQuick Rapid HIV-1 Antibody Test is Honored for Innovation with 2003 Circle of Excellence Award
BETHLEHEM, Pa., Jan 26, 2004 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody Test has received the prestigious 2003 Photonics Circle of Excellence Award. This Award is bestowed annually on the 25 most technically innovative new products of the year, as judged by members of the Photonics Spectra magazine Editorial Advisory Board. The award was announced today at the Photon... 
Printer Friendly Version
12/17/03FDA Completes Inspection of OraSure Manufacturing Facility; Manufacturing Consolidation Expected To Save $1 Million Annually
BETHLEHEM, Pa., Dec 17, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that the U.S. Food and Drug Administration ("FDA") has successfully completed a facility inspection required for the transfer of the Company's in-house and third party contract manufacturing operations from Oregon to Bethlehem, Pennsylvania. In August and October, 2003, the Company submitted pre-market approval ("PMA") supplements t... 
Printer Friendly Version
12/15/03OraSure Submits Additional Data to FDA for OraQuick HIV-2 Claim
BETHLEHEM, Pa., Dec 15, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it has submitted the additional data requested by the U.S. Food and Drug Administration ("FDA") in support of an HIV-2 claim for its OraQuick(R) Rapid HIV-1 Antibody Test. In June 2003, the Company submitted an application to the FDA for approval of the OraQuick(R) test for use in detecting HIV-2 antibodies. On November 14, 2003, t... 
Printer Friendly Version
12/01/03CDC Commits Additional $2 Million for Purchase of OraQuick Rapid HIV-1 Antibody Tests
BETHLEHEM, Pa.--(BUSINESS WIRE)--Dec. 1, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that The Centers for Disease Control and Prevention ("CDC") has committed to purchase an additional 250,000 OraQuick(R) Rapid HIV-1 Antibody Tests for a total of $2 million. The CDC purchase is expected to be fulfilled by September 1, 2004, and further supports its four-part HIV prevention strategy, which was previously announced on April... 
Printer Friendly Version
11/26/03OraSure Technologies to Open NASDAQ Stock Market on December 1, 2003 in Honor of World AIDS Day
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 26, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that in recognition of World AIDS Day, OraSure Technologies will open the NASDAQ Stock Market on Monday, December 1, 2003. OraSure's President and Chief Executive Officer Mike Gausling will preside over the NASDAQ Market Open ceremony beginning at 9:20 a.m. OraSure has been recognized as a leader in HIV testing with the intr... 
Printer Friendly Version
11/20/03OraSure Technologies Sets 2004 Annual Meeting Date
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 20, 2003--OraSure Technologies, Inc. (NasdaqNM:OSUR) today announced that its 2004 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 18, 2004, at the Radisson Hotel Bethlehem, Bethlehem, Pennsylvania, 18018. Stockholder proposals must be received no later than December 12, 2003, in order to be considered for inclusion in the Company's Proxy Statement under relevant Securities and Exchange Commission rules and no later than Februar... 
Printer Friendly Version
11/17/03OraSure To Submit Additional Data To FDA For OraQuick HIV-2 Claim
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 17, 2003--OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it will be submitting a small amount of additional data to the U.S. Food and Drug Administration ("FDA") in support of an HIV-2 claim for its OraQuick(R) Rapid HIV-1 Antibody Test. In June 2003, the Company submitted an application to the FDA for approval of the OraQuick(R) test for use in detecting HIV-2 antibodies. In response... 
Printer Friendly Version
11/07/03OraQuick Rapid HIV-1 Antibody Test Receives Popular Science Magazine's '2003 Best of What's New' Award
OraQuick(R) to be Featured in December 2003 Issue as Winner in Personal Health Category BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 7, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody Test has been awarded a 2003 Best of What's New award by Popular Science magazine in the Personal Health category. The award was announced on November 6, 2003, at the Best of What's New Showcase Ev... 
Printer Friendly Version
11/03/03OraSure Announces Exercise of Underwriters' Overallotment Option
BETHLEHEM, Pa., Nov 3, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that the underwriters of its recent public offering of 5,000,000 shares of common stock have purchased an additional 311,000 shares pursuant to an overallotment option granted in connection with the offering. This represents a partial exercise of the option, which originally covered 750,000 shares of the Company's common stock. With the exercise of the overallotment option, the offering... 
Printer Friendly Version
10/28/03OraSure Announces Record Revenues and Net Profit for Third Quarter 2003
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 28, 2003--OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its financial results for the quarter and nine months ended September 30, 2003, provided an update on its strategy to distribute OraQuick(R) to the hospital market, and reaffirmed its financial guidance for 2003 and 2004. Total revenues for the third quarter of 2003 increased 27% to $10.3 million, compared to $8.1 million for the quar... 
Printer Friendly Version
10/16/03OraSure Technologies Invites You to Join Its 2003 Third Quarter Financial Results Conference Call
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 16, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR) will host a conference call with analysts and an audio webcast to discuss the Company's third quarter 2003 financial results beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Tuesday, October 28, 2003. The call will be preceded by the release of the Company's third quarter 2003 financial results, which will occur immediately after the market closes that day. In order to listen t... 
Printer Friendly Version
10/15/03OraSure Technologies to Present at Rodman & Renshaw Techvest Healthcare Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 15, 2003--OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Mike Gausling, President and Chief Executive Officer, and Ronald H. Spair, Executive Vice President and Chief Financial Officer, will speak to the investment community at the Rodman & Renshaw Techvest Healthcare Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet. Messrs. Gausling and Spair are scheduled to speak on October 22... 
Printer Friendly Version
10/02/03OraSure Sells 5,000,000 Shares of Common Stock
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 2, 2003--OraSure Technologies, Inc. (Nasdaq:OSUR), today announced that it has entered into an underwriting agreement for the sale by the Company of 5,000,000 shares of common stock in a public offering under its shelf registration statement. Proceeds to the Company from the sale are expected to be $45 million before underwriting discounts and commissions and other offering expenses. The Company has also granted to the underwriters an option to purcha... 
Printer Friendly Version
09/29/03OraSure Seeks FDA Approval of Oral Fluid and Plasma Claims for OraQuick Rapid HIV-1 Antibody Test
BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 29, 2003--OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, announced that it is filing an application today with the U.S. Food and Drug Administration ("FDA") for pre-market approval of its OraQuick(R) Rapid HIV-1 Antibody Test for use in detecting HIV-1 antibodies in both oral fluid, or saliva, and plasma samples. Under applicable regulations, the FDA has 180 days to respond to the submission. "This filing ... 
Printer Friendly Version
09/22/03OraSure Technologies Seeks FDA Clearance for UPlink Oral Fluid NIDA-5 Drug Test System
BETHLEHEM, Pa., Sep 22, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced that it has filed an application for 510(k) clearance with the U.S. Food and Drug Administration ("FDA") for its UPlink(R) analyzer and oral fluid assays for the rapid, point-of-care detection of drugs of abuse commonly identified by the National Institute for Drug Abuse ("NIDA") as the NIDA-5, i.e., - cocaine, opiates, amphetamine/methamphet... 
Printer Friendly Version
09/17/03OraSure Technologies Renews Credit Facility with Comerica Bank
BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 17, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today the renewal of its existing credit facility with Comerica Bank (NYSE:CMA). In September 2002, Comerica's Technology and Life Sciences Division provided OraSure with a $10.9 million credit facility, composed of a $4 million line of credit for working capital, a $3 million term loan, a $3 million credit line for capital equipment p... 
Printer Friendly Version
09/16/03CDC Study Finds That OraQuick Test Provides Fast Results During Labor and Delivery
BETHLEHEM, Pa., Sep 16, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that the use of its OraQuick(R) Rapid HIV-1 Antibody Test at the point of care was found to provide testing results four-times faster than when the OraQuick(R) test was used in a laboratory setting. These findings resulted from the Mother Infant Rapid Intervention at Delivery (MIRIAD) study, which was conducted by the Centers for Disease... 
Printer Friendly Version
09/10/03OraSure Technologies Announces Public Offering
BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 10, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, today announced that it plans to publicly offer 5,000,000 shares of its common stock. The offering will be made pursuant to a registration statement covering shares of common stock that became effective on August 8, 2003. The Company will grant to the underwriters an option to purchase an additional 750,000 shares of its common stock not later than 30 ... 
Printer Friendly Version
09/09/03FDA Approves Venipuncture Whole Blood Claim for OraQuick Rapid HIV-1 Antibody Test
BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 9, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody Test has been approved by the U.S. Food and Drug Administration ("FDA") for use in detecting HIV-1 antibodies in venipuncture whole blood specimens. This is the second claim approved by the FDA for the OraQuick(R) test. In November 2002, the Company received approval for use of the OraQuic... 
Printer Friendly Version
09/02/03OraSure Technologies to Present at Thomas Weisel Partners' Healthcare Tailwinds 2003 Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 2, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR) today announced that Mike Gausling, President and Chief Executive Officer, will speak to the investment community at the Thomas Weisel Partners' Healthcare Tailwinds 2003 Conference in Boston, Massachusetts, at approximately 10:00 am Eastern Time (7:00 am Pacific Time) on September 5, 2003. The conference will be simultaneously webcast over the Internet. Interested investors can access the li... 
Printer Friendly Version
07/29/03OraSure Technologies Announces Record 2003 Second Quarter Results
BETHLEHEM, Pa.--(BUSINESS WIRE)--July 29, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, today announced its financial results for the quarter and six months ended June 30, 2003. Total revenues for the quarter increased 21% to $9.6 million, compared to $7.9 million for the quarter ended June 30, 2002. Product revenues for the second quarter of 2003 increased 20% to $9.4 million, compared to $7.9 million in 2002. Both amounts represent... 
Printer Friendly Version
07/29/03OraSure Receives Approval to Distribute OraQuick Rapid HIV-1 Antibody Test in Mexico; Approval Includes Oral Fluid Testing
BETHLEHEM, Pa., Jul 29, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that it has received approval from the Ministry of Health in Mexico for its OraQuick (R)Rapid HIV-1 Antibody Test. Pursuant to this approval, the Company can distribute the OraQuick(R) test to healthcare professionals in Mexico for the detection of HIV-1 antibodies in both finger-stick whole blood and oral fluid samples. The approva... 
Printer Friendly Version
07/17/03OraSure Ships over $1 Million of New Compound W Freeze Off Cryosurgical Wart Treatment Product
BETHLEHEM, Pa.--(BUSINESS WIRE)--July 17, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR) announced today that it has shipped more than $1 million of its cryosurgical wart treatment product to Medtech Products, Inc., for distribution in the over-the-counter ("OTC") market in the United States. The shipment was completed in June 2003. The product will be sold under Medtech's Compound W(R) brand name and Freeze Off(TM) trademark, and is expected to be available for retail purchase in drug... 
Printer Friendly Version
07/15/03OraSure Technologies Invites You To Join Its 2003 Second Quarter Financial Results Conference Call
BETHLEHEM, Penn.--(BUSINESS WIRE)--July 15, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR) will host a conference call with analysts and an audio webcast to discuss the Company's second quarter 2003 financial results beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Tuesday, July 29, 2003. The call will be preceded by the release of the Company's second quarter 2003 financial results and certain business developments, which will occur immediately after the market closes t... 
Printer Friendly Version
07/03/03OraSure Technologies Files Universal Shelf Registration Statement
BETHLEHEM, Pa.--(BUSINESS WIRE)--July 3, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, today announced that it has filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission ("SEC") for the registration and potential issuance of up to $75 million of OraSure securities. The securities covered by the universal shelf, which may include common stock, preferred stock or debt securities, are bein... 
Printer Friendly Version
06/26/03CDC Commits $2 Million for Purchase Of OraQuick Rapid HIV-1 Antibody Tests
Press Conference Footage and B-Roll Available via Satellite Uplink, Thursday, June 26 at 3:15 PM EDT WASHINGTON & BETHLEHEM, Pa., Jun 26, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that The Centers for Disease Control and Prevention ("CDC") has committed to a purchase of 250,000 OraQuick(R) Rapid HIV-1 Antibody Tests along with OraQuick(R) training materials and services for 50 locations across the Uni... 
Printer Friendly Version
06/25/03ADVISORY/Orasure Technologies and Senator Specter to Announce Major Initiative in Conjunction with CDC On Rapid HIV-1 Antibody Testing
Press Conference - Thursday, June 26 on Capitol Hill, Washington, D.C. --(BUSINESS WIRE)-- National HIV Testing Day Satellite Uplink Feed - 2:00 PM EDT, Today, June 25 EVENT: Senator Arlen Specter (R-PA), Chairman of the Labor, Health and Human Services, and Education Appropriations Subcommittee, along with OraSure Technologies, Inc. (Nasdaq:OSUR), and other federal government officials will announce a major initiative between OraSure and the Centers for Disease Contro... 
Printer Friendly Version
06/24/03OraSure to Donate OraQuick Rapid HIV-1 Antibody Test for National HIV Testing Day on June 27th; Interview Footage and B-Roll Available via Satellite Uplink Wednesday, June 25
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 24, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody Test will be donated to numerous locations across the United States to conduct free HIV testing in observance of National HIV Testing Day on June 27, 2003. This will mark the first time in the history of National HIV Testing Day that a rapid, point-of-care HIV test will be made available for this... 
Printer Friendly Version
06/06/03OraQuick Rapid HIV-1 Antibody Test Receives Gold Medical Design Excellence Award
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 6, 2003--OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody Test has received the Gold Medical Design Excellence Award in the "In Vitro Diagnostics" category in the sixth annual Medical Design Excellence Awards (MDEA) competition. The Gold Award, a top award in its category, was announced on June 3, 2003, at the Medical Design & Manufacturing East Exposition ... 
Printer Friendly Version
05/15/03OraSure Technologies to Host HHS Deputy Secretary Claude Allen at Event on HIV Testing and Prevention
BETHLEHEM, Pa.--(BUSINESS WIRE)--May 15, 2003--Claude Allen, Deputy Secretary of the U.S. Department of Health and Human Services, and other leading federal healthcare officials will offer remarks on HIV testing and prevention strategies in the United States and abroad, on Monday, May 19, 2003, from noon to 1:00 p.m. EDT, at the headquarters of OraSure Technologies, Inc. (Nasdaq:OSUR) in Bethlehem, PA. The event, hosted by OraSure in recognition of the FDA's recent approval of its ... 
Printer Friendly Version
05/13/03OraSure Technologies Appoints New Director
BETHLEHEM, Pa.--(BUSINESS WIRE)--May 13, 2003--OraSure Technologies, Inc. (NasdaqNM:OSUR), the market leader in oral fluid diagnostics, today announced the appointment of Ronny B. Lancaster to the Company's Board of Directors. Mr. Lancaster has extensive experience in the medical and public health fields, particularly in the development of public health policy and promotion of health education. Since March 1996, Mr. Lancaster has served as Senior Vice President for Management and Polic... 
Printer Friendly Version
05/12/03OraSure Technologies To Webcast Annual Stockholders' Meeting
BETHLEHEM, Pa., May 12, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced that it will webcast its 2003 Annual Meeting of Stockholders beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) on Tuesday, May 20, 2003. The formal portion of the meeting will be immediately followed by a management presentation and a question and answer session. Persons accessing the webcast who desire to ask questions will be pe... 
Printer Friendly Version
04/29/03OraSure Technologies Announces 2003 First Quarter Results
BETHLEHEM, Pa.--(BUSINESS WIRE)--April 29, 2003--OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its financial results for the quarter ended March 31, 2003. Total revenues for the quarter increased approximately 11% to $8.6 million, compared to $7.7 million for the quarter ended March 31, 2002. Product revenues for the first quarter of 2003 increased approximately 12% to $8.3 million, compared to $7.5 million in 2002. Both amou... 
Printer Friendly Version
04/28/03OraQuick Rapid HIV-1 Antibody Test is Highlighted in New CDC HIV Prevention Initiative
-CDC Recommends Use of Rapid Testing as Part of Comprehensive HIV Testing Strategy- BETHLEHEM, Pa.--(BUSINESS WIRE)--April 28, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that the Centers for Disease Control and Prevention ("CDC") stated that simple, rapid HIV testing would be a key component to its new HIV testing initiative announced by the CDC on Thursday, April 17, 2003, in the CDC's Morbidity an... 
Printer Friendly Version
04/25/03OraSure Expands Sales Into the Over-the-Counter Market; Cryosurgical Wart Treatment to Be Available Under Compound W Trademark
BETHLEHEM, Pa.--(BUSINESS WIRE)--April 25, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR) announced today the execution of an exclusive distribution agreement with Medtech Holdings, Inc. pursuant to which OraSure will manufacture and supply, and Medtech will purchase, the Company's cryosurgical wart removal product for distribution in the over-the-counter ("OTC") market in the United States and Canada. The product will be manufactured and sold under Medtech's Compound W(R) and F... 
Printer Friendly Version
04/22/03OraSure Technologies Invites You To Join Its 2003 First Quarter Financial Results Conference Call
BETHLEHEM, Pa.--(BUSINESS WIRE)--April 22, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR) will host a conference call with analysts and an audio webcast to discuss the Company's first quarter 2003 financial results beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Tuesday, April 29, 2003. The call will be preceded by the release of the Company's 2002 financial results, which will occur immediately after the market closes that day. In order to listen to the conferenc... 
Printer Friendly Version
03/10/03OraSure Technologies to Present at SG Cowen's Health Care Conference
BETHLEHEM, Pa., Mar 10, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Mike Gausling, President and Chief Executive Officer, will speak to the investment community at the SG Cowen Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet. Mr. Gausling is scheduled to speak on March 20, 2003, at approximately 10:15 am and again at 11:15 am Eastern Time (7:15 am and 8:15 am Pacific Time). Intere... 
Printer Friendly Version
03/03/03OraSure Appoints Chairman
BETHLEHEM, Pa., Mar 3, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that Douglas G. Watson has been appointed Chairman of the Company's Board of Directors. He is replacing William W. Crouse, who is retiring from the Board. Mr. Watson joined OraSure's Board in May 2002, after a distinguished career in the pharmaceutical industry, spanning 33 years. Prior to his retirement in May 1999, he served as President... 
Printer Friendly Version
02/11/03OraSure Announces Senior Management Promotions
BETHLEHEM, Pa., Feb 11, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), today announced the promotion of several members of its senior management team. P. Michael Formica has been promoted to Executive Vice President, Operations of the Company. Mr. Formica served as OraSure's Senior Vice President, Operations since May 2000, and has recently assumed overall supervisory responsibility for the Company's Regulatory Affairs and Quality Assurance Departments. Mr. Formic... 
Printer Friendly Version
02/07/03OraSure to Participate with Penn in Oral Fluid Research Grant
BETHLEHEM, Pa., Feb 7, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it will participate in a $4.2 million four-year grant for research and development of saliva/oral fluid-based diagnostic technologies, awarded by the National Institutes of Health to the University of Pennsylvania. The grant will fund work by a multidisciplinary group of scientists from OraSure and the University's School of Dental Me... 
Printer Friendly Version
02/05/03OraSure Technologies Announces 2002 Results
BETHLEHEM, Pa., Feb 5, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced total revenues of $32.0 million for the full year 2002 and $8.25 million for the quarter ended December 31, 2002. Full year 2002 revenues reflect a 2% decline from the $32.6 million in revenues recorded for 2001. Revenues for the quarter ended December 31, 2002, were 2% higher than those for the same period of 2001. The Company's net loss ... 
Printer Friendly Version
02/03/03U.S. Navy Purchases OraQuick HIV-1 Test; Part of Smallpox Vaccination Program
BETHLEHEM, Pa., Feb 3, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced that the United States Navy Military Sealift Command has purchased 10,000 OraQuick(R) Rapid HIV-1 Antibody Tests to screen its personnel participating in the smallpox vaccination program directed by the Federal government. OraQuick(R) is a finger-stick whole blood test and the first FDA-approved, CLIA-waived, rapid point-of-care test designed to... 
Printer Friendly Version
01/31/03OraSure Receives CLIA Waiver for OraQuick Rapid HIV-1 Antibody Test
BETHLEHEM, Pa., Jan 31, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NasdaqNM:OSUR), the market leader in oral fluid diagnostics, announced today that the U.S. Food and Drug Administration (FDA), through its Center for Devices and Radiological Health, has approved a waiver under the Clinical Laboratory Improvements Amendments of 1988 (CLIA) for the Company's OraQuick(R) Rapid HIV-1 Antibody Test. This waiver was granted on the basis of information contained in the Company's appl... 
Printer Friendly Version
01/31/03OraSure Applies for CLIA Waiver on OraQuick Rapid HIV-1 Antibody Test
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 31, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that it has submitted to the U.S. Food and Drug Administration (FDA) an application for a waiver under the Clinical Laboratory Improvements Amendments of 1988 (CLIA) for its OraQuick(R) Rapid HIV-1 Antibody Test. With an approved CLIA waiver, the OraQuick(R) test, which provides HIV-1 test results in just 20 minutes, would ... 
Printer Friendly Version
01/28/03OraSure Technologies Appoints New Vice President, Sales
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 28, 2003--OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced the hiring of Susan Schiller as Vice President, Sales. Ms. Schiller joins OraSure Technologies with extensive sales management experience in the biopharmaceutical and healthcare industries. Ms. Schiller comes to OraSure most recently from Viropharma, Incorporated, a developer and manufacturer of antiviral therapies. U... 
Printer Friendly Version
01/27/03OraSure Technologies Invites You To Join Its 2002 Fourth Quarter and Full-Year Financial Results Conference Call
BETHLEHEM, Penn.--(BUSINESS WIRE)--Jan. 27, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR) will host a conference call with analysts and an audio webcast to discuss the Company's 2002 fourth quarter and full-year financial results, certain financial expectations for 2003, and certain business developments, beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Wednesday, February 5, 2003. The call will be preceded by the release of the Company's 2002 financial re... 
Printer Friendly Version
01/07/03OraSure Begins Shipment of OraQuick Rapid HIV-1 Antibody Test; OraSure Fills Initial Stocking Order to Abbott Laboratories
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 7, 2003--OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it has shipped more than 50,000 OraQuick(R) Rapid HIV-1 Antibody Tests to Abbott Laboratories. This order was completed in late December 2002, and represents the first sale of OraQuick(R) tests under OraSure's agreement with Abbott, which is the Company's co-exclusive distributor of OraQuick(R) in the United Stat... 
Printer Friendly Version
12/20/02Intercept Oral Fluid Drug Test Equivalent to Urine Drug Testing; Landmark Study Published in the Journal of Analytical Toxicology
BETHLEHEM, Pa.--(BUSINESS WIRE)--Dec. 20, 2002--OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today the publication of results of the first large-scale study of oral fluid drug testing in private industry with its Intercept(R) oral fluid drug testing system. The results from the study demonstrate that oral fluid drug testing produces equivalent results to urine drug testing. This study, entitled "Oral Flu... 
Printer Friendly Version
11/14/02OraSure Technologies Sets Annual Meeting Date
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 14, 2002--OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2003 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 20, 2003, at the Radisson Hotel Bethlehem, Bethlehem, Pennsylvania, 18018. Stockholder proposals must be received no later than December 13, 2002, in order to be considered for inclusion in the Company's Proxy Statement under relevant Securities and Exchange Commission rules and no later ... 
Printer Friendly Version
11/07/02Multimedia Available: Image of OraQuick Rapid HIV-1 Test and OraSure Technologies Logo
ADVISORY...for Thursday (Nov. 7) NOTE TO EDITORS: Multimedia Assets Available With This Story Include Logos, Photos, Text News Releases --(BUSINESS WIRE)-- OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its OraQuick(R) Rapid HIV-1 Antibody Test. Pursuant to this approval, the C... 
Printer Friendly Version
11/07/02Image of OraQuick Rapid HIV-1 Test and OraSure Technologies Logo
NOTE TO MEDIA: Multimedia assets available A photo is available at URL: http://www.businesswire.com/cgi-bin/photo.cgi?pw.110702/bb12 BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 7, 2002--OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its OraQuick(R) Rapid HIV-1 Antibody Test. Pursuant to this approval, the Compan... 
Printer Friendly Version
11/07/02OraSure Receives FDA Approval for OraQuick Rapid HIV-1 Test; Investor Conference Call and Press Conference at 2:15 P.M. Eastern Time
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 7, 2002--OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its OraQuick(R) Rapid HIV-1 Antibody Test. Pursuant to this approval, the Company can manufacture and market the OraQuick(R) test in the United States for the detection of HIV-1 antibodies in finger-stick whole blood samples. ... 
Printer Friendly Version
10/28/02OraSure Technologies Reports 2002 Third Quarter Results; - $3 Million Increase In Cash Flow From Operations -
BETHLEHEM, Pa., Oct 28, 2002 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that it had revenues of $8.1 million for the three months ended September 30, 2002, down 6% when compared to revenues of $8.6 million for the three months ended September 30, 2001. The Company also recorded a net loss of $387,000, or ($0.01) per share, for the three months ended September 30, 2002. This compares to a net profit of $16,000 fo... 
Printer Friendly Version
10/23/02OraSure Technologies to Participate in U.S. Trade Mission to Africa; -OraSure to Highlight OraQuick Rapid HIV Antibody Test-
BETHLEHEM, Pa., Oct 23, 2002 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that the Company was selected by the United States Department of Commerce to join a business development mission to Ghana and South Africa, on November 12-15. Secretary of Commerce, Donald L. Evans, will lead a delegation of 12 U.S. firms that represent a variety of business sectors capable of assisting with Africa's infrastructure needs. ... 
Printer Friendly Version
10/15/02OraSure Technologies Invites You To Join Its 2002 Third Quarter Financial Results Conference Call
BETHLEHEM, Pa., Oct 15, 2002 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq NM:OSUR) will host a conference call with analysts and an audio webcast to discuss the Company's third quarter 2002 financial results and certain business developments beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Monday, October 28, 2002. The call will be preceded by the release of the Company's financial results, which will occur immediately after the market closes that day. In order ... 
Printer Friendly Version
10/07/02OraSure Technologies to Present at UBS Warburg Global Life Sciences Conference
BETHLEHEM, Pa., Oct 7, 2002 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Mike Gausling, President and Chief Executive Officer, will speak to the investment community at the UBS Warburg Global Life Sciences Conference in New York City. The conference will be simultaneously webcast over the Internet. Mr. Gausling is scheduled to speak on October 10, 2002, at approximately 10:30 am Eastern Time (7:30 am Pacific Time). Interested investors can access t... 
Printer Friendly Version
09/16/02OraSure Technologies Receives $10.9 Million Credit Facility From Comerica
PHILADELPHIA and BETHLEHEM, Pa., Sep 16, 2002 /PRNewswire/ -- Comerica (NYSE: CMA), a leading financial services company, and OraSure Technologies, Inc. (Nasdaq: OSUR), the market leader in oral fluid diagnostics, announced today that Comerica's Technology and Life Sciences Division has provided OraSure with a $10.9 million credit facility, composed of a $4 million line of credit for working capital, a $3 million term loan, a $3 million credit line for capital equipment purchases and expan... 
Printer Friendly Version
09/12/02OraSure Appoints New Executive Vice President, Marketing and Sales
BETHLEHEM, Pa., Sep 12, 2002 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced the hiring of Joseph E. Zack as Executive Vice President, Marketing and Sales. Mr. Zack joins OraSure Technologies with extensive marketing and sales experience in the medical product and pharmaceutical industries. Since 1998, Mr. Zack served as Vice President, Marketing and Sales for OraPharma, Inc., a specialty public pharmaceutical ... 
Printer Friendly Version
08/28/02OraSure Technologies to Present At Wells Fargo Securities' Class of 2002 Conference
BETHLEHEM, Pa., Aug 28, 2002 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Mike Gausling, President and Chief Executive Officer, will speak to the investment community at the Wells Fargo Securities' Class of 2002 Conference in San Francisco, California. The conference will be simultaneously webcast over the Internet. Mr. Gausling is scheduled to speak on September 4, 2002, at approximately 3:30 p.m. Eastern Time (12:30 pm Pacific Time). Interested i... 
Printer Friendly Version
07/29/02OraSure Technologies Reports 2002 Second Quarter Results
BETHLEHEM, Pa., Jul 29, 2002 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that, consistent with its previous forecast, it had revenues of approximately $7.9 million for the three months ended June 30, 2002, down 7% when compared to revenues of $8.5 million for the three months ended June 30, 2001. The Company also recorded a net loss of approximately $1.3 million, or ($0.03) per share, for the three months ende... 
Printer Friendly Version
07/19/02OraSure Technologies Invites You to Join Its 2002 Second Quarter Financial Results Conference Call
BETHLEHEM, Pa., Jul 19, 2002 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq NM:OSUR) will host a conference call with analysts and an audio webcast to discuss the Company's second quarter 2002 financial results and certain business developments beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Monday, July 29, 2002. The call will be preceded by the release of the Company's financial results, which will occur immediately after the market closes that day. In order to... 
Printer Friendly Version
06/17/02Abbott And OraSure Technologies Enter Distribution Agreement For OraQuick(R) Rapid HIV-1 Test In The United States
- Abbott To Focus On Hospital And Physician's Office Laboratory Markets; OraSure Also Sublicenses Certain Lateral-Flow Patents - ABBOTT PARK, Ill., and BETHLEHAM, Pa., Jun 17, 2002 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) and OraSure Technologies (Nasdaq: OSUR) today announced agreements for the co-exclusive distribution of OraSure Technologies' OraQuick(R) rapid test for the detection of antibodies to the Human Immunodeficiency Virus Type 1 (HIV-1) and for a non-exclusive subl... 
Printer Friendly Version
05/20/02OraSure Appoints Two New Directors
BETHLEHEM, Pa., May 20, 2002 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced the appointment of Richard J. Lane and Douglas G. Watson to the Company's Board of Directors. Mr. Lane has enjoyed a distinguished career in the pharmaceutical industry. Most recently, he was Executive Vice President of Bristol-Myers Squibb and President of its Worldwide Medicines Group, with responsibility for worldwide pharmaceutical o... 
Printer Friendly Version
05/15/02OraSure Technologies to Webcast Annual Stockholders' Meeting
BETHLEHEM, Pa., May 15, 2002 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced that it will webcast its 2002 Annual Meeting of Stockholders beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) on Monday, May 20, 2002. The formal portion of the meeting will be immediately followed by a management presentation and a question and answer session. Persons accessing the webcast who desire to ask questions will be permi... 
Printer Friendly Version
05/13/02OraSure Receives FDA Approvable Letter for OraQuick HIV-1 Test
BETHLEHEM, Pa., May 13, 2002 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it has received notification from the U.S. Food and Drug Administration ("FDA") that the OraQuick(R) Rapid HIV-1 Antibody Test is approvable, subject to the Company meeting certain conditions. The OraQuick(R) test is intended to detect HIV-1 antibodies in finger stick whole blood within 20 minutes. Sam Niedbala, OraSure's Chief S... 
Printer Friendly Version
04/30/02OraSure Technologies Announces 2002 First Quarter Results
BETHLEHEM, Pa., Apr 30, 2002 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its financial results for the quarter ended March 31, 2002. Total revenues for the quarter increased approximately 4% to $7.7 million compared to $7.4 million for the quarter ended March 31, 2001. Product revenues for the first quarter of 2002 increased approximately 8% to $7.5 million compared to $6.9 million in 2001. The Company rec... 
Printer Friendly Version
04/29/02OraSure Technologies Appoints New Vice President, Strategic Marketing
BETHLEHEM, Pa., Apr 29, 2002 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced the hiring of William F. Bruckner as Vice President, Strategic Marketing. Mr. Bruckner joins OraSure Technologies with extensive experience in strategic marketing and product management. Since 2000, Mr. Bruckner served as Senior Managing Director, Head of Marketing for Shaklee Corporation, a diversified global consumer products company, w... 
Printer Friendly Version
04/19/02OraSure Technologies Receives FDA Clearance for Ninth Intercept Oral Fluid Drug Test
BETHLEHEM, Pa., Apr 19, 2002 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that it has received 510(k) clearance from the FDA for a test for detecting benzodiazepines in oral fluid specimens, which will be available as part of the Company's Intercept(R) laboratory-based drug testing service. Benzodiazepines are a commonly prescribed class of tranquilizers and one of the most frequently abused prescription drugs.... 
Printer Friendly Version
04/18/02OraSure Technologies Invites You to Join Its 2002 First Quarter Financial Results Conference Call
BETHLEHEM, Pa., Apr 18, 2002 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, will host a conference call with analysts and an audio webcast to discuss the Company's first quarter 2002 financial results beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Tuesday, April 30, 2002. On the call will be Mike Gausling, Chief Executive Officer, Ronald H. Spair, Chief Financial Officer, and R. Sam Niedbala, Chief Science Offi... 
Printer Friendly Version
04/08/02OraSure Technologies Receives FDA Clearance for UPlink Test System
First FDA-Cleared Oral Fluid Point-of-Care Test - Conference Call and Webcast Scheduled for April 11, 2002 - BETHLEHEM, Pa.--(BW HealthWire)--April 8, 2002-- OraSure Technologies, Inc. (Nasdaq NM:OSUR), today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for its UPlink(TM) test system to detect opiates in oral fluid. This clearance is based on data submitted by the Company dem... 
Printer Friendly Version
02/15/02OraSure Technologies Announces 2001 Financial Results
BETHLEHEM, Pa., Feb 15, 2002 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced revenues of $32.6 million for the full year 2001 and $8.1 million for the quarter ended December 31, 2001. After excluding revenues in 2000 from the discontinued Serum Western Blot product, these amounts represent increases of 20 percent and 9 percent, respectively, over revenues reported for the same periods a year ago. The Company's net loss ... 
Printer Friendly Version
02/12/02OraSure Technologies Invites You to Join Its 2001 Fourth Quarter and Full-Year Results Conference Call
BETHLEHEM, Pa., Feb 12, 2002 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, will host a conference call with analysts and an audio webcast to discuss the Company's fourth quarter and full-year financial results beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Friday, February 15, 2002. On the call will be Mike Gausling, Chief Executive Officer, Ronald H. Spair, Chief Financial Officer, and R. Sam Niedbala, Chief ... 
Printer Friendly Version
02/07/02OraSure Technologies Submits UPlink Oral Fluid Point-Of-Care Drug Test Data To The FDA
BETHLEHEM, Pa., Feb 7, 2002 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that it has resubmitted a 510(k) application with the U.S. Food and Drug Administration (FDA) for its UPlink(TM) reader and related opiates oral fluid test. This application was filed in order to provide certain additional data requested by the FDA in response to the Company's June 2001 510(k) submission for the UPlink(TM) reader and five... 
Printer Friendly Version
02/01/02OraSure Technologies to Present At Emerald Groundhog Day Investment Forum
BETHLEHEM, Pa., Feb 1, 2002 (BW HealthWire) -- OraSure Technologies Inc. (Nasdaq:OSUR) today announced that Mike Gausling, Chief Executive Officer, will be presenting at the Ninth Annual Emerald Groundhog Day Investment Forum, scheduled for Tuesday, February 5, 2002, at the Wyndham Franklin Plaza Hotel in Philadelphia. Emerald will be providing an audio feed of the entire Forum via their Internet Web site at www.teamemerald.com/. All company presentations will be broadcast live and wil... 
Printer Friendly Version
01/31/02Michael Gausling New OraSure Technologies CEO
BETHLEHEM, Pa., Jan 31, 2002 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, appointed Michael Gausling as Chief Executive Officer. He replaces Robert D. Thompson who resigned his positions as CEO and a member of OraSure's Board of Directors to pursue other opportunities. In addition to being named CEO, Mr. Gausling will continue as President and a member of OraSure's Board of Directors. Mr. Gausling was a Founder and CEO o... 
Printer Friendly Version
01/30/02OraSure Technologies Announces Intercept Oral Fluid Drug Testing Solution to be Marketed by Quest Diagnostics
BETHLEHEM, Pa., Jan 30, 2002 (BW HealthWire) -- OraSure Technologies Inc. (Nasdaq:OSUR) announced today that Quest Diagnostics, Inc. (NYSE:DGX), the nation's leading provider of diagnostic testing, information and services, has signed an agreement to market Intercept(R), OraSure Technologies' oral fluid drug testing solution. Terms of the agreement were not disclosed. Quest Diagnostics is the nations leading provider of drugs of abuse testing, performing more than eight million drug... 
Printer Friendly Version
01/25/02OraSure Technologies Reschedules Annual Meeting Date
BETHLEHEM, Pa., Jan 25, 2002 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2002 Annual Meeting of Stockholders has been rescheduled and will now be held on May 20, 2002, in Bethlehem, Pennsylvania. A specific meeting site will be communicated to stockholders in the proxy materials distributed for the annual meeting. As previously announced, stockholder proposals had to be received no later than December 20, 2001, in order to be considered for incl... 
Printer Friendly Version
01/18/02OraSure Technologies Announces Preliminary Fourth Quarter and Full Year 2001 Results
BETHLEHEM, Pa., Jan 18, 2002 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced preliminary revenues of approximately $8.1 million for the quarter ended December 31, 2001, and $32.6 million for the full year 2001, which after excluding revenues in 2000 from discontinued products, represent increases of 9 percent and 20 percent, respectively, over revenues reported for the same periods a year ago. The Company also expects to r... 
Printer Friendly Version
12/07/01OraSure Technologies Appoints Carter H. Eckert to Board of Directors
BETHLEHEM, Pa., Dec 7, 2001 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the appointment of Carter H. Eckert to the Company's Board of Directors. This appointment increases the size of OraSure's Board to eight members. Mr. Eckert has enjoyed a distinguished career in the pharmaceutical industry spanning four decades. Most recently, Mr. Eckert was President and Chief Executive Officer of Knoll Pharmaceutical Company and President of the Americas for Kno... 
Printer Friendly Version
11/01/01OraSure Technologies Appoints New Chief Financial Officer
BETHLEHEM, Pa.--(BW HealthWire)--Nov. 1, 2001--OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the appointment of Ronald H. Spair to the position of Executive Vice President and Chief Financial Officer. Mr. Spair joins OraSure Technologies with extensive senior financial experience in the pharmaceutical and biotechnology industries. Mr. Spair has held the position of Chief Financial Officer with several pharmaceutical or biotechnology companies - Delsys Pharmaceu... 
Printer Friendly Version
10/26/01OraSure Technologies Sets Annual Meeting Date
BETHLEHEM, Pa.--(BW HealthWire)--Oct. 26, 2001--OraSure Technologies, Inc. (Nasdaq NM:OSUR) today announced that its 2002 Annual Meeting of Stockholders is scheduled to be held on May 9, 2002, in Bethlehem, Pennsylvania. A specific meeting site will be communicated to stockholders in the proxy materials distributed for the annual meeting. Stockholder proposals must be received no later than December 20, 2001, in order to be considered for inclusion in the Compa... 
Printer Friendly Version
10/24/01Orasure Technologies Reports Profit On Record Revenues
BETHLEHEM, Pa., Oct 24, 2001 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader for oral fluid diagnostics, today announced record third quarter revenues of $8.6 million, a 19 percent increase over the $7.2 million reported in the same period a year ago. The net profit for the quarter was $16,000, an improvement of $7.9 million over the third quarter of 2000, which included a one-time charge of $5.9 million for merger-related expenses. Excluding revenu... 
Printer Friendly Version
10/17/01OraSure Technologies Invites You to Join Its Third Quarter 2001 Financial Results Conference Call on the Web, Wednesday, October 24, 2001, at 11:00 a.m. ET, 8 a.m. PT
BETHLEHEM, Pa.--(BW HealthWire)--Oct. 17, 2001--OraSure Technologies, Inc. (Nasdaq:OSUR) will hold a conference call with financial analysts on Wednesday, October 24, 2001, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific), to discuss its 2001 third quarter financial results and other matters, including certain forward-looking statements. On the call will be Robert Thompson, Chief Executive Officer, Mike Gausling, President and Chief Operating Officer, Rich Hooper, Chief Fin... 
Printer Friendly Version
10/05/01OraSure Technologies to Present at UBS Warburg Global Life Sciences Conference
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 5, 2001--OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Robert D. Thompson, Chief Executive Officer, will be presenting at the UBS Warburg Global Life Sciences Conference on Monday, October 8, at 11:30 a.m. (Eastern). This conference will be held at the Pierre Hotel, New York, New York. UBS Warburg will be providing listen-only dial-in conference lines for public access to the presentation. Additionally, the c... 
Printer Friendly Version
08/31/01OraSure Technologies Announces Significant Additions to Management Team
BETHLEHEM, Pa., Aug 31, 2001 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq NM: OSUR) today announced two key additions to its management team - - Salvatore Salamone as Senior Vice President, Development, and Eve Damiano as Vice President, Regulatory Affairs. Dr. Salamone joins OraSure Technologies with 17 years of research and development experience at Roche Diagnostics. Dr. Salamone's most recent position at Roche was Vice President, Research and Development, where he was respo... 
Printer Friendly Version
08/14/01CDC Selects OraSure Technologies' OraQuick as the Exclusive Rapid HIV Test for the MIRIAD Project
BETHLEHEM, Pa., Aug 14, 2001 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq NM:OSUR), announced that the Centers for Disease Control and Prevention (CDC) has selected the OraQuick(R) rapid HIV test to be used to provide results to pregnant women as part of the CDC funded clinical study, the Maternal Infant Rapid Intervention at Delivery (MIRIAD) Project. Robert D. Thompson, Chief Executive Officer of OraSure Technologies, Inc., stated, "We are pleased to have been chosen once aga... 
Printer Friendly Version
08/07/01OraSure Announces Rule 10b5-1 Sales Plans
BETHLEHEM, Pa.--(BW HealthWire)--Aug. 7, 2001--OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that several executive officers of the Company have entered into predetermined sales plans for the purpose of selling limited amounts of their Company stock holdings. The plans, which were entered into pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, will enable these officers to diversify a small portion of their stockholdings in OraSure Technologies,... 
Printer Friendly Version
07/27/01OraSure Technologies Reports Record Revenues
BETHLEHEM, Pa.--(BW HealthWire)--July 27, 2001-- -Revenues Increase by 19%- -Operating Loss Improves by $540,000- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader for oral fluid diagnostics of infectious disease and drugs of abuse, today announced record revenues for the second quarter of approximately $8.5 million compared to $7.2 million for the same period a year ago, a 19% increase. This record was achie... 
Printer Friendly Version
07/20/01OraSure Technologies Invites You to Join Its Second Quarter 2001 Financial Results Conference Call on the Web, Friday, July 27, 2001, at 11:00 a.m. ET, 8 a.m. PT
BETHLEHEM, Pa.--(BUSINESS WIRE)--July 20, 2001--OraSure Technologies, Inc. (Nasdaq:OSUR) will hold its quarterly conference call with financial analysts to discuss second quarter 2001 financial results on Friday, July 27, 2001, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific). The call will be preceded by the release of the Company's results, which will occur before the market opens on that day. On the call will be Robert Thompson, Chief Executive Officer, Mike G... 
Printer Friendly Version
07/13/01OraSure Technologies Seeks FDA Clearance for UPlink Point-of-Care Reader and Expanded Oral Fluid Drugs of Abuse Test Panel
BETHLEHEM, Pa.--(BW HealthWire)--July 13, 2001--OraSure Technologies, Inc. (NASDAQ NM:OSUR) today announced that it filed a 510(k) application with the U.S. Food and Drug Administration (FDA) for its UPlink(TM) reader and six oral fluid drugs of abuse assays - cocaine, opiates, amphetamine, methamphetamine, PCP, and marijuana. UPlink will deliver rapid drug screen results in less than ten minutes at the point-of-care on an oral fluid specimen. This application supersedes the applica... 
Printer Friendly Version
07/11/01OraSure Technologies Files for Pre-Market Approval of OraQuick Rapid HIV Test
BETHLEHEM, Pa.--(BW HealthWire)--July 11, 2001--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that it filed with the U.S. Food and Drug Administration (FDA) for Pre-Market Approval of its OraQuick(R) HIV test. OraQuick is a rapid test device that can detect antibodies to the HIV disease within 20 minutes, and is the only rapid device in the world designed to use oral fluid, whole blood, serum or plasma samples. The submittal, which is for serum and w... 
Printer Friendly Version
06/25/01OraSure Technologies and Drager Successfully Conduct First UPlink Roadside Drugs of Abuse Test in Germany
BETHLEHEM, Penn., Jun 25, 2001 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR) headquartered in Bethlehem, Pennsylvania, and Drager Sicherheitstechnik GmbH, located in Lubeck, Germany, today jointly announced successful execution of the first large scale field trial of OraSure Technologies' UPlink(TM) Drugs of Abuse Testing System in a roadside setting. This new platform technology is the first practical test platform for on-site, oral fluid drug testing for roadside testing... 
Printer Friendly Version
06/20/01OraSure Technologies Announces Inclusion in the Russell 3000 Index
BETHLEHEM, Pa., Jun 20, 2001 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its stock has recently been included in the Russell 3000(R) Index. This index is compiled by the Frank Russell Company and is a ranking of the 3,000 largest U.S. stocks by market capitalization. At the close of trading on May 31, 2001, OraSure's market capitalization was approximately $413.9 million. "We're pleased to be included in this widely recognized market index," said ... 
Printer Friendly Version
06/07/01OraSure Technologies Announces First Preview of Uplink Technology at 2001 American Society of Microbiology Meeting
BETHLEHEM, Pa., Jun 7, 2001 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR) and its partner, Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced the demonstration, for the first time, of the unique abilities of the phosphor-based UPlink(TM) technology in the detection of infectious disease. The results were previewed in a poster session at the 2001 American Society for Microbiology Conference, held in Orlando, Fla. The initial product concept, UPlin... 
Printer Friendly Version
05/16/01OraSure Technologies Announces New Intercept Drug Testing Partner
BETHLEHEM, Penn.--(BW HealthWire)--May 16, 2001-- Deal Marks Growing Acceptance of Oral Fluid Drug Testing in Criminal Justice and Drug Rehabilitation Markets OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that it has signed an agreement with Comprehensive Toxicology Services (CTS) of Tacoma, Washington, for its Intercept(TM) Oral Fluid Drug Testing Service. The account is expected to reach over $750,000 in annual sales for OraSur... 
Printer Friendly Version
05/08/01OraSure Technologies Presentation At Deutsche Banc Alex. Brown Conference to be Webcast Live
BETHLEHEM, Pa.--(BW HealthWire)--May 8, 2001--OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Robert D. Thompson, Chief Executive Officer of OraSure, will speak to the investment community at Deutsche Banc Alex. Brown's 2001 Health Care Conference in Baltimore, Maryland. Thompson is scheduled to speak on May 10, 2001, at 8:00 a.m. Eastern Time. Interested investors can access a live audio webcast of the presentation and slide materials at http://www.db.com/co... 
Printer Friendly Version
04/30/01OraSure Technologies Announces First Quarter Results
BETHLEHEM, Penn.--(BW HealthWire)--April 30, 2001-- Loss Narrows to $547,000 Excluding Non-Recurring Charges; Manufacturing Realignment Substantially Complete OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader for oral fluid diagnostics of infectious disease and drugs-of-abuse, today announced its financial results for the quarter ended March 31, 2001. Total revenue for the quarter ended March 31, 2001, rose approximately 12% to $7.4 m... 
Printer Friendly Version
04/25/01OraSure Technologies Appoints Gregory B. Lawless to Board of Directors
BETHLEHEM, Pa.--(BW HealthWire)--April 25, 2001--OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the appointment of Gregory B. Lawless to the Company's Board of Directors. This appointment increases the size of OraSure's Board to seven members. Since 1998, Dr. Lawless has been the Managing Partner of Collins Mabry & Co., a strategic advisory firm for the life sciences industry, which he co-founded. From 1992 to 1998, Dr. Lawless served as President and Chief Execu... 
Printer Friendly Version
04/20/01OraSure Technologies Invites You to Join Its First Quarter 2001 Financial Results Conference Call on the Web, Monday, April 30, 2001, at 11:00 a.m. ET, 8:00 a.m. PT
BETHLEHEM, Pa.--(BUSINESS WIRE)--April 20, 2001--OraSure Technologies, Inc. (Nasdaq:OSUR) will hold its quarterly conference call with financial analysts to discuss first quarter results for 2001 on Monday, April 30, 2001, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific). The call will be preceded by the release of the company's results, which will occur before the market opens on that day. In addition to the company's financial performance, the call will cover business developments a... 
Printer Friendly Version
04/05/01OraSure Technologies Announces Large Commitment From Major Retailer For Intercept Drugs of Abuse System; Retailer To Use Oral Fluid Specimens For Workplace Drug Testing
BETHLEHEM, Pa.--(BW HealthWire)--April 5, 2001--OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that a major retailer has committed to use the Company's Intercept(TM) Drugs of Abuse product. With thousands of locations nationwide, the account is expected to generate approximately $1.2 million in annual sales for OraSure Technologies once the program is fully implemented. The retailer has indicated that it will immediately begin to use Intercept to test ... 
Printer Friendly Version
04/04/01OraSure Technologies Receives Order from Centers for Disease Control; OraQuick Device To Be Used As Part of LIFE Initiative
BETHLEHEM, Penn.--(BW HealthWire)--April 4, 2001--OraSure Technologies, Inc. (Nasdaq:OSUR) announced that the company has received an initial order from the Centers for Disease Control for 118,000 OraQuick(R) HIV-1/2 devices, in conjunction with the LIFE (Leadership and Investment in Fighting an Epidemic) Initiative. OraQuick HIV-1/2 is a rapid test device that can detect antibodies to the HIV disease within 20 minutes, and is the only rapid device in the world that uses e... 
Printer Friendly Version
03/15/01CDC Selects OraQuick as One of Two Rapid HIV Tests for Treatment Investigational Device Exemption Submittal
BETHLEHEM, Pa.--(BW HealthWire)--March 15, 2001-- OraQuick Selected After Accuracy Validated in Studies Conducted by CDC Over Past Year OraSure Technologies, Inc. (Nasdaq:OSUR), announced that the Centers for Disease Control and Prevention (CDC) has selected the OraQuick HIV-1/2 rapid HIV test to be used in the CDC sponsored Treatment Investigational Device Exemption (IDE). Under federal regulations, the FDA can authorize th... 
Printer Friendly Version
03/12/01OraSure Technologies UPT Technology Published in March Issue of Nature Biotechnology
BETHLEHEM, Pa.--(BW HealthWire)--March 12, 2001--OraSure Technologies, Inc. (Nasdaq:OSUR), announced that an article was published in the March edition of Nature Biotechnology, which describes the use of the Company's proprietary Up-Converting Phosphor Technology (UPT(TM)) particles to detect DNA in microchips. UPT particles are used to amplify and make easier the detection of biological materials such as DNA, infectious disease markers and drugs of abuse. In this article ... 
Printer Friendly Version
03/07/01OraSure Technologies Invites You to Join Its Discussion Regarding Recent Publication on the Company's UPT Technology, Monday, March 12, 2001, at 11:00 a.m. ET
BETHLEHEM, Pa.--(BUSINESS WIRE)----March 7, 2001--OraSure Technologies Inc. (NasdaqNM:OSUR) will hold a conference call to discuss the recently published research report about OraSure Technologies' UPT(TM) technology called, "Up-converting phosphor reporters for nucleic acid microarrays." The article was published in Nature Biotechnology, the premier magazine for the biotechnology industry. Due to the important findings of this article and the complex nature of the subject matter, O... 
Printer Friendly Version
02/26/01OraSure Technologies Announces Fourth Quarter and Year-end 2000 Results
BETHLEHEM, Pa.--(BW HealthWire)--Feb. 26, 2001-- -- Product Revenue Up 20% -- -- First International OraQuick Shipments Initiated -- -- UPlink System FDA Submission -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader for oral fluid diagnostics of infectious disease and drugs-of-abuse, today announced its fourth quarter and full-year financial results for 2000. OraSure Technologies was for... 
Printer Friendly Version
02/21/01OraSure Technologies Invites You to Join Its Fourth Quarter and Year-End Results Conference Call on the Web
BETHLEHEM, Pa--(BUSINESS WIRE)--Feb. 21, 2001--OraSure Technologies, Inc., (Nasdaq:OSUR) will hold its quarterly conference call with financial analysts to discuss fourth quarter and full year results for 2000 on Monday, February 26, 2001, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific). The call will be preceded by the release of the company's results, which will occur before the market opens on that day. In addition to the company's financial performance, the call will cover busine... 
Printer Friendly Version
02/15/01OraSure Technologies Seeks FDA Clearance for UPlink Point-of-Care Reader
BETHLEHEM, Pa.--(BW HealthWire)--Feb. 15, 2001--OraSure Technologies, Inc., (Nasdaq:OSUR) today announced that it has filed a 510(k) application with the U.S. Food and Drug Administration (FDA) for its UPlink(TM) reader and three oral fluid drugs-of-abuse assays cocaine, opiates and amphetamines. Two additional drugs-of-abuse assays, marijuana and PCP, are expected to be submitted within the next two months. UPlink is designed to be a highly sensitive, point-of-care diagnostic sys... 
Printer Friendly Version
02/02/01OraSure Technologies Appoints New Officers
BETHLEHEM, Pa.--(BW HealthWire)--Feb. 2, 2001--OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the appointment of Richard D. Hooper, 37, as the company's Chief Financial Officer. Mr. Hooper's appointment follows the retirement of Charles E. Bergeron in connection with the recent merger of Epitope, Inc., and STC Technologies, Inc., into the Company. The Company has also named Jack E. Jerrett as Secretary, Mark L. Kuna as Controller, and Michelle M. Sells as Manager... 
Printer Friendly Version
02/01/01OraSure Technologies Announces Plans to Realign its Global Manufacturing Operations; Company to Relocate and Expand Manufacturing of OraQuick Product
BETHLEHEM, Pa.--(BW HealthWire)--Feb. 1, 2001--OraSure Technologies, Inc. (Nasdaq:OSUR) today announced plans to realign its global manufacturing operations to maximize the operating strengths of its facilities in the United States and add capacity overseas. Implementation of this strategy will result in the elimination of the manufacturing of its OraQuick product line in the Beaverton, Oregon facility, the installation of automated manufacturing equipment for OraQuick in... 
Printer Friendly Version
01/26/01OraSure Announces New Intercept Drug Testing Partner; Company Also Receives FDA Clearance of Oral Fluid Assays for Barbiturates and Methadone
BETHLEHEM, Pa.--(BW HealthWire)--Jan. 26, 2001--OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that it has signed an agreement with a new lab partner, Bendiner & Schlesinger, Inc., of New York, N.Y., which will offer its Intercept(TM) Oral Fluid Drug Testing Service to the drug rehabilitation market in the New York metropolitan area. OraSure Technologies will be providing a turnkey solution of oral fluid collection devices and assays to Bendiner & Schlesinger, wi... 
Printer Friendly Version
01/17/01OraSure Receives ISO Certification and CE Mark
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 17, 2001--OraSure Technologies, Inc. (Nasdaq NM:OSUR) today announced that its Bethlehem facility has received formal certification to ISO 9001, EN 46001 and ISO 13485 standards from TUV Rheinland of North America, Inc. TUV also granted approval for the Medical Device Directive 93/42/EEC, thereby authorizing CE Mark for the Histofreezer(R) product line. ISO is the recognized name for an international quality agency working t... 
Printer Friendly Version
12/14/00OraSure Technologies Sets Annual Meeting Date
BEAVERTON, Ore.--(BW HealthWire)--Dec. 15, 2000--OraSure Technologies, Inc. (Nasdaq NM:OSUR) today announced that as a result of changing from a fiscal year to a calendar year ending Dec. 31 for financial reporting purposes, the Company has changed the date set for its next annual meeting of stockholders to June 14, 2001. The meeting will take place in Bethlehem, Penn., which is now the location of the executive offices for OraSure. A specific meeting site will be communic... 
Printer Friendly Version
12/06/00OraSure Technologies Announces Another Distribution Arrangement for OraQuick Rapid HIV Test; Minimum Purchase of Over $5 Million of OraQuick Devices in the First Year
BEAVERTON, Ore.--(BW HealthWire)--Dec. 6, 2000--OraSure Technologies, Inc. (Nasdaq/NM:OSUR) today announced that Edison Africa, its distributor for the OraQuick HIV device in sub-Saharan Africa, signed an agreement with the UCB Group of Brussels, Belgium to act as a distribution agent for this product in the physician and family care markets in that territory. The initial order of 100,000 units of OraQuick HIV will begin shipping this month to Edison Africa to assist in th... 
Printer Friendly Version
11/08/00OraSure Technologies Announces Phase II Funding for Syphilis Project; NIH Approves Nearly $1 Million in Added Funding for Oral Fluid Syphilis Test
BEAVERTON, Ore.--(BW HealthWire)--Nov. 8, 2000--OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader for oral fluid diagnostics of infectious disease and drugs-of-abuse, today announced that the National Institutes of Health (NIH) has approved a grant of nearly $1 million to fund Phase II of the Company's project to develop a test for syphilis using either blood or oral fluid samples. This "fast-track" grant came after OraSure Technologies reached specific milestone... 
Printer Friendly Version
10/30/00OraSure Technologies, Inc. Announces First Combined Results; Merger of Epitope, Inc. and STC Technologies Completed in the Quarter
BEAVERTON, Ore.--(BW HealthWire)--Oct. 30, 2000--OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader for oral fluid diagnostics of infectious disease and drugs-of-abuse, today announced financial results for the third quarter and first nine months of fiscal year 2000, as well as financial objectives for 2001. Quarterly revenues of $7.2 million represent a 9.3 percent increase over the prior year's comparable quarter of $6.6 million. Revenues for the first nine mont... 
Printer Friendly Version
10/23/00OraSure Technologies Announces First International Order for OraQuick Rapid HIV Test
First Clinical Trial Results Available BEAVERTON, Ore.--(BW HealthWire)--Oct. 23, 2000--OraSure Technologies, Inc. (Nasdaq:OSUR - news) today announced its first international order for the unique OraQuick® HIV-1/2 rapid test. The OraQuick product detects HIV disease from an oral fluid sample within 20 minutes after collection. The initial order of 100,000 units came from Edison Africa (S.A.) (Pty) Ltd., OraSure Technologies' new distributor in South Africa. OraSure Technologies exp... 
Printer Friendly Version
10/06/00OraSure Technologies Appoints Alan ''Kip'' Whitefield New Vice President, Insurance Sales
Whitefield to Lead Company's Sales and Marketing Efforts to Insurance Industry BEAVERTON, Ore.--(BW HealthWire)--Oct. 6, 2000--OraSure Technologies, Inc. (Nasdaq:OSUR - news) today announced that Alan ``Kip'' Whitefield has been appointed Vice President, Insurance Sales, effective October 16, 2000. Whitefield brings 35 years of experience in the insurance-related services industry to his new position at OraSure. He will be responsible for sales and marketing of OraSure products to the do... 
Printer Friendly Version
09/29/00Epitope and STC Technologies Merger Approved
New Company Created -- OraSure Technologies, Inc. BEAVERTON, Ore.--(BW HealthWire)--Sept. 29, 2000--Epitope, Inc. (Nasdaq:EPTO) today completed its merger with STC Technologies, Inc. (STC), a closely held private company based in Bethlehem, Pennsylvania, as stockholders of both companies voted in favor of the merger in separate meetings. The agreement, which was approved by the board of directors of both companies and announced in May of this year, is a $260 million, all-stock deal which... 
Printer Friendly Version
08/31/00Epitope's Merger Partner STC Technologies Signs With Meridian Diagnostics to Commercialize Rapid Infectious Disease Tests
BEAVERTON, Ore.--(BW HealthWire)--Aug. 31, 2000--Epitope, Inc., (Nasdaq:EPTO) its proposed merger partner, STC Technologies, Inc., and Meridian Diagnostics, Inc. (Nasdaq:KITS) announced today that they have entered into multi-year, multi-million dollar exclusive Research and Supply Agreements to develop, manufacture, and sell a broad range of point-of-care tests for the rapid detection of parasites, gastrointestinal, and upper respiratory diseases. The tests will utilize Up-Converting Phosp... 
Printer Friendly Version



Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet